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summARy
Pharmacotherapy is the most frequently used form of treatment in-
tervention. The benefits of the therapy need to be weighed carefully 
against its risks, as drugs also cause up to 25% of all emergency de-
partment visits. Preventable inappropriate prescribing and medication 
errors, including the patient’s own mishandling, manifest in drug the-
rapy failures and adverse drug events, which subsequently may gene-
rate costly hospitalisations. Of the adult Swiss population aged over 
65 years, 21% are prescribed a potentially inappropriate medication. 
Within this setting, medication reviews are a method of assessing the 
patient’s drug regimen regarding its appropriateness and the patient’s 
preferences in order to address inappropriate prescribing and prevent 
medication errors. Medication reviews reduce the number of drug-re-
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lated problems (DRPs) and decrease drug-related emergency depart-
ment visits as well as hospital length of stay. But medication reviews 
are a time-consuming intervention. In a country like Switzerland, whe-
re 35.9 full-time equivalents of clinical pharmacists should promote 
safe, economic, and appropriate medicinal therapies for 1.4 million 
hospitalisations per year, there is a demand for risk stratification and 
patient prioritisation. Newly developed algorithms that generate alerts 
for clinical pharmacists on pooled electronic data, however, do not 
take into account the patient-centred causes of DRPs. The Drug-As-
sociated Risk Tool (DART) was developed to identify hospitalised 
patients at greater risk of DRPs and in need of clinical pharmacy ser-
vices, i.e. medication reviews. As a self-administered questionnaire 
for patients, the screening tool assesses items concerning the patients’ 
medical information in combination with their opinions and concerns 
about the pharmacotherapy whilst not increasing the workload of any 
caregiver.
In this thesis, the DART was validated regarding its ability to discri-
minate between patients with lower and higher numbers of DRPs. Is-
sues concerning the patients’ current pharmacotherapy were identified 
with a medication review with pooled data on drug regimens, diagno-
ses, laboratory values, and structured patient interviews. The medica-
tion reviews combined implicit and explicit criteria of inappropriate 
prescribing to balance the benefits and drawbacks of each approach. 
This thesis looked into the performance of the criteria used and re-
ports on the number of DRPs identified with each method. The struc-
tured patient interview was newly developed by combining a remu-
nerated public pharmacy interview on adherence with questions on 
concerns about the medication. This thesis describes the benefits of 
the patient interview by presenting the type of DRPs identified and 
weighs it against the additional clinical pharmacy resource require-
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ments. The DART validation study also necessitated the use of a tool 
to estimate the potential relevance of pharmacists’ interventions. With 
the translation and subsequent reliability testing of the French tool 
CLEO, this thesis reports on the performance of a validated German 
version. CLEOde may help German-speaking pharmacists to estima-
te the potential relevance of their own interventions in three distin-
ct dimensions: Patient-centred clinical, cost-focusing economic, and 
institution-based organisational. The study focused on interrater and 
test–retest reliability of CLEOde and presented an overview of clini-
cal pharmacists’ activity within three Swiss-German hospitals. This 
thesis also critically evaluated the performance of another tool for 
risk stratification and patient prioritisation concerning one specific 
drug-related problem: The RISQ-PATH score and its ability to predict 
drug-induced QT-prolongation and heart arrhythmias. 
The thesis encompassed the execution of medication reviews, inclu-
ding patient interviews, for 110 geriatric patients within a study pe-
riod of 10 months, identifying 595 DRPs estimated to be of minor 
to lifesaving relevance. The performed patient interviews identified 
over one third of all DRPs with insufficient patient knowledge and 
incomplete patient documentation as most the prominent and not 
otherwise identifiable causes. This thesis reports an average time of 
16.6 minutes needed for the individual structured patient interviews. 
The ability of the DART to distinguish between patients with low and 
high numbers of current DRPs was demonstrated: Cluster analysis 
and subsequent discriminant function analysis allowed for an item 
reduction to five questions associated with the number of DRPs. The-
se questions allow targeting patients who would benefit most from 
direct engagement and bedside interventions. CLEOde was used by 
10 clinical pharmacists working in three hospitals during 13 days of 
routine clinical pharmacy services to estimate the relevance of 324 
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performed pharmacists’ interventions. The use of CLEOde was seen 
as appropriate, acceptable, feasible, and precise. Statistical analysis 
showed good interrater reliability and excellent test–retest reliability 
for the clinical and economic dimension, whereas the organisational 
dimension achieved poor interrater and fair test–retest reliability. By 
critically examining the association between the RISQ-PATH scores 
and the measured QTc intervals, we identified an already previously 
present prolonged QTc interval as moderating variable, necessitating 
subgroup generation for score interpretation. These results also allo-
wed this thesis to articulate a simple code of practice when handling 
drugs with the potential to prolong the QTc interval.
This thesis, entitled “Drug-Related Problems: Assessments of Risk 
and Relevance,” presents a validated self-administered patient ques-
tionnaire to stratify for drug-related risk, a validated assessment to 
estimate the relevance of drug-related problems, a structured patient 
interview to identify issues on drug-related adherence, handling, and 
concerns, and a valid score to detect patients at risk of drug-induced 
QT-prolongation.
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“Medicinal therapy is the most frequently 
used form of treatment intervention in any 
health practice setting. Its use has grown 
dramatically as the population has aged, 
the prevalence of chronic disease has in-
creased, new infectious diseases have emer-
ged and the range of effective medications 
has broadened.” – WHO & FIP 2006,1
I. medicines use and Patients on Polypharmacy
A proportion of 41.2% of Swiss men and wo-
men aged over 65 years is prescribed five or 
more medicines.2 The current life expectancy 
of 80.7 years of age for men and 84.9 for wo-
men leaves this population stratum with more 
than 15 years of polypharmacy.3 The demo-
graphic shift, in which the proportion of men 
and women over 65 years of age will increase 
from 18.0% in 2014 to 26.4% in 2045,4 will 
further enlarge the number of patients on polypharmacy. This shift towards polyphar-
macy has been shown in Scotland: Within a time span of 15 years, the proportion of 
adults in Tayside which got dispensed ≥ 5 drugs increased two-fold, and the proportion 
receiving ≥ 10 increased three-fold, doubling the number of potentially serious drug–
drug interactions.5 As polypharmacy is an independent predictor of hospitalisation and 
geneRAl 
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re-hospitalisation,6 the current Swiss hospitalisation rate of 121.7 per 1000 inhabitants 
may be expected to further increase.3 This development is relevant to the Swiss health 
care system in general.
II. Drug-Related Problems
Drug-related problems (DRPs) – also descri-
bed as medicine-related problems in American 
lierature8 – are distinguished by their preven-
tability, their presence, and their cause:9 (1) 
They are preventable or not, (2) they are po-
tential or present and manifest, and (3) they 
are caused by an error, a deviation from accepted medical practice, or an unpredictable 
reaction towards an appropriately selected drug. As the term DRP includes all aspects 
of drug therapy, DRPs are present in up to 81% of all hospitalised patients as they 
include, but are not restricted to, dosing issues, missing laboratory data, wrong drug 
selection, untreated indications, and medical chart errors.10 Within the terminology of 
DRPs, adverse drug reactions (ADRs) may be described as unpreventable, manifest, 
and often unpredictable DRPs: ADRs are noxious and unintended reactions occurring 
at labelled doses normally used in humans, more commonly described as side-effects.11 
One example is the capability of some drugs to potentially influence repolarisation of 
the heart, prolonging the QTc interval measured in ECG measurements. Prescribing 
multiple QT-prolonging drugs puts patients at risk of potentially lethal arrhythmias.12 
13 Adverse drug events (ADEs), on the other hand, are an undesired medical occurren-
ce during a drug treatment with a questionable causal relationship,8 an example being 
falls during drug treatment. Failures by health care providers or patients themselves in 
prescribing, dispensing, storing, preparation, and administration represent preventable 
DRPs and define medication errors – one being the previously described prescription of 
multiple QT interval-prolonging drugs for a high-risk patient.14 Similarly, unintentional 
non-adherence – the extent to which a patient’s behaviour does not correspond with 
agreed recommendations from a health care provider15 – can be described as medicati-
on error and hence marks a preventable and manifest DRP.9 The relationship of all the 
terms to DRPs is visualised in Figure 1. The definition of a DRP in the broadest sense of 
the term also embraces medication errors and ADRs that may remain potential and do 
not manifest in symptoms, hence remain potential DRPs without consequences. Figure 
1 highlights this circumstance with all areas not intersecting the area of ADEs. The area 
of ADEs marks symptoms of manifest medical situations.
“An undesirable event, a patient experien-
ce that involves, or is suspected to involve 
drug therapy, and that manifestly or poten-
tially, interferes with a desired patient out-
come” – Cipolle & Strand 1998,7
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Figure 1 Relationship of drug-related problems, medication errors, adverse drug reactions, and adverse drug 
events. The areas of medication errors and adverse drug reactions not intersecting adverse events display errors 
and potential sideeffects that do not manifest in symptoms and remain without consequences. Drug-related prob-
lems, being the broadest sense of the term, also include physical or psychological dependence, ineffectiveness and 
interactions, as well as potential issues. Size is not representative of prevalence. Visualisation inspired by Anita 
Maria Krähenbühl-Melcher.16
Undetected and therefore unresolved potential or manifest DRPs place the patient at 
risk for drug-related morbidity (DRM), where the patient suffers from an injury cau-
sally originating from the treatment or lack thereof.17 Subsequently, DRPs may lead to 
results diametrically opposed to the intentions for using pharmacotherapy in the first 
place: The modification of pathological states for the benefits of the patients places 
them at risk of injuries.11 DRM is estimated to be the cause of 8.6– 24.2% of all emer-
gency department visits.18 Of these visits, where over a fifth result in a subsequent hos-
pital admission as an inpatient, 70% would be preventable. It is the DRPs drug therapy 
failure, ADRs, and overdoses that most prominently result in a hospital admission.19
During the subsequent hospitalisation, patients may experience additional DRPs: About 
5% of all drug applications within the hospital are accompanied by a medication er-
ror. Given the number of 5–10 drugs per day for a patient treated on a medical ward, 
the probability of an erroneous drug application is increased with each day spent in 
17
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“The rational use of drugs requires that 
patients receive medicines appropriate 
to their clinical needs, in doses that meet 
their own individual requirements, for an 
adequate period of time, and at the lowest 
cost to them and the community.” – WHO 
1985,23
“However, rational use of medicines re-
mains the exception rather than the rule. 
For those people who do receive medicines, 
more than half of all prescriptions are in-
correct and more than half of the people in-
volved fail to take them correctly.” – WHO 
2004,1
General Introduction
the hospital.20 In 2000, the publication „To Err is Human“ was a major landmark in 
medication-error awareness:21 The report referred to 44,000 extrapolated deaths due to 
medication errors in a total of 33.6 million hospital admissions. Put into perspective, 
this number presented medication errors as one of the 10 leading causes of deaths in 
the United States of America. Besides causing patient harm, the errors also incur addi-
tional costs for the health care system: Preventable adverse drug events add $4,700 per 
admission.22 „To Err is Human“ underpinned its goal of improving patient safety with 
the words: „The status quo is not acceptable and cannot be tolerated any longer. Despite 
the cost pressures, liability constraints, resistance to change and other seemingly insur-
mountable barriers, it is simply not acceptable for patients to be harmed by the same 
health care system that is supposed to offer healing and comfort.“
III. Inappropriate Prescribing
Pharmacotherapy is considered to be approp-
riate when there is an evident indication, the 
therapy is tolerated by most patients within the 
same population, and the treatment is cost-ef-
fective.24 Inappropriate prescribing as a whole 
encompasses misprescribing, overprescribing, 
and underprescribing, and may be regarded as 
a DRP in the realm of medication errors. Mi-
sprescribing describes the selection of a drug 
that increases the risk for ADEs for the trea-
ted population. It also describes choosing the 
wrong dose, frequency, modality, or duration 
for an otherwise appropriate pharmacothera-
py. Overprescribing is used for when there is 
no evident indication apparent for the drug. 
Underprescribing is the omission of a drug, 
which would be indicated for the treatment or prevention of a disease.24 In addition, 
the tolerance for many drugs changes in the elderly: The patients are at higher risk for 
ADRs as the pharmacologic effects increase or decrease.25 For this reason, a drug for 
which there is a safer or more effective alternative for the treatment of the elderly is 
considered a potentially inappropriate medication (PIM).25
Patients exposed to PIMs use more health care services and incur higher costs as the 
association between PIM use and ADEs has shown.24 26 The number of concurrent PIMs 
correlates with hospitalisation rates for the Swiss population aged more than 65 years: 
18
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In the study of Blozik and colleagues, the adjusted hazard ratio for hospitalisation was 
1.13 (95%-confidence interval [CI] 1.07–1.19) for 1 PIM, 1.27 (95%-CI 1.19–1.35) for 
2 PIMs, 1.35 (95%-CI 1.22–1.50) for 3 PIMs, and 1.63 (95%-CI 1.40– 1.90) for more 
than 3 PIMs compared to no PIM use.27 Of the population stratum, 21.1% of the patients 
received at least one PIM.2 The prevalence of PIM prescribing increased with a positive 
correlation to age. Putting the financial burden into perspective, Blozik and colleagues 
showed that the costs for the 15 most prevalent PIMs affect the Swiss health care and 
insurance systems, with 145.9 million Swiss francs in direct costs – while not further 
assessing the additional indirect costs for subsequent hospitalisations and management 
of ADRs associated with PIM use.
Inappropriate prescribing can be measured and approached by using explicit and im-
plicit criteria for prescribing appropriateness.24 Explicit criteria are rigid lists of drugs 
and recommendations, usually based on expert opinions and literature reviews.24 28 Ex-
amples of explicit criteria are the Beers’ List,29 the PRISCUS List,30 and the STOPP 
criteria.31 Explicit criteria allow for a quick evaluation of prescribing appropriateness as 
they do not require clinical judgement and may be implemented in automated algorith-
ms.28 As rigid lists, these criteria need to be updated regularly in vast validation proces-
ses.31 As the answers to the incorporated items are dichotomous, explicit criteria do not 
allow for patient tailoring or involvement:28 Patients either receive a drug that is listed 
as a PIM, or they do not. The use of the STOPP criteria, which target misprescribing 
and overprescribing in the elderly, is shown to improve medication appropriateness and 
to reduce the prevalence of ADRs, as the items are associated with ADEs.31 Contrarily 
to explicit criteria, implicit criteria are tools filled with information based on clinical 
judgement. An example of an implicit tool is the Medication Appropriateness Index 
(MAI).32 The results of such an assessment are unique to the affected patient, but de-
pend on the user’s knowledge and capabilities. For each medicine, 10 items are judged 
to be “appropriate”, “marginally appropriate”, or “not appropriate”. A weighted score is 
applied for the judgements “partially appropriate” and “marginally appropriate”.33 The 
total score of a medication indicates the appropriateness while each contributing item 
indicates an opportunity for optimisation. For the MAI, feasibility, content validity, 
predictive validity, and reliability have been shown.34 Improvements in drug therapy 
are reflected in a better (i.e. decreased) total MAI score.35 As the assessments are per-
formed per patient or even per drug, implicit criteria are time-consuming.28 Explicit and 
implicit criteria are best used in conjunction as their benefits may be combined whilst 
minimising their drawbacks.28
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“Medication review is, at heart, a diag-
nostic intervention which aims to identify 
problems for action by the prescriber, pati-
ent, or both but can also be regarded as an 
educational intervention to support patient 
knowledge and adherence.” – Blenkinsopp 
2012,36 
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Iv. medication Reviews
Medication review (MRs) is a process in 
which health care professionals assess the 
appropriateness of a drug therapy in regard to 
the patient’s illnesses and in respect of the pa-
tient’s own preferences. MRs involve evalua-
ting therapeutic efficacy, adherence, manifest 
and potential DRPs, interactions, and the pa-
tient’s understanding of the condition and its 
treatment. MRs may include explicit and implicit criteria of inappropriate prescribing if 
suitable for the specific patient population. After an MR, a decision is made on changes 
to the drug treatment in order to improve its appropriateness.36 37 The quality of an MR 
is affected by the amount of information available to the assessor and the relationship 
to the prescriber.36
MRs are categorised into three distinctive categories with varying degrees of clinical 
data and patient involvement.38 A Simple Medication Review (MR Type 1) is based so-
lely on the available patient medication history. MRs Type 1 may reveal interactions, 
treated ADRs, inappropriate prescribing, and adherence issues. An Intermediate Medi-
cation Review (Type 2A and Type 2B) is additionally based either on information about 
the patient being present for an interview or on clinical information. Compared to MRs 
Type 1, MRs Type 2A additionally reveal drug–food interactions, drug effectiveness 
issues, insufficient understanding by the patient, and problems with over-the-counter 
medicines. MRs Type 2B replace the additional information gained from the patient 
interview with the possibility of detecting overprescribing and underprescribing, as 
laboratory values and diagnoses are available. Finally, an Advanced Medication Re-
view (MR Type 3) is based on all data, hence consisting of drug treatment information, 
patient interviews, and clinical data. MRs Type 3 are best suited to identifying the pre-
viously described vast diversity of possible DRPs.
MRs are shown to improve the quality of prescribing.39 They reduce the total MAI sco-
re of the patient’s drug treatment and lower the numbers of present PIMs.35 MRs that 
involve patient counselling also positively affect adherence.6 40 Outpatient MRs seem 
to reduce emergency department visits and early in-hospital MRs positively influence 
hospital length of stay;41 however, evidence on reduced mortality or hospital readmis-
sions is still sparse.42
Projects
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“Pharmaceutical care is the responsible 
provision of drug therapy for the purpose 
of achieving definite outcomes that impro-
ve a patient’s quality of life”– Hepler & 
Strand 1990,43
“Clinical pharmacists work in collabora-
tion with other providers to deliver com-
prehensive medication management that 
optimizes patient outcomes.” – American 
College of Clinical Pharmacy 2014,47
v. Pharmaceutical care and clinical Pharmacy
The pharmacy profession is shifting away from 
its traditional role as compounders and medi-
cine suppliers. Pharmacists are becoming pro-
viders of services, information and, ultimately, 
of care.1 By optimising their patients’ medici-
nes use, pharmacists contribute to the overall 
care of a patient and get involved in the improvement of health outcomes.44 Pharma-
ceutical care includes liable decisions on the drug needs of a patient and provides ser-
vices surrounding these drugs to assure a safe and effective medicines therapy, e.g. 
MRs. In order to establish a continuity of care, the provided services require a feedback 
mechanism.45 For this reason, patient-centred care is a collaborative service.46 More 
recently, the lead for providing pharmaceutical care was attributed to the pharmacist: 
“Pharmaceutical Care is the pharmacist’s contribution to the care of individuals in order 
to optimise medicines use and improve health outcomes.”44 This definition respects the 
circumstances that pharmacists should be involved in the care of their patients and that 
other health care professionals can provide medicines-related services.44 In order to 
establish pharmaceutical care, pharmacists may apply clinical pharmacy techniques as 
a continuous and recurring service.
Clinical pharmacists are responsible for the 
development and promotion of a safe, appro-
priate, and economic use of medicines. They 
are collaborators in care with a patient-centred 
approach towards drug treatment.48 Clinical 
pharmacists optimise medication therapy by 
applying in-depth pharmacologic knowledge and evidence-based therapeutic guide-
lines. As primary source for advice on objective therapeutic drug information, clinical 
pharmacists are accountable for advancing rational drug use and averting inappropriate 
prescribing.49
Pharmacists’ interventions aim at improving the use of medicines to address manifest or 
potential DRPs.50 Such interventions may be defined as “any action that directly results 
in a change in patient management or therapy.”51 Documenting these interventions de-
monstrates accountability for the actions taken and helps in facilitating pharmaceutical 
care research.1 50 51 More importantly, the documentation improves the patient’s quality 
of care as it is a way of communicating with other health care providers – a necessity 
for the continuous provision of pharmaceutical care, as described.51 Hence it is important 
that the relevance of a pharmacist’s intervention is assessed in addition to its documenta-
21
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tion.52 Examples of pharmacists‘ interventions include adaptions of the application form 
from tablets to granulate according to the patient’s preference, identifying an untreated 
atrial fibrillation, or asking nurses to wear protective masks while crushing tablets con-
taining cancerogenic drugs. The impact of pharmacists’ interventions varies in affected 
processes and outcomes.52 Therefore, the impact and relevance of an intervention depends 
on the measured traits: Focusing on the effect for the patient’s quality of life will trivialise 
the relevance of reducing the nurses’ exposure to a cancerogenic drug. The variety of me-
thods to assess the relevance of the interventions reflects this diversity: Studies may use 
(1) small expert panels who decide on the relevance of the interventions and often have to 
reduce the amount of interventions by sampling,53 (2) specific tools for self-assessment,54 
or (3) pairs of pharmacists and physicians using scales.55 Consensus-finding processes 
in teams or expert panels are possible in study settings, but are too resource-exhaustive 
for daily practice. However, tools to assess the relevance of pharmacists’ interventions 
mainly focus on clinical impacts and neglect effects on hospital costs or workplace safety. 
Additionally, only sparse information on reliability and validity is available.52
Casting aside issues on measuring the relevance of the interventions, pharmacists’ partici-
pation on ward rounds, provision of medication reconciliation, and delivery of drug-spe-
cific services are shown to reduce the occurrence of ADRs and medication errors. They 
also improve medication adherence, knowledge, and appropriateness and shorten hospi-
tal length of stay.56 In a sample of over one fifth of all US hospital admissions (22.4%, 
7,892,430), pharmacy services were found to reduce mortality rates.57 A pooled median 
benefit-to-risk ratio across 15 studies of 4.81 to 1 was calculated, showing $4.81 in re-
duced costs or other economic benefits for every $1 spent on clinical pharmacy services.58 
However, clinical pharmacy is not common in Switzerland:59 From a total of 239.2 full-
time equivalents of Swiss hospital pharmacists, only 15% were assigned to clinical phar-
macy in 2013. This put 35.9 full-time equivalents of clinical pharmacists in stark contrast 
to 1.4 million hospitalisations. Weekly performed treatment recommendations during 
ward rounds are restricted to selected wards only and direct patient engagement is espe-
cially rare, leaving the general patient unapproached and with unresolved DRPs. Current 
resources are not sufficient to provide pharmaceutical care through Swiss clinical phar-
macists and necessitate patient prioritisation.
vI. Assessment of Risk for Drug-Related Problems
Prioritising patients in order to structure the daily workload is an accepted requirement 
to maintain effective clinical pharmacy services with finite resources.60 61 However, 
recommendations from official guidelines on patient prioritisation remain vague regar-
ding risk factors:60 “High risk disease states”, “difficulty with managing own medici-
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nes”, or “complex medication regimens” depend on a subjective risk stratification or 
previously completed additional assessments. Hence, tools to assess the risk for DRPs 
have been developed – some as algorithms, some as paper-based questionnaires. An 
overview of popular tools is presented in Table 1.
Table 1 Overview of tools to assess the risk for drug-related problems (DRPs).
the gerontonet ADR risk score62 63
The GerontoNet ADR risk score allows prioritisation of patients according to their likelihood of developing ADRs.
variables
Comorbid conditions (≥ 4); Heart failure; Liver disease; Number of drugs (≤ 5; 5 – 7; ≥ 8); Previous ADR; Renal 
failure  (< 60 mL/min)
Population
Inpatients > 65 years of age
validation status
Validated
Comment: The score focuses on clinical data with number of drugs (> 5) and previously experienced ADRs as 
strongest predictors. There was no association between age and increased risk for an ADR.
the brighton Adverse Drug Reactions Risk model (bADRI)64
The Brighton Adverse Drug Reactions Risk Model (BADRI) is another tool to predict ADRs and is aimed at a 
population of patients older than 85 years of age.
variables
Hyperlipidaemia; Number of drugs  (> 8); Hospital length of stay  (≥ 12 days); Use of anti-diabetics; High white 
cell count on admission
Population
Inpatients > 85 years of age
validation status
Validated
Comment: Out-performing all other models, this score has been described as fairly discriminative and sufficiently 
validated by the systematic review of Falconer and colleagues.61
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the self-Administered medication-Risk Questionnaire65
Barenholtz Levy developed the Self-Administered Medication-Risk Questionnaire containing questions on risk 
factors for DRPs. This questionnaire was designed to be completed by patients while they are waiting to be seen 
by their physician or pharmacist.
variables
Number of drugs (> 5); Number of doses  (≥ 12 /day); Certain drugs (carbamazepine, lithium, phenytoin, quinidi-
ne, warfarin, digoxin, phenobarbital, procainamide, theophylline); Number of prescribers  (> 1); Comorbid condi-
tions  (≥ 3); Number of pharmacies  (> 1); Third-party medication preparation; Adherence; Number of changes to 
the drug therapy regimen  (≥ 4/ year); Medication literacy
Population
Outpatients > 60 years of age
validation status
Reliability; Correlation with Drug Regimen 
Review Scores
Comment: The association with the Drug Regimen Review scores, which was additionally developed, was only 
present for the five items on number of drugs  (> 5), number of doses  (≥ 12 /day), certain drugs  (carbamazepine, 
lithium, phenytoin, quinidine, warfarin, digoxin, phenobarbital, procainamide, theophylline), comorbid conditions 
(≥ 3), and number of changes to the drug therapy regimen  (≥ 4/ year).
the medication Risk Assessment Questionnaire66
This questionnaire is an excerpt of Barenholtz Levy’s questionnaire. The authors used the five items of the original 
questionnaire that showed a statistically significant correlation and added a threshold of three “Yes”-answers as a 
definition of risk patients.
variables
Number of drugs (> 5); Number of doses (≥ 12 /day); Certain drugs (carbamazepine, lithium, phenytoin, quinidine, 
warfarin, digoxin, phenobarbital, procainamide, theophylline); Comorbid conditions (≥ 3); Number of changes to 
the drug therapy regimen (≥ 4/ year)
Population
Ambulatory patients > 18 years of age
validation status
Not validated
Comment: Questionable performance analysis. The study only compared referral rates to a specialised pharmacist 
between a control group and an intervention group: Within the control group, the referral was prescribed by a 
physician; within the intervention group, the referral was performed by three “Yes”-answers on the questionnaire. 
The questionnaire was described as a capable identification tool due to a significant proportion of patients within 
the control group who were not referred but also ticked three “Yes”-answers on the questionnaire.
the university of Alberta hospital family medicine clinic’s medication Risk Assessment Questionnaire67
This questionnaire is reported to be the combination of Barenholtz Levy’s questionnaire and The Medication Risk 
Assessment Questionnaire, although the latter is manifestly an excerpt from the former. The study assessed the 
number of patients presenting three “Yes”-answers as in the study of The Medication Risk Assessment Questi-
onnaire, but missed validating the questionnaire regarding identifying patients with high numbers of DRPs.
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the Assessment of Risk tool68 69
The Assessment of Risk Tool is an application that monitors clinical data on specified medication and other risk 
factors. The risk factors are grouped into five categories: Patient profile (e.g. age), patient encounter (e.g. mental 
health history), clinical profile (e.g. co-morbidity COPD), high-risk medications (e.g. anti-diabetic medication), 
and laboratory values (e.g. renal function < 30 mL/min). Each trigger has a weighted score assigned and helps in 
prioritising patients into low, medium, and high risk for ADEs. The score also recommends pharmacists’ inter-
ventions.
variables
The application is triggered by a total of 38 risk factors on patient traits, recent hospitalisation, chronic conditions, 
certain drugs, and exceeding laboratory values
Population
Inpatients with mean age 66 ± 19 years (SD)
validation status
Validated
Comment: The ART score is validated in regard to identifying patients with a higher risk for unintentional medi-
cation discrepancies as recognised in a medication reconciliation process. Some of the risk factors need clinical 
pharmacy processes in order to be evaluated, e.g. “Admitted patients identified via medication reconciliation pro-
cess as having comprehension difficulties or as poorly compliant with medications.” The category of risk factors 
on laboratory values was excluded from the validation study as there were technical difficulties, which reduced 
the ART score to 25 items.
the Drug-Related Problem Risk Assessment tool70
Dimitrow and colleagues introduced a questionnaire completed by nurses to assess the risk for DRPs of patients 
older than 65 years of age in homecare.
variables
Number of drugs (> 7); Number of doses (≥ 12 /day); Comorbid conditions (≥ 3); Number of changes to the drug 
therapy regimen (≥ 1/ 4 weeks); Certain drugs (non-steroidal antirheumatics drugs, diuretics, statins, amiodaro-
ne, carbamazepine, digoxin, fluoxetine, lithium, methotrexate, theophylline, warfarin); Use of over-the-counter 
(OTC) drugs; Previous ADR; Number of prescribers (> 1); Adherence; Recent hospitalisation; Certain symptoms; 
Third-party medication preparation
Population
Homecare patients > 65 years of age
validation status
Content validity
Comment: Content validity of the tool was evaluated by Delphi surveys with members of geriatric care, where an 
agreement of ≥ 80 % for an item had to be reached. Feasibility was assessed by distributing the questionnaire to 
nurses and collecting feedback.
Tools such as those described in Table 1 were comprehensively evaluated by Falconer 
and colleagues.61 For this systematic analysis, Falconer included studies where the pri-
mary outcome measures were ADRs, DRPs, and medication errors. Hence, this review 
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delivers a critical appraisal of the published tools to prioritise patients according to 
their risk for DRPs in general. Studies were, however, only included if they used mul-
tivariable logistic regression for model development, which excluded questionnaires 
like the one of Barenholtz-Levy (Table 1) or even their own model, which was based 
on clinical experience. Of the 11 models in their final assessment, only the Brighton 
Adverse Drug Reactions Risk (BADRI) model by Tangiisuran and colleagues remained 
as a tool with fair discrimination, sufficient validation, and reasonable performance. As 
outlined in Table 1, the BADRI score focuses on the five clinical variables hyperlipi-
daemia, number of drugs (> 8), length of hospital stay (≥ 12 days), use of anti-diabetics, 
and high white cell count on admission, and is validated for an inpatient population 
with a median age of 85 years. With its variables, the score is able to be implemented 
into automated screening algorithms, but requires laboratory measurements involving 
further effort by a health care profession.
Contrary to a model based on clinical data, a well-developed paper-based questionnaire 
can be distributed to patients while they are waiting to be seen by their physician or 
pharmacist.65 Patient-completed questionnaires also help in identifying additional pa-
tient-centred DRPs, e.g. low adherence and poor medication literacy. But, as pointed 
out in Table 1, patient-completed questionnaires are rarely sufficiently validated. The 
Self-Administered Medication-Risk Questionnaire by Barenholtz-Levy is validated, 
but was developed by one researcher on basis of an unsystematic literature review.65
vII. Rationale and Project Description
With the Drug-Associated Risk Tool (DART), we aimed to develop a valid tool to 
screen for patients at higher risk of DRPs. As other tools, the DART should help clini-
cal pharmacists in prioritising their patients and in tailoring specific clinical pharmacy 
services in order to ameliorate efficiency and effectiveness. Given the already finite 
resources at hand, we also aimed for a tool that does not increase the workload of any 
health care professional. The DART was designed to be a patient self-administered 
questionnaire to be distributed to patients at the time of hospitalisation. The questi-
onnaire is displayed in Figure 2.
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The 35-items questionnaire was generated on the results of a triangulation process in-
cluding the opinions of experts (structured by the Nominal Group Technique71), a li-
terature search as enrichment, and two Delphi-Rounds72 73 as prioritisation. The expert 
panel consisted of representatives of patient care: Family physicians, emergency phy-
sicians, geriatricians, pharmacologists, homecare nurses, community pharmacists, and 
clinical pharmacists. The transition of the gathered risk factors into a self-administered 
questionnaire and the first reliability tests were performed by Dr. Carole Kaufmann.74 
The questionnaire is divided into six sections on two pages: Health, polypharmacy, 
medication, adherence, concerns, and handling. The health section covers illnesses as-
sociated with an increased risk of DRPs, i.e. renal insufficiency, hepatic insufficiency, 
asthma/COPD, diabetes, and heart insufficiency. The polypharmacy section asks about 
the intake of more than five medicines and use of OTC drugs. The medication section 
focuses on specific drugs and drug classes deemed to be associated with an increased 
risk for DRPs and DRM. The adherence section consists of one question asking the pa-
tient about compliance with the medication regimen. The concerns section consists of 
the five questions from the Beliefs about Medicines Questionnaire (BMQ) focusing on 
concerns about the drug treatment negatively affecting knowledge and adherence.75 The 
handling section is aimed at detecting difficulties in splitting, recognising, and swallo-
Figure 2 The Drug-Associated Risk Tool (DART).
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wing the medicines. All original questions were designed as being dichotomous “Yes” 
and “No” answers. Those from the BMQ kept their Likert scale. Reliability testing 
focused on patients’ ability to reproduce their own medical information as compared to 
clinical information, i.e. medication charts and diagnoses.76
The difference between the DART and the aforementioned tools is its ability to combi-
ne clinical information and patient opinions within one self-administered questionnai-
re. Contrary to other published tools we also aimed for a full evaluation including all 
seven criteria for patient-based measures:77 (1) Appropriateness: Are the items of the 
questionnaire appropriate for the identification of DRPs? (2) Acceptability: Is the ques-
tionnaire acceptable to the patients? (3) Feasibility: Is the questionnaire easy to use? 
(4) Interpretability: How well can the answers be interpreted? (5) Reliability: Does the 
tool generate answers that are reproducible? (6) Validity: Does the tool measure what 
it claims to measure? (7) Responsiveness: Is the questionnaire responsive to changes 
over time? We were able to incorporate appropriateness and responsiveness by de-
sign: The items of the questionnaire represent risk factors assimilated by expert opinion 
and studies on DRPs. The dichotomous and ordinal answers are able to reflect change 
in the patient’s health, medicinal treatment, or handling of medicines. Acceptability, 
feasibility, and reliability testing are described in the project “Drug Associated Risk 
Tool – Development and Validation of a Self-Assessment Questionnaire to Screen for 
Hospitalised Patients at Risk for Drug-Related Problems”, where hospitalised patients 
were given the questionnaire to complete themselves and their answers were compared 
to their clinical records.
The questionnaire’s ability to distinguish patients into low and high levels of risk, its 
true validity, remained to be proven – as for many of the questionnaires previously 
described (Table 1). The DART validation study, with its linkage between a subset of 
items and specific clinical pharmacy services, is described in the project ‘Assessing 
the ability of the Drug-Associated Risk Tool (DART) questionnaire to stratify patients 
according to their risk of Drug-Related Problems.’
Not all pharmacists’ interventions and underlying DRPs have the same relevance. It 
was therefore necessary to have a tool at hand that enables the estimation of relevance. 
CLEO respects the variety of pharmacists’ interventions in the perceived impacts on 
processes, outcomes, and probability. The tool is based on a systematic review on mea-
sures of relevance and combines humanistic, ecologic, and process-related outcomes. 
Translation and reliability testing of CLEOde are described in the project “Translation 
and Validation of a Tool to Assess the Impact of Clinical Pharmacists’ Interventions.” 
The German version of the tool, CLEOde, gave us the opportunity to make statements 
on the relevance of the DRPs that the DART is able to detect. 
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The validation study of the DART encompassed patient interviews. With the data we 
collected we had the opportunity to demonstrate the value of direct patient contact in 
detecting DRPs in Swiss hospitalised patients. This analysis is described in “Patient 
Interviews as Part of a Comprehensive Approach Contribute to the Identification of 
Drug-Related Problems on Geriatric Wards.”
Lessons learned from the validation study of the DART were transposed into an additi-
onal dataset on one specific DRP: Drug-induced QTc interval prolongation, previously 
described as an example for ADRs. The RISQ-PATH score is an assessment of risk 
much like the DART, but focuses only on the specific DRP of QT-prolongation. Vandael 
and colleagues investigated identified risk factors and a baseline ECG as predictors for 
a follow-up ECG when a new QTc-prolonging drug was started. With their results, they 
developed the RISQ-PATH score, which aims to rule out low-risk patients from further 
ECG measurements when starting QTc-prolonging drugs. The project entitled ‘Risk of 
Drug-Induced QTc Interval Prolongation – A Step Closer to a Clinical Risk Manage-
ment’ aimed to investigate the performance of the RISQ-PATH score in a geriatric, 
hospitalised patient population and is presented in this thesis.
vIII. goal and Aims
The goals of this thesis were (1) the validation of a self-administered patient ques-
tionnaire as a risk stratification tool on DRPs and (2) the external validation of the 
RISQ-PATH score. Aims to achieve these goals were (1) establish an evaluation tool to 
estimate the relevance of DRPs, (2) develop a structured patient interview as an infor-
mation source for MR Type 3s, (3) validate the DART by correlation with MR Type 3s 
including patient interviews, and (4) validate the RISQ-PATH score by correlation with 
measured QTc intervals.
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Project Description
Translation and Validation of a Tool to Assess the Im-
pact of Clinical Pharmacists’ Interventions [Manuscript 
ready for submission]
The French evaluation tool CLEO helps pharmacists 
to assess the relevance of their own interventions in 
the view of the patients, the hospital, and the staff. It 
was the first tool concerning clinical relevance to be 
developed according to the findings of a systematic 
literature review. We translated this tool into German 
following accepted principles and tested its interrater 
and test–retest reliability.
Drug Associated Risk Tool – Development and Valida-
tion of a Self-Assessment Questionnaire to Screen for 
Hospitalised Patients at Risk for Drug-Related Prob-
lems [Published in BMJ Open]
In this shared first-authorship article we describe in 
detail the development of the Drug-Associated Risk 
Tool (DART). The DART is a patient self-adminis-
tered questionnaire which aims to help pharmacists 
tailor their services according to the patient’s risk of 
drug-related problems We also report the results of two 
tests on the patients’ ability to use the questionnaire as 
a self-administered questionnaire and our subsequent 
changes to the item formulation.
31
Assessments of Risk and Relevance
Thesis overview
Project Description
Assessing the ability of the Drug-Associated Risk Tool 
(DART) questionnaire to stratify patients according to 
their risk of Drug-Related Problems [Published in BMJ 
Open]
In this main project we validated the DART by cor-
relating its score to DRPs identified in MRs Type 3. 
Cluster analysis and discriminatory function analysis 
reduced the questionnaire to a set of five items for its 
main purpose.
Patient Interviews as Part of a Comprehensive Appro-
ach Contribute to the Identification of Drug-Related 
Problems on Geriatric Wards [Published in Drugs & 
Aging]
MRs Type 3 involve the patients’ opinion, their attri-
butes and their knowledge. Based on established tools, 
we developed a structured interview and highlighted 
its capabilities to identify DRPs.
Risk of Drug-Induced QTc Interval Prolongation – A 
Step Closer to a Clinical Risk Management [Draft]
The RISQ-PATH score aims to deliver guidance on 
when to order an ECG measurement when a new 
QTc-interval prolonging drug is started. We externally 
validated the score for geriatric, hospitalised patients 
and identified a moderation effect by one of the risk 
factors. The results restricted the score’s generalisabi-
lity, but provided a simple code of practice for starting 
a new QTc-interval prolonging drug.
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I. translation and validation of a tool to Assess the Impact of clinical Phar-
macists’ Interventions
To appropriately research and report DRPs, data on their relevance is necessary.78 This 
relevance comprises the evaluation of actual negative consequences of an unresolved 
DRP, the evaluation of actual positive consequences of a resolved DRP, or the esti-
mation of potential risk for the patient.52 As the assessment of actual consequences is 
often hindered by difficulties in follow-up, lack of resources, or the determination of 
causality, the estimation of potential risks is used to report the relevance of DRPs or 
pharmacists’ interventions. To reduce the subjectivity and simultaneously increase the 
reliability of this estimation, expert panels may be consulted; however they often only 
evaluate subsets of the data, as focus groups are a resource-intensive method.79-81 A dif-
ferent method of estimating the potential risks for a patient without introducing issues 
about subjectivity and reliability is the use of an appropriate tool.52 Such a tool was 
developed and validated in Grenoble: CLEO lets pharmacists rate the impact of their 
interventions in three proposed dimensions.
PRojects
Projects
33
Assessments of Risk and Relevance
Focusing on methodological aspects, CLEO was translated and culturally adap-
ted into CLEOde in a process proposed by the ISPOR Task Force for Translation and 
Cultural Adaptation for Patient-Reported Outcome Measures.82 This process consists 
of 10 steps: (1) Preparation, (2) Forward Translation, (3) Reconciliation, (4) Back 
Translation, (5) Back Translation Review, (6) Harmonisation, (7) Cognitive Debrie-
fing, (8) Review of Cognitive Debriefing Results and Finalisation, (9) Proofreading, 
and (10) Final Report. As recommended, the translation steps were conducted with 
the help of two professional translators. The cognitive debriefing, where comprehen-
siveness and linguistic style are measured, included clinical pharmacy experts from 
all native German-speaking countries. Interrater and test–retest reliability of CLEOde 
were assessed in order to be able to report comparability across different raters and 
consistency in coding. As recommended by Hallgren,83 the intra-class correlation (ICC) 
was used to calculate the interrater reliability instead of the often-used methods Cohen’s 
kappa or percentage of agreement. Cohen’s kappa is only suitable for up to two coders 
and percentage of agreement has been rejected as an adequate measure of interrater 
reliability. To report the potential clinical implications of CLEOde, the tool was distri-
buted to 10 clinical pharmacists to be used in their daily clinical pharmacy practice. 
The collected data were supplemented with subjective feedback on appropriateness, 
acceptability, feasibility, and precision of CLEOde.
Projects
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Abstract 
Background 
The tool CLEO in French language is designed for estimating the potential relevance of pharmacists’ 
interventions (PIs) in three independent dimensions with regard to process-related, clinical, economic, and 
humanistic impact. We aimed to translate CLEO into German (CLEOde), to demonstrate its feasibility in daily 
practice and to validate the German version. 
Methods 
We initially translated CLEO according to the ISPOR Principles of Good Practice. The potential relevance of 
PIs performed within a 13-day period of routine clinical pharmacy services of three Swiss hospitals was then 
estimated with CLEOde. Ten clinical pharmacists experienced with CLEOde subsequently completed a 19-item 
questionnaire to assess user’s agreement on appropriateness, acceptability, feasibility, and precision of the 
tool. To test for interrater and test-retest reliability, each pharmacist evaluated 10 model cases with CLEOde. 
Results 
CLEOde was used to estimate the potential relevance of 324 PIs. The reported time needed to complete a single 
estimation was less than one minute. The use of CLEOde was seen as appropriate, acceptable, feasible, and 
precise. Interrater reliability was good for the clinical and economic dimensions and was poor for the 
organisational dimension; test-retest correlation was strong for all three dimensions with excellent to fair 
reliability. 
Conclusion 
We present CLEOde as a validated tool in German language suitable to estimate the potential relevance of PIs. 
After further refinement of the organisational dimension, CLEOde could provide a qualitative value to 
quantitative information on PIs.
Projects
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Background 
A drug-related problem (DRP) is defined as “an event or circumstance involving drug treatment that actually 
or potentially interferes with the patient's experiencing an optimum outcome of medical care [1].” DRPs are 
multidimensional in that they may be preventable or not; potential or actual; and be caused by a medication 
error, by a deviation from current guidelines, or by an unpredictable reaction to an appropriate 
pharmacological treatment [2]. DRPs are frequent in hospitalised patients [3]. Approximately 5% of all drug 
applications in hospitals are medication errors that may lead to DRPs [3]. These occur during drug 
prescription, dispensing, or administration. Due to the high number of drug applications on medical wards, 
medication errors are expected to affect most hospitalised patients. Approximately 6% of all hospitalised 
patients experience an adverse drug reaction, which is judged to be preventable in 59% of the cases, suspecting 
medication errors as underlying reason [3]. 
A pharmacist’s task in a health care team is to promote drug therapies that are appropriately indicated, 
effective, and safe [4], hence averting medication errors and consequentially preventing adverse drug 
reactions. In this role, pharmacists are engaged in interprofessional collaborations with other health care 
professionals to improve health outcomes to the optimum of medical care for patients [5]. Pharmacists’ 
interventions (PIs), defined as discrete activities by pharmacists related to patient care [6], are shown to 
improve health outcomes when carried out on ward rounds, in patient interviews, medication reconciliation, 
and patient counselling [7]. However, pharmacists often fail to take responsibility for their interventions and 
tend to not adequately document, monitor, and review their services [4]. In Switzerland, the Swiss Association 
of Public Health Administration and Hospital Pharmacists (GSASA) promotes the use of the GSASA 
classification system [8] for clinical pharmacists to appropriately report their identified DRPs and proposed 
PIs. This system classifies DRPs in five categories: problem (5 subcategories), type of problem (2 
subcategories), cause of intervention (18 subcategories), intervention (11 subcategories), and outcome of 
intervention (5 subcategories). 
Such classification of DRPs and their corresponding intervention ensures that the services of clinical 
pharmacists are adequately documented, but fails to report their impact. Data on the relevance of PIs is 
necessary to publicise the value pharmacists add to health care [9]. There are three distinct approaches to 
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assess the relevance of PIs: 1) The evaluation of actual consequences of an unresolved DRP; 2) The evaluation 
of actual consequences of a resolved DRP by follow-up; or 3) The estimation of potential relevance of a PI or 
the estimation of possible risk of a DRP for the patient [10]. The assessment of actual clinical outcomes 
(approaches 1 and 2) is often hindered by difficulties in follow-up, lack of resources, or the determination of 
causality. The estimation of potential relevance of PIs (approach 3) does not suffer from these drawbacks, but 
is prone to issues on subjectivity, reliability, and validity. To address some of these issues, expert panels could 
be consulted to report on the potential relevance of the PIs being investigated [11-13], which is a resource 
intensive method only feasible in study settings. 
Vo et al. [10] identified and reviewed 46 tools that estimate the potential relevance of PIs. They concluded 
that the majority of tools primarily focus on the clinical aspect of PIs and fail to evaluate their potential 
relevance more comprehensively, such as when information to other health care professionals is provided. As 
stated, DRPs may be multidimensional, and the PIs provided to resolve them will follow this structure. Vo 
and colleagues developed a new tool named CLEO to estimate the potential relevance of PIs within its three 
dimensions CLinical, Economic, and Organisational. The clinical dimension focuses on impact related to the 
patient’s well-being from the patient’s perspective: Averted damages, improved quality of life, and improved 
adherence. The economic dimension assesses the immediate impact of the PI on the current costs of therapy 
from the institution’s perspective. The organisational dimension evaluates the impact on the process of care, 
focusing on the view of the health care professionals: reduced time expenditures, decreased work load, 
improved work place safety, and simplified collaborations. The French version of CLEO has since been 
validated within the hospital setting [14]. 
Aim of the study 
Our aims were 1) to translate the French version of CLEO into German (termed CLEOde); 2) to demonstrate 
feasibility in daily practice; 3) and to validate the German version. 
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Methods 
Translation 
We asked the original developers of CLEO for permission to translate their work. The translation into German 
was performed according to the ten steps of the ISPOR Principles of Good Practice for the Translation and 
Cultural Adaption Process for Patient-Reported Outcome Measures [15]. Two independent translators with 
knowledge of pharmaceutical terminology simultaneously translated the original French version with focus 
on equality of sense/analogous meaning. We merged the two translations into a single German version with 
the aid of one of the translators. Discrepancies were discussed in a reconciliation meeting to ensure that 
semantic and conceptual equivalence between source and target language versions was achieved. We sought 
the second translator’s approval for all changes made. Back-translation from German into French was done 
by a third translator unfamiliar with the original version with focus on equality of words. We sought agreement 
on the back-translated version from the developers of the original tool. The adapted target language version 
was sent to six native German-speaking and experienced clinical pharmacists, each two from Austria, 
Germany, and Switzerland for cognitive debriefing using a modified evaluation sheet of Breuer et al. [16]. 
We asked for their ratings (Likert scale; 1: poor, 6: very good) on each item of the tool with regard to 
comprehensiveness and linguistic style using an online questionnaire form (Flexiform© version 2.7.1g, IT-
services University of Basel). The threshold of acceptance was pre-defined to sufficient (4) for the standard 
deviations. All suggestions in the comments section were evaluated after categorisation into technical 
(orthographic, grammatical and stylistic remarks), conceptual (substantial discrepancies), and 
questions/uncertainties. We added a final back-translation as an 11th step to the ISPOR Principles of Good 
Practice for agreement with the original developers to possible changes due to feedback from the cognitive 
debriefing. 
Validation 
We validated the CLEOde version according to Fitzpatrick’s criteria [17] appropriateness, acceptability, 
feasibility, interpretability, precision, and reliability. We did not test for the remaining two criteria 
responsiveness and validity as the tool does not measure changes in health status and validity was already 
tested for the original French version. The validation process is visualised in Figure 1. 
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 Part 1: Translation 
 
Part 2: Validation  
Interpretability Appropriateness, 
Acceptability, 
Precision, Feasability 
Interrater 
reliability, test-
retest reliability 
Methods ISPOR Principles of 
Good Practice for 
the Translation and 
Cultural Adaption 
Process for Patient 
Reported Outcome 
Measures 
Performed pharmacists' 
interventions during 13 
days in three Swiss 
hospitals 
 Classification with GSASA 
 Evaluation with CLEOde 
User’s agreement 
― 10 clinical 
pharmacists 
― 19-items 
questionnaire 
― 7-point Likert scale 
 
 10 model cases 
 10 clinical 
pharmacists 
 Wash-out: 7 days 
Figure 1 Translation and validation process. 
 
Data collection and interpretability 
We asked for a convenience sample of three Swiss hospitals (capacities of 679, 337, and 290 beds) to collect 
performed PIs during routine clinical pharmacy services. All PIs were classified with the GSASA 
classification system [8] according to common practice in these hospitals. Additionally, the participating 
clinical pharmacists estimated the potential relevance of their PIs with CLEOde, which was integrated into 
their own electronic adaption of the GSASA classification system (either Microsoft® Excel® spreadsheet or 
Microsoft® Access® database). Training prior to data collection consisted of written instructions on the use of 
CLEOde and two instructional videos including general information and two model cases. To demonstrate 
interpretability and future applications, we performed descriptive statistics on the data set obtained. 
Appropriateness, acceptability, feasibility, and precision 
In a second step of the validation, we tested for appropriateness, acceptability, feasibility, and precision of 
CLEOde with an adapted questionnaire of AbuRuz et al. [18], which has been used in earlier studies [8, 19]. 
The questionnaire was sent as an online form to the clinical pharmacists who had been involved in the 13-day 
data collection. The questionnaire consisted of 19 items with a 7-point Likert scale to assess the extent of their 
agreement (1: entirely disagree, 4: neutral, 7: entirely agree). 
Reliability 
The clinical pharmacists previously involved in data collection classified 10 model cases and estimated the 
potential relevance of the PIs described with CLEOde (see Box 1 for an example). The model cases consisted 
of five validated cases from literature [20] which have been used previously [8], and five descriptive cases 
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from the validation studies of the original French version of CLEO. Drug names and therapy costs were 
adapted to the local situation. All clinical pharmacists received the model cases in a randomized order. We 
distributed the link to an online questionnaire form with restricted access via e-mail for data collection 
(Flexiform©). There was a wash-out phase of seven days prior to the test-retest reliability evaluation. 
«Mrs. A., 81 years, 167 cm, 59 kg is hospitalised because of her derailed Diabetes mellitus 
type 2. Due to an episode of depression, she is treated with Seropram (Citalopram) 20 mg 
tablets 0-0-1 (Fr. 1.10 / day). Since her arrival, Mrs. A. complains about insomnia. You ask 
her why the drug was prescribed to be taken in the evening. There was no plausible reason 
for the evening dose. Therefore, you propose a morning dose. Your intervention will be 
implemented.» 
Box 1 Example of a model case used to assess interrater and test-retest reliability. 
 
We used a two-way mixed, agreement, single-measures intra-class correlation (ICCA, 1) to assess the inter-
rater reliability of each dimension [21]. For reasons of comparability to other studies, we additionally 
calculated weighted (squared) Kappa values (κw) [22] of each rater pair, reporting the arithmetic mean as 
proposed for multiple rater [23]. To assess test-retest reliability, we compared both ratings of each rater 
individually and calculated ICCA, 1 means (I̅C̅C̅A, 1) and Spearman’s rank correlation coefficient means (ρ̅) 
[24]. We performed all calculations using RStudio [25] (version 0.99.903) running R version 3.3.1 [26] with 
the package irr [27] (version 0.84). We interpreted the ICCA, 1 and I̅C̅C̅A, 1 results according to Cicchetti [28]: 
ICCA, 1 < .40 as poor, .40 to .59 as fair, .60 to .74 as good, and .75 to 1.0 as excellent. κw were interpreted 
according to Landis and Koch [29]: κw .00 to .20 as slight agreement, .21 to .40 as fair agreement, .41 to .60 
as moderate agreement, .61 to .80 as substantial agreement, and .81 to 1.00 as almost perfect or perfect 
agreement. ρ̅ values were interpreted as follows: ρ̅ = .1 as weak, .3 as intermediate, and .5 as strong. 
Ethics 
According to the requirements of the Swiss federal law on human research this study did not need an ethics 
approval. 
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Results 
Translation 
We received permission from the original developers to translate the CLEO tool into German. The translation 
process was completed within 10 weeks and produced 10 different German versions. The two initial 
independent forward translations had 20 linguistic discrepancies between each other which were resolved at 
the reconciliation meeting with one of the translators. We received approval for the merged version by the 
second translator. The original developers identified two discrepancies in our back-translated version when 
compared with their original version. Additionally, the developers proposed the use a slightly modified version 
of the definition of the organisational dimension, which was introduced into the original tool after the start of 
our translation process. We were able to address the discrepancies and to introduce the new definition as part 
of the back-translation review process. For the cognitive debriefing, we received responses from five of six 
clinical pharmacy experts (Austria: 1, Germany: 2, Switzerland: 2). The means of each of the 21 items were 
at least sufficient (4) for both, linguistic style and comprehensiveness. The standard deviations of 11 items 
exceeded our threshold of sufficient (4) in comprehensiveness or linguistic style. We reviewed all 11 items 
and changed 12 words according to the suggestions in the comments section of the questionnaire. The changes 
focused on the cultural adaption process (e.g., “Medikamententreue” was changed to “Therapietreue 
[Adhärenz]”). The five clinical pharmacists provided 60 suggestions, which were categorised into technical 
(n = 23), conceptual (n = 19), and questions/uncertainties (n = 18). Proofreading of the final version resulted 
in one last change of wording in the organisational dimension. Our final back-translated version was accepted 
by the original developers. The finalised German version CLEOde is shown in Figure 2. 
Projects
42
Drug-Related Problems
Page 9 of 18 
 
Figure 2 CLEOde 
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Validation 
Data collection, interpretability 
CLEOde was used for 13 working days within routine clinical pharmacy practice in April and May 2016 in 
three Swiss hospitals. A total of 324 PIs were performed by ten clinical pharmacists. They were classified 
with the GSASA classification tool and evaluated with CLEOde. Twenty-one PIs (6.5%) were evaluated as 
‘not determined’ in all three dimensions. Frequencies of all PI evaluations by CLEOde are presented in Figure 
3. Most PIs (n = 138, 42.7%) were evaluated to have a minor clinical relevance (starting/restarting or stopping 
a therapy, 37.0%; dose adjustment, 21.7%; optimisation of dosing modalities, 15.2%; 
substitution/replacement, 9.4%; others, 16.7%), whereas 9.9% were evaluated to have a major or vital clinical 
relevance. PIs which were evaluated to decrease costs (n = 116, 36.0%) were classified as stopping a therapy 
(44.0%), dose adjustment (25.9%), substitution/replacement (10.3%), optimisation of dosing modalities 
(7.8%), or others (12.1%). Almost half of the PIs that were evaluated to increase costs (n = 66, 20.5%) were 
starting/restarting a therapy (48.5%), followed by therapy monitoring (15.0%), dose adjustment (12.2 %), 
information to health care professionals (10.6%), and others (13.6%). The PIs were judged to have a positive 
(39.4%), a negative (16.0%) or no relevance (35.7%) within the organisational dimension of CLEOde. The 
underlying interventions were present in all three levels of the organisational dimension. Examples of PIs for 
all possible evaluations with CLEOde are presented in Table 1. 
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Figure 3 Estimated potential relevance of pharmacists‘ interventions during 13 days in three Swiss German hospitals, sorted according to the 
dimensions of CLEOde (n = 324). 
 
Table 1 Examples of PIs documented with the GSASA classification and evaluated with CLEOde. 
Description GSASA 
Problem 
GSASA Reason GSASA 
Intervention 
CLEOde Clinical CLEOde 
Economic 
CLEOde 
Organisational 
Anticoagulation is currently paused 
because patient is awaiting pericard 
puction. Preventive therapy with heparin 
is recommended for short hospital leave 
Untreated 
indication 
Treatment not 
received 
Therapy 
started/restarted 
Major Increase of cost Favourable 
Information to the health care team: 
SGLT2-inhibitors may cause urinary tract 
infections 
Safety of 
treatment 
Adverse effect Information to 
care givers 
Null Null Favourable 
Amlodipin 5 mg twice a day replaced 
with 10 mg once a day 
Patient 
dissatisfaction 
Inappropriate 
timing or 
frequency of 
administration 
Optimisation of 
administration 
Minor Decrease of cost Favourable 
Taking of thyroid hormone changed to 30 
minutes before a meal 
Treatment 
effectiveness 
Inappropriate 
timing or 
frequency of 
administration 
Optimisation of 
administration 
Medium Null Unfavourable 
Treatment of atrial fibrilation has been 
forgotten when the patient changed wards 
Untreated 
indication 
Treatment not 
received 
Therapy 
started/restarted 
Vital Increase of cost Favourable 
Metamizol prescribed twice as reserve in 
case of pain 
Safety of 
treatment 
Drug not 
indicated or 
duplication 
Clarification in 
the case notes 
Not determined Not determined Not determined 
Pharmacist proposed alternative first-line 
treatment for hypertension (currently: 
Beta-blocker). Patient informed care 
providers about his history of tachycardia 
Safety of 
treatment 
No concordance 
with guidelines 
or 
contraindication 
Substitution Harmful Null Null 
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Appropriateness, acceptability, feasibility, and precision 
All ten clinical pharmacists completed our 19-items questionnaire on user’s agreement. CLEOde was seen as 
appropriate (mean = 5.45; SD = 0.76), acceptable (4.43; 1.28), feasible (5.27; 1.44), and precise (5.90; 1.16) 
to evaluate the potential relevance of PIs. One item received a mean rating of below neutral (3.70; 1.3): Six 
out of ten clinical pharmacists stated that they had issues to estimate the potential relevance of PIs with 
CLEOde. The results are reported in Figure 4. Five clinical pharmacists reported an evaluation time of ‘less 
than 30 seconds’ per PI; none reported an evaluation time of ‘more than one minute’. 
 
Figure 4 User’s agreement on appropriateness, acceptability, precision, and feasibility of the tool. 7-point Likert scale; 1: entirely disagree, 4: 
neutral, 7: entirely agree (mean ± SD). 
Reliability 
Each of the ten clinical pharmacists classified all ten model cases and estimated the potential relevance of the 
PIs twice with a washout phase of seven days in between. Clinical experience of the participating pharmacists 
ranged from < 6 months (n = 3) to > 5 years (n = 1); the median was one year of clinical experience. 
The interrater reliability for CLEOde was good for the dimensions clinical (intra-class correlation ICCA, 1 = 
.63) and economic (ICCA, 1 = .65) and poor for organisational (ICCA, 1 = .30). Mean weighted Kappa values 
obtained were: Substantial for the dimensions clinical (mean weighted Kappa κ̅w = .62) and economic (κ̅w = 
.61), fair for organisational (κ̅w = .23). Test-retest correlation was strong for all three dimensions (clinical: 
mean Spearman’s rank correlation coefficient ρ̅ = .77; economic: ρ̅ = .85; organisational: ρ ̅= .58), yielding in 
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excellent test-retest reliability for the dimensions clinical (mean intra-class correlation I̅C̅C̅A, 1 = .76) and 
economic (I̅C̅C̅A, 1 = .85) and fair for organisational (I̅C̅C̅A, 1 = .53). 
Discussion 
We successfully translated the French evaluation system for PIs CLEO into German by following the ten steps 
of the ISPOR Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-
Reported Outcomes Measurement. In a time period of 13 days we collected 324 PIs routinely performed by 
10 clinical pharmacists at three Swiss hospitals. The participating pharmacists classified their PIs with the 
GSASA classification system and estimated the potential relevance with CLEOde. 
Data collection, interpretability 
The 324 PIs were estimated to mainly (42.7%) have a minor clinical relevance. This low level of clinical 
relevance describes improvements in humanistic outcomes (better knowledge, satisfaction, adherence, quality 
of life) or avoided potential physical or psychological damages which would not require additional 
surveillance or treatments. The clinical pharmacists may have evaluated their PI as minor instead of the next 
higher level (i.e. moderate) because the (laboratory) measurements were routinely planned and easily feasible 
in the hospital setting anyway, skewing the data on clinical relevance. The levels ‘moderate’, ‘major’ and 
‘vital’ all describe the avoidance of potential damages, which at least need an additional test or treatment to 
be resolved, i.e., they describe actions needed to be taken to prevent patient harm. Levels moderate to vital 
combined amounted to 26.3% of all 324 evaluated PIs. Dean et al. [13] collected data on 538 prescribing 
errors identified by clinical pharmacists within four weeks, and similarly detected 26% (n=142) potentially 
serious errors (“likely to cause patient harm”) rated by one researcher and one clinical pharmacologist. 
The allocation of PIs that were evaluated to increase (20.5%) or decrease (36.0%) the costs corresponds to the 
categorisation of the proposed PI: Approximately 76% of the PIs evaluated as cost-raising were categorised 
as starts or restarts of therapies, dose increases, or recommended therapy monitoring, all of which generate 
immediate costs; Approximately 80% of the PIs evaluated as cost-lowering were categorised as termination 
of therapies, dose decreases, or substitutions, all of which decrease the immediate costs. This congruence of 
evaluation and categorisation of PIs suggests validity of the economic dimension. Furthermore, the proportion 
of PIs evaluated to decrease the costs (36.0%) is consistent with a peer-review team’s evaluation on the 
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economic relevance of 1027 PIs who indicated the interventions as improvement of cost in 41.7% of the cases 
[30]. In contrast to CLEO, they also took avoidable costs due to toxic effects and reduction of days spent in 
hospital as savings into account. With the use of CLEOde in common clinical practice, regular reviewing of 
the cost generating interventions might help to identify potentially unnecessary recommendations and save 
costs. 
The evaluation of the organisational impact was inconsistent: The ten clinical pharmacists rated the same 
interventions (e.g. ‘starting/restarting a therapy’, ‘terminating a therapy’’ substitution/replacement’) as having 
a positive, having a negative, or having no impact on organisational aspects, thus preventing a clear 
interpretation of the findings. The evaluation of the organisational impact hence seems heavily dependent on 
the point of view: The same intervention may cause additional work load for nurses, but improves the indicator 
‘workplace safety’. The current version of CLEO leaves the decision up to the rater on which indicators they 
focus to estimate the organisational impact of their PI. 
In our study, only 21 PIs (6.5%) were evaluated as ‘not determined’ in all three dimensions, confirming 
appropriateness of CLEOde. As these 21 PIs were heterogeneous in their underlying DRP, we were not able 
to define a certain intervention as not determinable by CLEOde. 
Appropriateness, acceptability, feasibility, and precision 
Clinical pharmacists familiar with the tool rated CLEOde as appropriate, acceptable, feasible, and precise. In 
addition, they reported ‘less than one minute’ needed for the estimation of the potential relevance of one PI. 
As time expenditure is an essential element for the acceptance of a new tool, this result removes a hurdle for 
future implementation. However, the standard deviations on individual questions in the evaluation exceeding 
4 on the Likert scale (see Figure 4) highlight issues that need to be addressed prior to implementation: These 
evaluation issues, especially within the organisational dimension, were reported by the users in the comments 
section and affected user satisfaction. Each clinical pharmacy team may discuss their most common PIs and 
agree on a uniform evaluation for all three dimensions. With guidance established by using typical examples 
from daily practice, a greater degree of consistency could be achieved. Some clinical pharmacists also stated 
that the training video with two sample cases was insufficient as preparation. We suggest an intensified 
training process addressing the identified issues.  
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Reliability 
CLEOde achieved good (ICCA, 1) and substantial (κ̅w) interrater and excellent (I̅C̅C̅A, 1) test-retest reliability for 
the dimensions clinical and economic in a sample of 10 selected clinical pharmacists, working in three 
different hospitals and having different levels of clinical experience. The obtained interrater reliabilities 
(weighted Kappa) are in line with the results of Vo and colleagues: They reported moderate (clinical), 
substantial (economic) and fair (organisational) interrater reliability between a sample of pharmacists working 
at a centralised chemotherapy preparation unit and peer reviewing pharmacists [14]. 
The interrater reliability can only be compared to few other tools and only for the clinical dimension of CLEOde 
because the majority of published tools primarily focus on the clinical aspect of PIs [10]. Interrater reliability 
data from specifically tools designed for the estimation of potential relevance of a PI are sparse. Rupp reported 
a Kappa (κ) value of .68 for a four item questionnaire which assesses the potential for patient harm [31]. Chua 
and colleagues used Stubbs' four categories of clinical significance [32] in their study and calculated a Kappa 
(κ) value of .73 [33]. Similar to the clinical dimension of CLEOde, both of these values may be interpreted as 
substantial according to Landis and Koch [29]. A high degree of reliability is a key factor when considering a 
specific tool for the estimation of the potential relevance of a PI [10]. This aim is met for CLEO and CLEOde 
for the clinical and economic dimensions, similar to the above mentioned tools. 
Similar to the interpretability and user’s agreement results, we identified issues in the reliability of the 
organisational relevance evaluation: This dimension achieved poor (ICCA, 1) and fair (κ̅w) interrater and fair 
(I̅C̅C̅A, 1) test-retest reliability. These issues have already been identified for the French version of CLEO: Vo 
et al. [14] reported fair interrater reliability. Our results again highlight the necessity to facilitate the evaluation 
in this dimension by reducing the number of indicators to choose from and by intensifying the training process, 
as proposed above. It may be argued that in contrast to the other two dimensions, clinical pharmacists might 
not be familiar with judging their PIs from the perspective of the process of care. When proposing a PI, they 
may not account for/focus on the impact on time expenditure, work load, work place safety, and collaborations. 
Combined with the many organisational indicators to choose from in this dimension, the evaluation of the 
organisational impact with CLEO becomes difficult. 
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Clinical implications 
We defined PIs as discrete activities by pharmacists related to patient care. These activities and their 
underlying causes should be documented for the development of pharmaceutical care practice and for future 
research [34]. CLEOde is a reliable and user-friendly approach to the estimation of the potential relevance of 
PIs whilst respecting the multidimensionality and diversity of the service. With less than one minute per PI 
evaluation, CLEOde is suitable for implementation in daily practice. Evaluated PIs will help in generating and 
ameliorating clinical services, decreasing costs, identifying current issues in medication safety, and portraying 
the relevance of clinical pharmacy services. 
Strengths and limitations 
The strengths of the work presented here lie in the structured methodological approach of the translation 
process and the consecutive validation of the translated version: We minimised the risk of mistranslating or 
inserting our own interpretations by closely following the steps of the ISPOR Principles [15]. Cognitive 
debriefing with native speaking clinical pharmacy experts from all three German speaking countries ensures 
comprehensibility and correct linguistic style for the targeted users. We tested for appropriateness, 
acceptability, feasibility, interpretability, precision, and reliability, covering all criteria which might be 
influenced by the quality of a translation. Each of the tests presented its own value by either confirming 
previously identified issues or highlighting new aspects to consider. Simultaneously we were able to 
demonstrate feasibility for implementation and possibilities for evaluation in daily routine clinical pharmacy 
services. 
One limitation of this study is that only ten clinical pharmacists were involved in the validation process of 
CLEOde, of which five had a clinical working experience of less than one year. This imposes selection bias 
that potentially affected our data collection and our assessment of Fitzpatrick's criteria. However, the 
composition of clinical pharmacists represents the current situation in the involved hospitals, i.e., Junior 
clinical pharmacists are responsible for the documentation of PIs which were previously discussed with their 
experienced supervisors. 
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Conclusion 
We present CLEOde as a correctly translated and culturally adapted tool, validated with regard to reported 
acceptability, appropriateness, feasibility, and precision, as well as interpretability and reliability. CLEOde is 
a promising tool for both, research and practice, which may in combination with existing classification systems 
for drug-related problems add qualitative value to quantitative information on PIs. With less than one minute 
per evaluated PI, CLEOde enables quick grading of data collection on interventions and allows reviewing 
pharmacy services. 
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II. Drug Associated Risk tool –  Development and validation of a self-As-
sessment Questionnaire to screen for hospitalised Patients at Risk for 
Drug-Related Problems
In this joint first-authorship article we describe the development of the DART from 
items deemed to be associated with a higher risk of DRPs into a patient-completed 
questionnaire. The questionnaire was assessed by Dr. Carole Kaufmann regarding fea-
sibility, acceptability, and the ability of the patients to reproduce medical information 
in reference to medical charts.
Items with an unsatisfactory performance regarding patient understanding were re-wor-
ded as part of this thesis. The revised items included disease descriptions from Swiss 
patient information leaflets. These patient information leaflets are contained in the of-
ficial packages of the medicines and are bound by Swiss legal requirements concer-
ning readability and understandability, as they directly address the patients. This appro-
ach ensured the use of wording that patients should be most familiar with. The thesis 
re-checked the ability of the patients to reproduce the presence of a certain disease in 
reference to their medical charts, this time focusing on patients presenting with one or 
more of the re-worded diseases.
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Research
AbstrACt
Introduction Identifying patients with a high risk for drug-
related problems (DRPs) might optimise the allocation of 
targeted pharmaceutical care during the hospital stay and 
on discharge.
Objective To develop a self-assessment screening tool 
to identify patients at risk for DRPs and validate the tool 
regarding feasibility, acceptability and the reliability of the 
patients’ answers.
Design Prospective validation study.
setting Two mid-sized hospitals (300–400 beds).
Participants 195 patients, exclusion criteria: under 18 
years old, patients with a health status not allowing a 
meaningful communication (eg, delirium, acute psychosis, 
advanced dementia, aphasia, clouded consciousness 
state), palliative or terminally ill patients.
Methods Twenty-seven risk factors for the development 
of DRPs, identified in a previous study, provided the basis 
of the self-assessment questionnaire, the Drug-Associated 
Risk Tool (DART). Consenting patients filled in DART, and 
we compared their answers with objective patient data 
from medical records and laboratory data.
results One hundred and sixty-four patients filled in DART 
V.1.0 in an average time of 7 min. After a first validation, we 
identified statements with a low sensitivity and revised the 
wording of the questions related to heart insufficiency, renal 
impairment or liver impairment. The revised DART (V.2.0) 
was validated in 31 patients presenting heart insufficiency, 
renal impairment or liver impairment as comorbidity and 
reached an average specificity of 88% (range 27–100) and 
an average sensitivity of 67% (range 21–100).
Conclusions DART showed a satisfying feasibility and 
reliability. The specificity of the statements was mostly 
high. The sensitivity varied and was higher in statements 
concerning diseases that require regular disease control 
and attention to self-care and drug management. Asking 
patients about their conditions, medications and related 
problems can facilitate getting a first, broad picture of the 
risk for DRPs and possible pharmaceutical needs.
IntrODuCtIOn 
Drug-related problems (DRPs) are defined 
as an event or circumstance involving drug 
therapy that actually or potentially interferes 
with desired health outcomes.1 The term 
‘DRPs’ has mostly taken hold in European 
countries where English is not the native 
language, while pharmacists in the USA tend 
to use the term ‘medicine-related problems’ 
or ‘drug-therapy problems’ instead of DRPs.2 
DRPs are a frequent issue among hospital-
ised patients, leading to patient harm and 
increased healthcare costs.3 Many unplanned 
admissions are medication related4 and a 
considerable number could be prevented.5 
Complexity and often poorly designed 
processes foster the development of DRPs 
inside and outside of the hospital. Unsurpris-
ingly, a remarkable number of patients expe-
rience adverse drug events after discharge.6 
A study from Switzerland showed that 36% 
of all discharge prescriptions contained tech-
nical DRPs like unreadable prescriptions, 
missing drug form and package size, and 
strengths and limitations of this study
 ► The Drug-Associated Risk Tool (DART) is a patient 
self-assessment risk screening tool, based on a 
selection of risk factors for the development of drug-
related problems  (DRPs), previously identified in a 
combination of literature search and the opinion of a 
multidisciplinary expert panel.
 ► DART should enable clinical pharmacists to identify 
patients at risk for DRPs and target their clinical 
pharmacy activities to patients who benefit the most 
thereof.
 ► A first validation of DART showed good acceptability 
and feasibility and a satisfactory reliability of 
patient’s answers.
 ► The low prevalence of some risk factors hinders 
clear conclusions about the validity of the respective 
statements in DART.
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19.6% showed clinical DRPs like drug–drug interactions, 
inappropriate drug choice and wrong dosing.7
Clinical pharmacy services in hospitals have been shown 
to increase patient safety by reducing medication errors 
and adverse drug events, as well as adverse drug reactions. 
They increase medication appropriateness, improve 
patients’ knowledge about drug therapy and adherence, 
and finally reduce the length of hospital stays.8 Limited 
resources and capacities force clinical pharmacists to 
target their clinical activities to those patients who are most 
likely to benefit therefrom, or in other words, to those 
patients who are at the highest risk of experiencing DRPs, 
and in consequence, adverse drug events. An effective 
screening tool to identify high-risk patients might prove 
a successful approach. The literature provides risk factors 
for the development of DRPs such as polypharmacy, renal 
impairment or the use of non-steroidal anti-inflammatory 
drugs .4 9 10 The literature is replete with assessment tools, 
which focus on various combinations of risk factors for 
DRPs. They may be created either for a specific group 
of patients (eg, those with renal impairment,11 geriatric 
patients,12–16 patients with prescribed medication for 
cardiovascular disease17) or for a special environment 
(eg, in an emergency department,18 primary care19 20). 
The tools may also need special resources to be applied in 
the hospital (eg, computerised patient files21). Screening 
tools often have the disadvantage of being time and 
personnel intensive; some are hardly applicable without 
electronic data. Many have not been validated.22
Therefore, we decided to develop a new risk assessment 
tool. The ‘Drug-Associated Risk Tool (DART)’ should 
serve as a reliable, easy-to-use screening instrument to 
detect patients at risk for DRPs. Developed as a self-assess-
ment questionnaire for the patients, DART should save 
personnel resources and time.
In a previous study,23 we identified 27 risk factors for 
the development of DRPs, which provided the basis of the 
self-assessment questionnaire. Risk factors identified in 
relevant literature were supplemented with results from 
qualitative research methods: We conducted a Nominal 
Group Technique with practitioners to ensure relevance 
in everyday practice and to identify risk factors possibly 
neglected in quantitative research methods.
The aim of this study was to create a self-assessment ques-
tionnaire out of the identified risk factors and to validate 
the questionnaire regarding feasibility, acceptability and 
the reliability of the patients’ answers by comparing them 
to reference information retrieved from medical charts.
MethODs
Development of the questionnaire
Figure 1 shows the development process of the 
questionnaire.
Twenty-seven risk factors for the development of DRPs, 
identified in a previous study,23 provided the basis of the 
self-assessment questionnaire, DART. With the intention 
of creating a questionnaire for patients, we formulated a 
statement for each risk factor that could be answered by 
medical laypersons (cf. table 1).
We covered the risk factor ‘non-adherence’ with an 
adapted question retrieved from the adherence risk 
prediction tool of Krousel-Wood,24 a validated self-re-
port 4-item questionnaire used to measure adherence. 
A validated self-report four-item questionnaire used to 
measure adherence. Risk factors with regard to patients’ 
concerns about medicines were covered by using five 
questions from the Beliefs about Medicines Question-
naire (BMQ),25 a questionnaire that comprises two five-
item scales assessing patients’ opinions about the necessity 
of prescribed medication for controlling their illness and 
their concerns about the potential adverse consequences 
of taking it.
Amateur test
Prior to the study, we conducted an amateur test and 
asked 10 medical laypersons from the personal environ-
ment of the authors (no patients) to fill out DART. We 
did not provide any support during its completion. We 
asked the participants for their judgement concerning 
the comprehensibility of the statements and edited issues 
that arose within the statements. In cases of ambiguity, 
the study investigators (CPK, MLL, NM, DS) discussed 
and clarified the unclear statements.
Validation of the questionnaire
Study design and setting
For the prospective validation study, we recruited patients 
in two mid-sized hospitals with 300–400 beds each. 
We recruited on orthopaedic, geriatric and internal 
Figure 1 Development process of the questionnaire. BMQ, Beliefs about Medicines Questionnaire; DART, Drug-Associated 
Risk Tool; DRP, drug-related problem; MMT, Micro-Mental Test; NGT, nominal group technique.
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medicine wards in order to validate the questionnaire in 
very diverse patients.
Patient selection
Eligibility criteria were stationary hospitalisation, age over 
18 years and ability to speak German in order to commu-
nicate with the investigator. We excluded patients with 
a health status not allowing a meaningful communica-
tion (eg, delirium, acute psychosis, advanced dementia, 
aphasia, clouded consciousness state) as well as palliative 
or terminally ill patients. We included patients suffering 
from mild dementia in case a meaningful communica-
tion was possible.
Study flow
During a predefined period, the investigators (CPK, DS, 
NM) and two additional trained clinical pharmacists met 
with every hospitalised patient on the included wards 
who met the inclusion criteria. They informed each 
patient orally and with an informational letter about 
the study. After giving informed consent, the patient 
received DART and filled in the questionnaire inde-
pendently, that is, the investigator gave no assistance in 
filling in the questionnaire. If a patient had impaired 
manual skills, the investigator was only allowed to assist 
with writing. When finished, the investigator asked the 
patient five questions about the structure and content 
Table 1 Risk factors, their corresponding statement in the Drug-Associated Risk Tool (DART) and criteria to evaluate 
correlation between the answers in DART and objective data
Risk factor
Corresponding 
statement 
in DART Acceptance criteria for correlation
Language issues (eg, migration background) 1 No comparison with objective data
Polymorbidity: divided in subcategories
  Renal impairment 2 Diagnosis of renal impairment and/or GFR <60 mL/min for at 
least 3 months33
  Hepatic impairment 3 Diagnosis of hepatic impairment and/or chronic hepatitis 
and/or hepatic cirrhosis
  Chronic cardiac disease 4 Diagnosis of chronic cardiac disease (heart failure, coronary 
heart disease, arrhythmias)
  Chronic respiratory disease 5 Diagnosis of asthma or chronic obstructive pulmonary 
disease
  Diabetes 6 Diagnosis of diabetes mellitus type 1 or 2 or diabetes 
caused by steroids
  Cognitive impairment/dementia 7 Diagnosis of cognitive impairment or dementia or 25/30 
points in the Mini-Mental State Examination34 or <14/20 
points in the Micro-Mental Test26
The patient takes medication(s) besides the prescribed 
ones (eg, over-the-counter, vitamin supplementation)
8 No comparison with objective data possible
Polypharmacy 9 The patient takes more than five medicines when admitted 
to the hospital
Antiepileptic, anticoagulants, non-steroidal anti-
inflammatory drugs (NSAIDs), combination of NSAIDs 
and anticoagulants, digoxin, corticosteroids, diuretics, 
tricyclic antidepressants, anticholinergic drugs, 
benzodiazepines, opiates/opioids, oral antidiabetics/
insulin, medication with a narrow therapeutic range
10 The drug is present on patients’ medication list at hospital 
admission
Non-adherence 11 No comparison with objective data24
Earlier experience of adverse drug reactions 12–16 Negative total score in both—the statements 12–16 and the 
Beliefs about Medicines Questionnaire (BMQ)25 or a positive 
total score in both—the statements 12–16 and the BMQ25
Missing information, partial knowledge of the patient, 
the patient does not understand the goal of the 
therapy
17 No comparison with objective data
Impaired manual skills—causing handling difficulties 18 No comparison with objective data
Visual impairment/impaired eyesight 18 No comparison with objective data
Difficult to handle medication 19 Medicines for parenteral, transdermal or inhalative 
application at time of hospital admission
GFR, glomerular filtration rate. 
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of DART in order to see if the questionnaire was easy 
to understand and not too intrusive. Furthermore, the 
investigator interviewed the patient in detail with regard 
to the patient’s attitude towards health and medicine. 
Validated questionnaires were used to investigate 
concerns and beliefs towards medicines (BMQ25) and 
mental health (Micro-Mental Test (MMT)26). Participa-
tion in the study was voluntary, the investigators offered 
no inducement or payment for subjects to participate. 
The patient was allowed to terminate the interview at 
any time without stating a reason.
Pretest
With a first draft of DART, we conducted a pretest with 
five inpatients. The procedure followed the same study 
flow we determined for the validation study (see the Study 
flow section). This pretest with inpatients served as an 
opportunity to correct any remaining issues of compre-
hensibility or ambiguity.
Data collection and analysis
All data were processed anonymously. In order to ensure 
traceability, we assigned each patient a unique identi-
fying number coding for the particular hospital/ward/
investigator/patient.
We used IBM SPSS Statistics Software, V.22 for data 
analysis. We evaluated sensitivity, specificity and prev-
alence of each question of DART by comparing the 
subjective answers in DART with objective data from 
medical records (diagnosis, laboratory values and medi-
cines at entry) and answers from the BMQ25 and the 
MMT.26 Acceptance criteria for correlation of subjective 
and objective data were defined a priori (cf. table 1). In 
addition we calculated the negative and positive predic-
tive values for each question in DART. Missing data were 
excluded from analysis.
Revision of statements
Statements with an unsatisfactory performance within 
reliability testing of the questionnaire (ie, sensi-
tivity <0.5 and possible poor patient understanding) 
were revised in their wording. In order to find a termi-
nology patients may be familiar with, we used official 
patient information leaflets (PILs) of selected drugs, 
which are either contraindicated or in need of a dose 
adaptation in presence of the risk factor assessed by 
the statement under revision. These PILs are contained 
in the official packages of the medicines, are created 
by the manufacturer and are bound to the Swiss legal 
requirements concerning readability and understand-
ability. We extracted and analysed the wording from 
these PILs which is used to describe the risk factor to 
patients and phrased new statements. We retested the 
new statements with the same study flow. In this cycle, 
we only recruited patients presenting one or more 
of the risk factors assessed by the statements under 
revision.
results
Development of the questionnaire
The first page of DART consists of items concerning 
the presence of diseases and high-risk medicines. The 
second page includes items reflecting the patient’s atti-
tude towards his/her medicines and statements about 
medication management and handling difficulties. The 
10 non-patient participants from the amateur test had no 
difficulties completing the questionnaire, and only minor 
adjustments in wording were necessary.
Validation of the questionnaire
The pretest with five inpatients did not reveal any addi-
tional issues.
During ward visits, we approached 208 eligible patients. 
One hundred and sixty-five (79.3%) consented to partic-
ipate, and we were able to complete 164 patient inter-
views (cf. figure 2). The median age was 74 years (range 
20–95) and 49% of participants were women. The mean 
number of drugs per patient at time of admission was 4 
and ranged from 0 to 19. Fifty-six patients (34%) came 
from the geriatric ward with a mean age of 81 (40–95) 
years and a mean number of drugs of 5 (0–19). Sixty-eight 
patients (42%) were from the medical ward with a mean 
age of 65 (20–91) years and a mean number of drugs of 3 
(0–15) and 40 patients (24%) were orthopaedic patients 
with a median age of 67.5 (20–91) years and a mean 
number of drugs of 4 (0–10).
After 51 interviews, we reduced the number of ques-
tions. We eliminated the questions about feasibility and 
understandability of DART, because we had enough 
meaningful data with a clear conclusion. For the same 
reason, we stopped answering the BMQ questionnaire 
that we used for comparison with the answers from DART. 
This allowed us to shorten the duration of the patient 
interview.
On average, it took patients 7 min to complete DART by 
themselves. None of the patients experienced any of the 
statements as bothersome or too intrusive on his privacy. 
Ten out of 51 patients (19.6%) showed some difficul-
ties in completing the questionnaire, 7 (13.7%) did not 
understand the wording of a statement and in three cases 
we had no clear statements what the difficulties were.
DART questions of the version V.1.0 reached speci-
ficity values from 27% to 100% and sensitivity values 
from 21% to 100%. Positive predictive values varied 
between 26% and 100% and negative predictive value 
varied between 20% and 100%. Regarding the intake 
of over-the-counter (OTC) drugs, 85 patients (35%) 
affirmed, 103 patients (63%) denied and 3 patients 
(2%) gave no answer. On the question ‘I feel well 
informed about my medication’, 85 patients (52%) 
answered with ‘strongly agree’, 45 (27%) agreed, 
18 (11%) disagreed, 3 (2%) strongly disagreed and 
13 patients (8%) gave no answer. Ten patients (6%) 
named difficulties with tablet splitting, 17 (10%) 
mentioned swallowing difficulties, 5 patients (3%) 
affirmed difficulties with visual recognition and 122 
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(74%) stated no such difficulties. Fifteen answers 
(9%) were missing. One hundred and twenty-five 
patients (74%) managed their medication by them-
selves, 12 (7%) had a relative or a friend who did the 
management, 15 patients (9%) named a home care 
person as their medication manager and 16 patients 
(10%) gave no answer. Sixteen patients (10%) indi-
cated the use of an inhaler, 15 (9%) the use of a trans-
dermal therapeutic system and 18 (12%) the use of 
a syringe for self-injection. One hundred and one 
patients (62%) did not use any of these application 
forms and 20 (12%) gave no answer.
Figure 2 Flow chart of the validation study. DART, Drug-Associated Risk Tool.
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revision of statements
Initially, statements about heart insufficiency, renal 
impairment and liver impairment showed low sensitivity 
(0.43, 0.28 and 0.33, respectively) due to possibly poor 
patient understanding. The PILs of in total 134 medi-
cines, either contraindicated or in need of dose adapta-
tion in presence of heart insufficiency, renal impairment 
or liver impairment, were used to identify expressions 
most frequently used to describe these conditions to 
patients. For DART V.2.0, the statements were changed 
accordingly: ‘I am suffering from a chronic renal disease’ 
was changed to ‘I have a restricted kidney function/
kidney dysfunction/kidney disease’, ‘I am suffering 
from a chronic cardiac disease’ was changed to ‘I have a 
heart weakness/heart performance weakness’ and ‘I am 
suffering from a chronic hepatic disease’ was changed 
to ‘I have a liver disease/liver dysfunction’ (cf. figure 3). 
These expressions were directly translated from German 
to English and may be written differently in English-
speaking countries.
A total of 31 patients (median age: 82 years (range 
59–96 years), 61% women), each presenting heart insuf-
ficiency, renal impairment or liver impairment as comor-
bidity, filled out the revised questionnaire (cf. figure 2).
After the second comparison to medical records, the 
sensitivity of the reworded item ‘heart failure’ improved 
from 0.43 to 0.80, while the specificity dropped from 
0.96 to 0.60. Similarly, the sensitivity for ‘renal insuffi-
ciency’ ameliorated from 0.28 to 0.38, while the spec-
ificity was lowered from 0.98 to 0.80. The small sample 
size combined with the low prevalence of liver insuffi-
ciency prohibited the evaluation of the refined statement 
covering liver insufficiency. With these modifications 
DART V.2.0 reached an overall sensitivity of 67% with an 
overall specificity of 88% (cf. table 2).
DIsCussIOn
We intended to create an easy-to-use and reliable screening 
tool to identify patients who are at increased risk for 
DRPs. The application of such a tool has the potential to 
support the healthcare professionals in choosing patients 
who benefit the most of intensified pharmaceutical care. 
A patient self-assessment tool may save time and resources 
of caregivers, but also allows the better involvement of 
the patient. Assessing DRPs with such involvement of the 
patient may reveal more issues.27
Figure 3 Drug-Associated Risk Tool (DART). Drug names mentioned in the section ‘My medicine’ correspond to the most 
commonly used medicines in the respective therapeutic class from the Swiss market.
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We used risk factors for the development of DART, 
previously identified in a combination of a literature 
search and an expert panel.23 To our knowledge, this 
approach has not been adopted previously in this area of 
research.
DART V.1.0 showed good acceptability and feasibility. 
The patients were able to complete the self-assessment 
within on average 7 min and indicated no major difficul-
ties with understanding the content of the questionnaire. 
The 48 patients (23%) who refused to participate were 
either not interested in participating or felt too tired to 
follow an interview.
After the validation of the first version of DART (V.1.0), 
we engaged three statements with an identified low sensi-
tivity and possible poor patient understanding and aimed 
to improve their wording by implementing expressions 
into our questionnaire which are frequently used in PILs. 
We were able to include a statement covering heart failure 
with an acceptable sensitivity, while observing some more 
false positive answers. The reliability of patients to answer 
questions about renal insufficiency remains a challenge: 
Disease awareness among patients with chronic kidney 
disease is generally low,24 28 29 hence making it difficult 
to retrieve information on from a self-assessment ques-
tionnaire. The low knowledge of chronic comorbidities 
like chronic kidney disease may show a lack of patient 
education within counselling and may therefore pose an 
additional task for pharmaceutical care.
Finally, after the validation of the revised questionnaire, 
most statements of DART V.2.0 showed high specificity 
(mean value 88%, range 27%–100%) preventing false 
positive answers with a high probability. The sensitivity 
of the statements was lower and showed higher vari-
ability (mean value 67%, range 21%–100%). The sensi-
tivity turned out to be higher in statements addressing 
conditions that require regular disease control and daily 
attention to self-care and drug management. Drugs 
requiring a high level of self-management showed the 
highest sensitivity (eg, oral anticoagulants, insulin and 
oral antidiabetics).
Several factors may have influenced the sensitivity 
values. First, the defined criteria for correlation (cf. 
table 1) served as a basis for the validation of the ques-
tionnaire. Depending on how we defined the criteria, we 
reached a certain degree of correlation between patients’ 
answers and the objective data.  Second, we evaluated the 
sensitivity and specificity of each question by comparing 
the subjective answers in DART with objective data from 
medical records. Literature shows that medication histo-
ries at the time of admission are often erroneous and 
incomplete,30 which might have influenced our results. 
Especially the statement ‘I take more than 5 drugs every 
day, prescribed by my physician’, showed surprisingly 
weak correlation between subjective patient answers and 
objective medical data. Lau et al31 stated that regarding 
at the medication history in the hospital medical record, 
25% of the prescription drugs in use are not recorded and 
61% of all patients have one or more drugs not registered. 
Bedell et al32 evaluated the discrepancies between what 
physicians prescribe and what patients report they 
actually take. They showed that discrepancies between 
recorded and reported medication are common. Half of 
the discrepancies (51%) result from patients taking medi-
cations that were not recorded. One-third of the discrep-
ancies involved OTC drugs or herbal therapies. We used 
medical records as reference for testing our statements’ 
and the patients’ reliability to provide correct answers 
in our self-assessment questionnaire. Errors within the 
medical histories as described above would carry over to 
our findings about the statements. Third, patients stated 
that they had no problems with filling in DART; however, 
we noticed some problems with their understanding of 
the word ‘chronic’. And we were aware of the possible 
existence of a social desirability bias when we directly 
asked patients for their opinion about the questionnaire.
Finally, the low prevalence of some risk factors (eg, 
antiepileptic drugs, tricyclic antidepressants, digoxin and 
anticholinergic drugs) hinders clear conclusions about 
the validity of the respective statements in DART.
COnClusIOns
The self-assessment questionnaire ‘DART’ showed a satis-
fying feasibility and reliability. Despite some low sensi-
tivity values, this questionnaire seems to be applicable 
to patients in a hospital setting. Patients may be a valu-
able, but often neglected source of information. Asking 
them about their conditions, their medicines and related 
concerns and problems may facilitate getting a first, but 
broad picture of the risk for DRPs and possible pharma-
ceutical needs. Compared with gathering all the relevant 
data from case notes, electronic patient files and other 
sources, a self-assessment questionnaire seems to be a 
quick and easy method to identify patients in need for 
intensified pharmaceutical care.
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III. Assessing the ability of the Drug-Associated Risk tool (DARt) questi-
onnaire to stratify patients according to their risk of Drug-Related Problems
As the association between DRPs and negative outcomes such as DRM and subse-
quently, hospitalisation, had already been shown, it was adequate to demonstrate the 
validity of the DART as a screening tool for DRP risk by demonstrating its ability to 
discriminate between patients in populations with low and high numbers of present 
manifest or potential DRPs – its concurrent criterion validity. DRPs were to be detected 
by MRs Type 3 as they pose the most advanced assessment of drug treatment appro-
priateness. A patient interview had to be an integral part of the assessment as patient 
interviews are (1) a required information for a MR Type 3 definition-wise and (2) the 
DART poses questions on information only accessible via direct patient contact, i.e. 
OTC medication, adherence, concerns, and handling. The screening for DRPs consisted 
of the recommended combination of implicit and explicit criteria of prescribing appro-
priateness. The validation process is displayed in Figure 3.
Figure 3 Study design of the DART validation. PMC = Polymedication Check; BMQ = Beliefs about Medicines 
Quesiotnnaire; MAI = Medication Appropriateness Index; START = Screening Tool to Alert doctors to the Right 
Treatment; STOPP = Screening Tool of Older Persons‘ potentially inappropriate Prescriptions; ATC = Anatomical 
Therapeutic Chemical classificaiton; GSASA = Society of Swiss administrative and hospital pharmacists’ classifi-
cation.
To study the concurrent criterion validity of the DART, statistical analyses beyond scale 
correlations (i.e. score of the DART with numbers of identified DRPs) were desirable 
as we aimed to investigate in detail the possible associations between the items and the 
identified DRPs in order to draw conclusions on item reduction and clinical pharmacy 
services linking. As studies reported means of eight to ten identified DRPs per patient,79 
84 our dependent variable (i.e. numbers of DRPs) was expected to lack a predefined cut-
off value, i.e. low risk patients having zero DRPs. Instead of defining an artificial cut-
off for a tolerable number of DRPs (e.g. low risk patients having four DRPs), a cluster 
analysis was used. Cluster analyses group observations into collectives with respect to 
all defined variables without necessitating previous categorisation:85 The analyses were 
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To investigate a statistical procedure that is used to form groups of observations, a 
structural assessment such as the discriminant function analysis may be used. Using 
both procedures in conjunction is recommended.85 The discriminant function analysis 
in the validation study focused on the discriminatory potential of subsets of items of 
the questionnaire and hence identified the possibility of reducing the number of items 
in the questionnaire. In the study presented in this thesis, the subset of items identified 
by the discriminatory function analysis also enhanced the association between the inde-
pendent predictor variable (i.e. score) and the dependent outcome variable (i.e. number 
of DRPs), further advising on the reduction of items.
hence expected to form patient clusters with high DART scores and high numbers of 
DRPs and low DART scores and low numbers of DRPs in the absence of an artificial 
definition of high and low. Figure 4 visualises the cluster formation.
Figure 4 Cluster formation. Cluster analyses group observations into collectives with respect to all defined variables 
without necessitating previous categorisation.85 The cluster analysis was expected to group patients with a higher 
DART score (+) and higher numbers of identified DRPs (+) together in one cluster.
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AbstrACt
Objectives The Drug-Associated Risk Tool (DART) has 
been developed as a self-administered questionnaire for 
patients with the aim of stratifying patients according 
to their risk of drug-related problems (DRPs). We aimed 
to validate the ability of the questionnaire to distinguish 
between hospitalised patients showing lower and higher 
numbers of DRPs.
Design Cross-sectional study assessing the 
questionnaire’s concurrent criterion validity.
setting Five geriatric and the associated physical and 
neurological rehabilitation wards of a Swiss regional 
secondary care hospital with 617 beds.
Participants We recruited 110 patients from a total 
of 437 admissions. Exclusion criteria were insufficient 
knowledge in spoken or written German, medical 
conditions preventing meaningful conversations and 
already receiving pharmacy services.
Interventions Comprehensive pharmacist-led 
clinical medication reviews were performed, including 
patient interviews, to identify potential and manifest 
DRPs. A cluster analysis was conducted to assess the 
discriminatory potential of the DART to group patients 
according to number (low and high) of identified DRPs. 
A subsequent discriminatory function analysis was 
performed to reduce the number of items. We determined 
which DART items may be used to trigger what type of 
medication review.
results Recruited patients had a median age of 79 years 
and were prescribed a median of 11 drugs. Patients with 
a median DART score of 10 and a median of 3 DRPs 
represented one cluster, whereas patients with a median 
DART score of 15 and a median of 8 DRPs represented 
another cluster. Discriminatory function analysis reduced 
the questionnaire to five items with a moderate to 
strong correlation with the number of DRPs per patient 
(Spearman’s rank correlation ρ=0.44). Additional items 
were associated with patients benefiting from interviews.
Conclusions As a self-administered questionnaire for 
patients, the DART may be used to stratify hospitalised 
non-acute older patients in groups of having low and 
high likelihood of DRPs. The analyses showed that a short 
form of the DART can be used instead of the full tool to 
identify older inpatients at risk for DRPs. Additional eight 
items from the DART may be used to initiate additional 
clinical pharmacy services. The linkage between certain 
DART questions and type of medication review enables 
pharmacist resource allocation.
bACkgrOunD 
When pharmacists take responsibility for 
the optimisation of medicines use, they are 
practising pharmaceutical care.1 This care 
includes the prevention, identification and 
resolution of drug-related problems (DRPs).2 
DRPs are defined as ‘events or circumstances 
involving drug therapy that actually or poten-
tially interfere with desired health outcomes’ 
and are distinguished by preventability, pres-
ence and cause.3 The DRPs that pharmacists 
are able to avert are preventable potential or 
strengths and limitations of this study
 ► The performed comprehensive clinical medication 
reviews were performed by one pharmacist to en-
sure consistency and repeated by a second pharma-
cist to ensure their validity.
 ► Item reduction was possible following a cluster 
analysis and a subsequent discriminant function 
analysis making the Drug-Associated Risk Tool less 
time consuming.
 ► However, the questionnaire is currently only vali-
dated in older non-acute patients with the ability to 
engage in conversation hospitalised on geriatric and 
associated rehabilitation wards.
 ► Patients with cognitive impairments (eg, dementia) 
had to be excluded, which further restricts the gen-
eralisability of the results.
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manifest DRPs, which are erroneously caused by devia-
tions from accepted guidelines or by patients’ behaviour. 
Within hospitals, clinical pharmacists practise pharmaceu-
tical care and advise on appropriate, safe and economic 
use of medicines.4 Hospitals are a point of care where 
new medicines are introduced to treat acute illnesses in 
addition to existing treatment for chronic conditions—a 
process growing more complex with each added medi-
cine.5 Besides focusing on newly introduced medicines, 
hospitalisation can be an opportunity for clinical phar-
macists to perform medication reviews on the patient’s 
whole drug therapy while having access to the vast amount 
of information provided by medical records, laboratory 
measurements and patients’ opinions and experiences.5 6 
Drug therapy evaluations including this information are 
classified as Medication Reviews Type 3 (MRT3).7 MRT3s 
take into account the circumstances in which patient inter-
views are necessary for the identification of the majority 
of DRPs. Whereas Medication Reviews Type 2a (MRT2a) 
rely on information from medication histories and patient 
interviews, MRT3s also take clinical data and laboratory 
measurements into consideration.6 They are conducted 
using a combination of methods for DRP identification, 
are structured and multifaceted and therefore yield 
optimal results.5 6 8 The combination of methods needs to 
include explicit as well as implicit criteria of inappropriate 
prescribing to balance the benefits and drawbacks of each 
method.9 Explicit criteria are rigid statements that enable 
quick evaluation of the therapy appropriateness with 
little clinical judgement but do not allow for individual 
patient tailoring. Implicit criteria are individual assess-
ments that enable a patient-specific evaluation of complex 
drug therapy regimens but require clinical knowledge and 
time.9 Such comprehensive drug therapy evaluations can 
reduce the number of days spent in hospital for selected 
patients10 but require human resources currently not 
available in Swiss hospitals: the 35.9 full-time equivalent 
clinical pharmacist positions stand in strong contrast to 
1.4 million hospitalisations per year.11 
Prioritising patients in order to structure the daily work-
load is an accepted requirement to maintain effective 
clinical pharmacy services with finite resources.12 13 The 
systematic review of Falconer and colleagues comprehen-
sively evaluated published algorithms to prioritise patients 
according to their risk for DRPs.13 Of the 11 models in 
their final assessment, only the Brighton Adverse Drug 
Reactions Risk model by Tangiisuran and colleagues14 
remained as tool with fair discrimination, sufficient vali-
dation and reasonable performance. The score requires 
laboratory measurements further necessitating effort by 
a healthcare professional (ie, high white cell count on 
admission). Contrary to a model based on clinical data, a 
well-developed paper-based questionnaire may be distrib-
uted to the patients while they are waiting to be seen by 
their physician or pharmacist.15 Patient-filled question-
naires also help in identifying additional patient-cen-
tred DRPs, for example, low adherence and poor health 
literacy.
The Drug-Associated Risk Tool (DART) is a 35-item 
questionnaire about risk factors deemed to be associated 
with DRPs.16 The DART was developed to assist clinical 
pharmacists in stratifying their patients for medication 
reviews and to tailor clinical pharmacy services according 
to available resources. The items of the questionnaire 
were identified by triangulation, including quantitative 
and qualitative methods, described elsewhere.17 The tool 
is designed to be a self-administered questionnaire for 
patients in order not to increase the workload of either 
clinical pharmacists or other healthcare professionals. 
The applicability of the DART used as a self-administered 
questionnaire has been shown for hospitalised patients; 
compared with documented medical records, patients 
from geriatric, medical and orthopaedic wards with a 
median age of 81, 65 and 67.5 years, respectively, were 
able to adequately reproduce their medical information, 
limitations being renal and hepatic insufficiency.16
In order to evaluate the DART as a risk stratification 
tool, the goal of the present study was to validate its ability 
to distinguish between hospitalised patients showing 
lower and higher numbers of currently present potential 
and manifest DRPs.
MethODs
setting and study design
Prospective patient enrolment and data collection were 
conducted in a Swiss regional secondary care hospital with 
617 beds from February to November 2016. The hospital 
administration gave permission to recruit patients for 
10 months; we aimed to recruit at least 100 study partic-
ipants, as discussed for self-administered questionnaires 
by Barenholtz Levy.15 We chose to prove the concurrent 
criterion validity for the DART,18 as there is currently 
no gold standard for the risk assessment of DRPs. The 
concurrent criterion validity assessment correlates a new 
tool with another measure of the trait under study, both 
administered at the same time.
recruitment
We recruited patients from five geriatric and the associ-
ated physical and neurological rehabilitation wards with 
approximately 60 beds and a reported mean hospital 
stay of 17 days.19 In this hospital, patients get transmitted 
from other wards to the rehabilitation wards after acute 
care and generally mark less acutely ill patients. Patients 
were included in the study when admitted to one of the 
participating wards and were approached within 72 hours 
of admission. Exclusion criteria were insufficient knowl-
edge in spoken or written German, medical conditions 
preventing meaningful conversations (eg, deliria, acute 
psychosis, dementia, aphasia and cognitive impairment), 
patients treated within palliative care and patients who 
were already subject to other clinical pharmacy services 
(ie, ward rounds and phone consultation). Ethical consid-
erations required the approval of the ward physician or 
responsible caregiver before patient contact.
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Data collection
After giving informed consent, the patients received the 
DART questionnaire to complete in self-admission. The 
DART consists of 29 questions with dichotomous answers 
and 6 questions with Likert scale answers. The question-
naire is divided in sections on health, polypharmacy, 
self-medication, specific drugs, adherence, concerns 
over the medication, medication literacy and medica-
tion application. The study pharmacist collected clinical 
data on medical conditions, drug treatment (inpatient 
medication list) and laboratory values (ie, renal and 
hepatic function, nutritional state, health and disease 
markers and drug-monitoring values) from the elec-
tronic patient charts. The completed questionnaires were 
collected and stored separately without evaluation. The 
collected clinical data were entered on a case report form.
tools and measures
As criterion measure we chose MRT3s7 to identify DRPs, 
using the implicit criteria on potentially inappropriate 
medications (PIMs) ‘Medication Appropriateness Index’ 
(MAI)20 and current Swiss treatment guidelines,21 and the 
explicit criteria on PIMs ‘STOPP/START criteria version 2’ 
(STOPP, Screening Tool of Older People’s Prescriptions; 
START, Screening Tool to Alert to Right Treatment)22 as 
part of the review. Feasibility, content validity, predictive 
validity and reliability have all been demonstrated for the 
MAI.23 Improvements in drug therapy appropriateness 
have been shown to decrease the total MAI score.8 For 
each medicine, 10 criteria are judged to be ‘appropriate’, 
‘marginally appropriate’ or ‘not appropriate’. A weighted 
score is applied for evaluations deemed to be ‘partially 
appropriate’ or ‘marginally appropriate’.24 The medi-
cine’s total score indicates its appropriateness, whereas 
each contributing criterion indicates an opportunity for 
optimisation. The STOPP/START criteria are shown 
to improve medication appropriateness and to reduce 
adverse drug reactions, whereas the STOPP statements are 
associated with adverse drug events.22 The drug regimens 
were screened for drug–drug interactions by the commer-
cial online database mediQ.25 A structured interview for 
detection of patient-centred DRPs was newly developed 
as part of the MRT3s; the interview was based on the 
Polymedication Check (PMC),26 a reimbursed cognitive 
service provided by Swiss community pharmacists that 
focuses on adherence problems, patients’ knowledge 
and handling problems. We supplemented the PMC with 
items from the Beliefs about Medicines Questionnaire in 
order to identify drug-related concerns.27 The interviews 
took place within 24 hours of study inclusion. Thus, the 
assessments took place within 4 days of ward admission. 
All answers to the interview questions were dichotomous. 
The study pharmacist performed the patient interviews 
with each patient using an iPad Air, V.2 (Apple, Cuper-
tino, California, USA), where interview guide and data 
entry were combined within the online questionnaire 
form Flexiform, V.2.7.1 g (IT-services University of Basel).
Data classification
We coded the medication using the anatomical thera-
peutic chemical (ATC) classification.28 DRPs were docu-
mented with the GSASA (Swiss Association of Public 
Health Administration and Hospital Pharmacists) classi-
fication system for DRPs, for which inter-rater reliability 
has been shown.29 We assessed the potential clinical rele-
vance of the DRPs by using a German version of CLEO, 
CLEOde, which was tested for inter-rater and test–retest 
reliability.30 CLEO assists pharmacists in assessing the 
potential relevance of their own interventions and the 
underlying DRPs identified in the three distinct dimen-
sions: clinical/patient, economic/hospital and organisa-
tional/staff. For our research, we focused on the clinical 
dimension, with its six levels: ‘harmful’, ‘null’, ‘minor’, 
‘moderate’, ‘major’ and ‘lifesaving,’ which achieved good 
inter-rater (intraclass correlation ICC=0.63) and excel-
lent test–retest reliability (mean ICC=0.76). Levels equal 
to or higher than moderate describe interventions that 
prohibit potential damage requiring additional treat-
ment or that recommend further surveillance.
Based on all collected data, the study pharmacist 
performed MRT3s and then a second clinical pharmacist 
repeated the medication reviews independently. Iden-
tified potential and manifest DRPs and their estimated 
relevance were compared; divergence was resolved by 
discussion until consensus was reached.
Patient and public involvement
Patients were not involved in the development of the 
research question or the execution of the study. The 
interview was pilot tested with two inpatients to sort out 
any issues regarding its understandability. Study partici-
pants were encouraged to contact the study pharmacist in 
case they wanted to be informed on the results. Contact 
information was available on the study information.
statistical analysis
The total DART risk score was calculated by assigning 
points to each answer. Dichotomous answers were 
assigned a risk score with one (1) point being assigned 
to each ‘Yes’ answer and zero (0) points given to each 
‘No’ answer. Ordinal answers were assigned a corre-
sponding dummy variable. As studies reported means 
of 8–10 identified DRPs per patient,31 32 the dependent 
variable (ie, numbers of DRPs) was expected to lack a 
predefined cut-off value, that is, low-risk patients having 
zero DRPs. Instead of defining an artificial cut-off for a 
tolerable number of DRPs (eg, low-risk patients having 
four DRPs), we used a cluster analysis. Cluster analyses 
group observations into collectives with respect to all 
defined variables (ie, DART score and number of DRPs) 
without necessitating previous categorisation: the analysis 
was expected to form patient clusters with high DART 
scores and high numbers of DRPs and low DART scores 
and low numbers of DRPs in the absence of an artificial 
definition of high and low. We performed a Ward’s hier-
archical cluster analysis with squared Euclidian distance 
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using the variables DART score and number of DRPs. This 
analysis necessitated the elimination of statistical outliers 
in order to be performed. For this reason, Backhaus and 
colleagues recommend a preceding single linkage hier-
archical cluster analysis with squared Euclidian distance. 
Statistical outliers can be objectively identified from 
the resulting dendrogram.33 We assessed the appropri-
ateness of the clusters generated by the Ward’s hierar-
chical cluster analysis by homogeneity and calculated the 
F-values for each cluster and variable (ie, DART total risk-
score and number of DRPs). F-values of below 1 represent 
a homogeneity that is lower within the proposed cluster 
than within all observations.33 We performed effect size 
calculations using Pearson’s correlation coefficient r, 
which were interpreted according to Gignac: r=0.1 as 
small,. 0.2 as medium and 0.3 as large.34 We compared the 
obtained clusters concerning their total number of iden-
tified DRPs and their total DART risk score by a Mann-
Whitney U test.35 Furthermore, we performed a stepwise 
discriminant function analysis in order to investigate the 
discriminatory potential of subsets of items of the ques-
tionnaire for the generated clusters and hence to identify 
possibilities to reduce the number of items in the ques-
tionnaire. We calculated Wilks’ lambda (λ) for the whole 
DART questionnaire and the subsets of items (‘reduced 
items’) to report on discriminatory values. Lower Wilk’s 
λ values indicate a higher differential potential.33 For 
scale correlations, we used Spearman’s rank correlation 
coefficient ρ, which we interpreted as follows: ρ=0.1 as 
weak, 0.3 as moderate and 0.5 as strong.36 An area under 
the receiver operating characteristic curve (AUROC) 
analysis for the reduced items was performed.
As described above, cluster analysis and subsequent 
discriminant factor analysis were again used to addition-
ally determine discriminatory DART items concerning 
DRPs identified within the patient interviews only.
Additionally, we calculated Spearman’s rank correla-
tion coefficient ρ to assess the correlation between the 
score of the reduced items and the potential relevance of 
the detected DRPs. For the single items, we used a Mann-
Whitney U test. These additional tests were used to assign 
the necessary type of medication review (ie, MRT3 or 
MRT2a) to certain items of the DART.
We defined statistical significance as p values <0.05. The 
statistical analysis was performed using IBM SPSS Statis-
tics for Windows, V.24.0. Interview data preparation was 
performed using RStudio, V.1.0.136 (RStudio, Boston, 
Massachusetts, USA) and running R, V.3.3.2 (R Founda-
tion for Statistical Computing, Vienna, Austria).
results
Dataset
We recruited 110 patients from a total of 437 admissions 
to the five wards during the enrolment period from 
February to November 2016. Figure 1 summarises the 
recruitment flow. Study population characteristics are 
presented in table 1.
We identified a total of 595 DRPs, averaging 5.4 DRPs 
per patient (range: 0–17). One hundred and eight 
patients had at least one DRP (98.2%). Thirty-four 
DRPs were deemed to be manifest, that is, patients 
showing signs of adverse drug events. Identified DRPs are 
presented in table 2. The most frequent causes of DRPs 
were ‘Insufficient knowledge of the patient’ (n=138, 
23.2%; for example, not knowing the indication of the 
drug) and ‘Incomplete patient documentation’ (n=118, 
19.8%; for example, missing diagnoses or treatments), 
summating in the most frequent problems ‘Safety of 
treatment’ (n=182, 30.6%) and ‘Patient dissatisfaction’ 
(n=154, 25.9%) as classified by the GSASA documenta-
tion tool. Analgesics were the drug class linked to most 
DRPs (71 DRPs, 13.7%), with acetaminophen causing 
most of the potential issues within this class (26 DRPs). 
On a drug level, pantoprazole was accountable for most 
DRPs (35 DRPs, 6.3%), followed by acetaminophen (26 
DRPs, 4.7%) and then calcium and cholecalciferol (19 
DRPs, 3.4%). With the help of the CLEOde tool, we esti-
mated the potential clinical relevance of the DRPs to be 
‘null’ (n=47, 7.9%), ‘minor’ (n=399, 67.1%), ‘moderate’ 
(n=106, 17.8%), ‘major’ (n=40, 6.7%) and ‘lifesaving’ 
(n=3, 0.5%).
Validation of the DArt
We analysed the datasets for correlation of risk factors 
identified by the DART questionnaire with the number 
of DRPs. Seven datasets were excluded from this analysis: 
two patient cases had incomplete data and another five 
cases were identified as statistical outliers by the single-
linkage cluster analysis. Two of these five patients had a 
DART score of 16 and 15 and a number of DRPs of 13 
and 17, respectively; two patients had a low DART score 
(0 and 3) and a high number of DRPs (9 and 8); one 
patient had a high DART score (21) and a low number of 
DRPs (2). These preliminary steps reduced the analysed 
dataset to a total of 103 patients.
The DART total risk score showed a weak to moderate 
correlation with the number of DRPs identified (Spear-
man’s rank correlation ρ=0.27, p<0.01). Using the cluster 
analysis, we were able to identify two clusters with 61 
and 42 observations, respectively. The two clusters may 
be regarded as completely homogeneous, as all F-values 
are below 1 (FCluster1, DART risk-score=0.51; FCluster1, identified DRPs=0.21; 
FCluster2, DART risk-score=0.97; and FCluster2, identified DRPs=0.72). The 
effect sizes were large for both variables (DART risk-score 
Pearson’s: r=0.54; identified DRPs: r=0.79). Comparing 
the two clusters, a Mann-Whitney U test revealed a statis-
tically significant tendency for the DART total risk-score 
(U=476.5, p<0.001) and number of identified DRPs 
(U=100.0, p<0.001). Cluster 1 represented patients with a 
median of 10 risk factors (range: 3–16) and three identi-
fied DRPs (range: 1–6) and cluster 2 represented patients 
with a median of 15 risk factors (range: 9–23) and 8 DRPs 
(range: 4–15). The clusters also presented a difference 
in summated MAI scores per patients: clusters 1 and 2 
contained patients averaging at an MAI score of 5.6 and 
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13.2, respectively. In the discriminant function analysis, 
the DART total risk score achieved a Wilks’ λ of 0.69 
(p<0.001). Stepwise discriminant function analysis identi-
fied the DART items on diabetes, polypharmacy (>5 medi-
cines), missing doses, concerns on dependency and heart 
failure as important discriminators between the two clus-
ters. These items achieved a combined Wilks’ λ of 0.57 
(p<0.001), indicating a higher differential potential than 
the total DART risk score itself. The score of the five items 
alone showed a moderate to strong correlation with the 
number of DRPs identified (Spearman’s rank correlation 
ρ=0.44, p<0.01) and a strong correlation with the orig-
inal total risk score (ρ=0.714, p<0.01). The AUROC was 
0.865 (SE=0.035, p<0.001, 95% CI 0.797 to 0.932), further 
displaying the discriminatory potential of the summated 
five items. The r eceiver  o perating  c haracteristic (ROC) 
curve is shown in figure 2. The coordinates of the ROC 
curve presented in table 3 show cut-offs at either one (1) 
Figure 1 Recruitment flow.
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or two (2) ‘Yes’ answers with decreasing sensitivity but 
increasing specificity.
Concerning the DRPs identified within the patient 
interviews only, Spearman’s rank correlation showed a 
moderate correlation between the score of the reduced 
five items and the number of DRPs identified (ρ=0.45, 
p<0.01). Cluster analysis and subsequent discriminant 
factor analysis on the whole questionnaire classified the 
DART items on the use of drugs (non-steroidal antirheu-
matics, antidiabetics and digoxin), restricted kidney func-
tion, concerns about dependency, concerns at having to 
use medicines, use of therapeutic skin patches, prepa-
ration of medicines by home care and polypharmacy as 
predictors of DRPs identified during patient interviews.
The score of the reduced items showed a statisti-
cally significant correlation with DRPs estimated to 
be of moderate (ρ=0.40, p<0.001) and minor (ρ=0.23, 
p=0.02) clinical relevance. In the evaluation tool CLEO, 
patient-centred DRPs are estimated to be of minor rele-
vance; these include restricted knowledge of medicines, 
restricted satisfaction, compliance or quality of life and 
damage that does not require monitoring or treatment. 
Mann-Whitney U tests showed a statistically significant 
correlation between DRPs with high clinical relevance 
(ie, CLEO ‘major’, ‘lifesaving’) and the DART items on 
issues such as tablet-splitting (U=419.5, p=0.020), heart 
failure (U=590.0, p=0.018) and use of oral anticoagulants 
(U=696.5, p=0.004). Use of steroids (U=182.5, p=0.010) 
was associated with DRPs with moderate clinical rele-
vance. Table 4 presents the synopsis of the statistical 
results, combining single DART items with two types of 
medication review.
DIsCussIOn
The goal of the present study was to validate the ability 
of the DART questionnaire to distinguish between hospi-
talised patients showing lower and higher numbers of 
currently present potential and manifest DRPs. With 
a weak to moderate correlation (ρ=0.27, p<0.01), the 
total risk score of the DART allowed for the discrimina-
tion of two patient groups as a result of a cluster anal-
ysis: patients with a median DART score of 10 presented 
a median of 3 identified DRPs and an average MAI score 
of 5.6, whereas patients with a median DART score of 15 
presented a median of 8 DRPs and an average MAI score 
of 13.2, supporting the validity of the generated clusters. 
We identified the five items, diabetes, polypharmacy (>5 
Table 1 Dataset characteristics
Characteristic Value
Demographic (n=110)
  Age, median (IQR) (years) 79.0 (15.0)
  Female, n (%) 76 (69.1)
Clinical status
  Glomerular filtration rate* (CKD-EPI), 
mean±SD (mL/min)
70.5±20.5
  Patients with moderate renal insufficiency 
up to renal failure, n (%)
29 (27.7)
  Diagnosed heart failure, n (%) 4 (3.6)
  Diagnosed liver insufficiency, n (%) 0 (0.0)
  Diagnosed COPD, n (%) 10 (9.1)
  Diagnosed diabetes, n (%) 24 (21.8)
Medication
  Prescribed drugs†, median (IQR) 11.0 (6.0)
*Missing values n=5.
†As reported on the inpatient medication list, including already 
used as needed medications.
CKD-EPI, chronic kidney disease epidemiology collaboration; 
COPD, chronic obstructive pulmonary disease.
Table 2 Identified drug-related problems (DRPs) as 
classified by the GSASA classification system29
Description Total=595, n (%)
Detected problem
  Safety of treatment 182 (30.6)
  Patient dissatisfaction 154 (25.9)
  Treatment effectiveness 107 (18.0)
  Untreated indication 52 (8.7)
  Treatment costs 7 (1.2)
  Classification not possible 93 (15.6)
Cause of problem
  Insufficient knowledge of the patient 138 (23.2)
  Incomplete patient documentation 118 (19.8)
  No concordance with guidelines or 
contraindication
60 (10.1)
  Drug not indicated or duplication 46 (7.7)
  Treatment not received 46 (7.7)
  Interaction 36 (6.1)
  Overdose 29 (4.9)
  Underdose 25 (4.2)
  Inappropriate therapy duration 20 (3.4)
  Insufficient adherence 19 (3.2)
  Inappropriate timing or frequency of 
administration
14 (2.4)
  Adverse effect 12 (2.0)
  Dose not adjusted to organ function 9 (1.5)
  Inappropriate dosage form 7 (1.2)
  Error in medication process 3 (0.5)
  Insufficient knowledge of healthcare 
professionals
2 (0.3)
  Prescribed drug not available 1 (0.2)
  Classification not possible 10 (1.7)
Manifest 34 (5.7)
Potential 561 (94.3)
GSASA, Swiss Association of Public Health Administration and 
Hospital Pharmacists.
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medicines), missed doses, concerns about dependency 
and heart failure, as important discriminators between 
these two patient collectives. The weak to moderate 
correlation between the DART total score and identified 
DRPs increased when only these five items of the DART 
were taken into account, resulting in a moderate to strong 
correlation (ρ=0.44, p<0.01). Reducing the DART items 
represents a less time-consuming and more valid measure 
of identifying DRPs compared with the total DART scale. 
Because we indicated the source of identification in our 
dataset, we were able to show that the risk score of the 
reduced items correlated moderately with the number of 
DRPs identified only in direct patient interviews (ρ=0.45). 
With a second cluster analysis and subsequent discrimi-
natory function analysis, we identified additional DART 
items that were of discriminatory value for patients 
who specifically benefited from the interviews. Further-
more, stated tablet-splitting issues, heart failure and use 
of steroids or oral anticoagulants showed a statistically 
significant correlation to DRPs with moderate to high 
clinical relevance. Table 4 combines these findings into a 
repository of patient questions that may be used by practi-
tioners with limited resources to tailor two types of medi-
cation reviews.
The items identified as being of discriminatory value 
for the DART questionnaire and the overall number of 
DRPs are well in line with previous research on DRPs. The 
symptoms of heart failure may worsen when drugs are 
not taken as prescribed,37 patients with diabetes mellitus 
who are non-adherent to their medication regimen are 
especially prone to hospitalisation,38 polypharmacy and 
non-adherence in general are established risk factors for 
medication-related hospitalisations,39 steroids40 41 and 
anticoagulants41–44 are drugs frequently associated with 
re-hospitalisation or adverse drug events; tablet-splitting 
is a known safety issue, as problems with handling and 
adherence are associated with it.45 As many as 52.5% of 
Swedish patients with prescriptions for split-tablets stated 
a preference and wished for whole tablets instead.46
The risk score of the reduced items was associated with 
DRPs estimated to be of minor and moderate clinical rele-
vance by the CLEO evaluation tool. CLEO associates the 
level ‘minor’ with problems being mainly patient centred 
and without the potential to produce harm that needs 
further monitoring or treatment.30 These patient-centred 
problems include restricted knowledge about the medi-
cines and restricted satisfaction, compliance and quality 
of life, for example, swallowing difficulties. The assign-
ment of patient-centred DRPs like these to a minor clin-
ical relevance is bound to the use of CLEO in estimating 
the potential clinical relevance of our identified DRPs 
and might be argued otherwise: health illiteracy and swal-
lowing difficulties are risk factors for DRPs and non-ad-
herence47 48 and may cause patient harm. We identified 
four items of the DART that had a statistically significant 
correlation with problems deemed to cause patient harm: 
tablet-splitting issues, heart failure and the use of steroids 
or use of oral anticoagulants.
As part of ongoing processes to shift medical documen-
tation to electronic datasets, risk stratification tools are 
currently being developed as automated algorithms.22 49 
Tools that take advantage of computer-based algorithms 
allow for the surveillance of the whole hospital, showing 
a clear advantage over paper-based questionnaires 
such as the DART. In our analysis, we also identified 11 
items of the DART that could seamlessly be integrated 
into an automated algorithm (see table 4); however, we 
also present five items that necessitate direct patient 
contact. The WHO expects ‘seven-star pharmacists’ 
(caregiver, communicator, decision maker, teacher, 
life-long learner, leader and manager) to focus on 
patient-centred care (ie, respect the patients’ opinions 
and concerns).50 Patients’ opinions and sorrows cannot 
be assessed with automated algorithms processing elec-
tronic documentation. With the DART, we present a 
questionnaire that asks the patients about their medi-
cine use and is intended to be completed by the patient 
Figure 2 Receiver operating characteristic (ROC) curve 
of the five DART items on diabetes, polypharmacy (>5 
medicines), missing doses, concerns on dependency and 
heart failure. DART, Drug-Associated Risk Tool.
Table 3 Coordinates of the receiver operating 
characteristic (ROC) curve
Positive if greater than 
or equal to Sensitivity Specificity
0.5 1.000 0.443
1.5 0.738 0.820
2.5 0.429 0.967
3.5 0.071 1.000
5 0.000 1.000
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to trigger clinical pharmacy services promoting tailored 
patient care.
strengths and limitations
A strength of the study presented here is the validation 
procedure: (1) the completed questionnaires were not 
evaluated until after the MRT3; (2) MRT3 were performed 
by one pharmacist to ensure consistency and repeated by 
a second pharmacist to ensure their validity; and (3) the 
cluster analysis with subsequent discriminant factor anal-
ysis showed its additional value over a simple scale correla-
tion by highlighting items for item reduction. Our results 
contribute to the growing evidence on risk factors asso-
ciated with DRPs. The items we identified as being valu-
able within our questionnaire are risk factors that have 
been judged to be potentially harmful elsewhere.37–45 
Past research has been able to show that these risk factors 
negatively influenced rehospitalisation and occurrence of 
adverse drug reaction rates,37–45 and we showed that they 
should be used to trigger clinical pharmacy services that 
include patient interviews.
The limitations of this work constitute the generalis-
ability of the results. The 110 medication reviews of the 
dataset were performed with older patients hospitalised 
Table 4 Combination of DART items and possible triggered type of medication review
DART item (translated from German) Outcome in statistical analysis
Possible triggered clinical pharmacy 
service
I have a heart weakness/heart 
performance weakness.
Correlated with DRPs with high clinical 
relevance.
Consider immediate MRT3 inclusive of a 
patient interview.
I have trouble taking my medicine 
because of splitting tablets.
Correlated with DRPs with high clinical 
relevance.
Consider immediate MRT3 inclusive of a 
patient interview.
I use Marcoumar (phenprocoumon), 
Xarelto (rivaroxaban), 
Sintrom (acenocoumarol), 
Eliquis (apixaban), Lixiana (edoxaban) or 
Pradaxa (dabigatran) at home.
Correlated with DRPs with high clinical 
relevance.
Consider immediate MRT3 inclusive of a 
patient interview.
I use cortisone at home. Correlated with DRPs with moderate 
clinical relevance.
Consider immediate MRT3 inclusive of a 
patient interview.
I have diabetes. Discriminated for cluster of patients with 
a high number of DRPs.
Consider MRT3 inclusive of a patient 
interview.
I take more than five drugs every day, 
which are prescribed by my physician.
Discriminated for cluster of patients with 
a high number of DRPs.
Consider MRT3 inclusive of a patient 
interview.
Do you sometimes forget to take your 
medicine?
Discriminated for cluster of patients with 
a high number of DRPs.
Consider MRT3 inclusive of a patient 
interview.
I sometimes worry about becoming too 
dependent on my medicines.
Discriminated for cluster of patients with 
a high number of DRPs.
Consider MRT3 inclusive of a patient 
interview.
I use medicines against rheumatism/
inflammation at home.
Discriminated for cluster of patients with 
DRPs only identified in patient interview.
Consider patient interview (MRT2a).
I use insulin/medicines against diabetes 
at home.
Discriminated for cluster of patients with 
DRPs only identified in patient interview.
Consider patient interview (MRT2a).
I use digoxin at home. Discriminated for cluster of patients with 
DRPs only identified in patient interview.
Consider patient interview (MRT2a).
I sometimes worry about the long-term 
effects of my medicines.
Discriminated for cluster of patients with 
DRPs only identified in patient interview.
Consider patient interview (MRT2a).
Having to take this medicine worries me. Discriminated for cluster of patients with 
DRPs only identified in patient interview.
Consider patient interview (MRT2a).
I apply my medication in the form of skin 
patches.
Discriminated for cluster of patients with 
DRPs only identified in patient interview.
Consider patient interview (MRT2a).
I have a restricted kidney function/kidney 
dysfunction/kidney disease.
Discriminated for cluster of patients with 
DRPs only identified in patient interview.
Consider patient interview (MRT2a).
The preparation of my medicine is done 
by a homecare institution.
Discriminated for cluster of patients with 
DRPs only identified in patient interview.
Consider patient interview (MRT2a).
MRT3, Medication Review Type 3; drug therapy evaluations using medical records, laboratory measurements, and the patient’s opinions 
and experiences. MRT2a, Medication Review Type 2a; drug therapy evaluations using medication history and the patient’s opinions and 
experiences.7
DART, Drug-Associated Risk Tool; DRPs, drug-related problems.
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on geriatric and the associated physical and neurolog-
ical rehabilitation wards, having a median age of 79 years 
and a median of 11 prescribed drugs. This represents 
an elderly, highly polymedicated population. Addition-
ally, we included patients from rehabilitation wards, who 
generally mark less acutely ill inpatients. Furthermore, 
the exclusion criterion ‘medical conditions preventing 
meaningful conversations’ was a necessity for patient 
interviews but excluded patients vulnerable to DRPs, 
especially cognitively impaired patients that have an 
independent risk for medication-related hospitalisa-
tion.39 Since the DART was developed as a self-adminis-
tered questionnaire, cognitive impairment is inherently 
a limitation of this tool. Combining these limitations, 
the DART currently proved to be suitable for older 
non-acute patients with the ability to engage in conver-
sation. Furthermore, the use of a Ward’s hierarchical 
cluster analysis necessitated the exclusion of five statis-
tical outliers as identified by a preceding single linkage 
hierarchical cluster analysis, which impeded a desirable 
intention-to-treat analysis. However, the exclusion of two 
patients who later would have fallen within the cluster of 
high DART risk score and high number of DRPs demon-
strates the objectivity of this outlier identification. The 
additional three excluded outliers having contradictory 
DART risk score and numbers of DRPs show that the 
DART does not perform well for all patients but may be 
regarded in the lights of restricted specificity and sensi-
tivity of the tool, which are present in any risk assessment. 
An additional limitation is that we did not correlate the 
DART with clinical outcomes (ie, rehospitalisation rates). 
This is because the DART is a screening tool pointing at 
patients at risk. Identifying risks as such cannot improve 
outcomes; it has to be followed by appropriate interven-
tions. The DART, however, may help to direct interven-
tions to patients in need of optimising pharmacotherapy 
and by this improve clinical outcomes.
Implication for practice
The implication of our research for practice is the addition 
of a self-administered questionnaire to the list of available 
tools that may be used for risk stratification. Distributed 
at the beginning of a hospitalisation, the DART may be 
completed by the patients themselves without increasing 
the workload for healthcare providers. The results can 
be used to tailor clinical pharmacy services and to allo-
cate available resources to older non-acute patients who 
most need them. We suggest as triggers for MRT3 within a 
hospitalised older population the eight items of the DART 
on heart insufficiency, tablet-splitting issues, use of anti-
coagulants or steroids, diabetes, polypharmacy (>5 medi-
cines), adherence and concerns about dependency. If 
resources permit, the additional eight items on the use of 
non-steroidal antirheumatic drugs, antidiabetics, digoxin, 
and restricted kidney function, concerns on dependency, 
concerns at having to use medicines, use of therapeutic 
skin patches and preparation of medicines by home care 
services may be used as indicators for patients who benefit 
from a patient interview focusing on adherence prob-
lems, patients’ knowledge and handling problems (ie, 
MRT2a). As the items of the original DART were carefully 
selected by a triangulation process, the remaining items 
may still be used to shape the contents of an MRT3 or a 
patient interview.
COnClusIOn
We present the DART as a validated self-administered 
questionnaire that may be used to identify a high risk 
of DRPs in hospitalised older non-acute patients able to 
engage in a conversation. Subsets of the items may trigger 
different clinical pharmacy services for patients in need 
and allow for rational allocation of work resources.
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Iv. Patient Interviews as Part of a comprehensive Approach contribute to 
the Identification of Drug-Related Problems on Geriatric Wards
The dataset generated in the validation study of the DART, with its 110 patient cases 
and 595 documented DRPs, was an opportunity to further evaluate the capabilities of 
the deployed MRs Type 3. The MRs Type 3 consisted of different measures of inappro-
priate prescribing and a patient interview. As the sources of DRP identification were 
documented in the dataset, this newly developed patient interview could be evaluated in 
light of additional information gained from it. Furthermore, the use of CLEOde allowed 
for a listing of potential relevance by identification source. And most importantly, per-
forming analyses on the dataset – besides the validation of the DART – permitted the 
identification of currently present DRPs in a population of Swiss geriatric inpatients.
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Approach to the Identification of Drug-Related Problems
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Abstract
Background Inappropriate prescribing is linked to
increased risks for adverse drug reactions and hospitalisa-
tion. Combining explicit and implicit criteria of inappro-
priate prescribing with the information obtained in patient
interviews seems beneficial with regard to the identification
of drug-related problems (DRPs) in hospitalised patients.
Objective We aimed to investigate the inclusion of phar-
macist interviews as part of medication reviews (including
the use of explicit and implicit criteria of inappropriate
prescribing) to identify DRPs in older inpatients.
Methods Clinical medication reviews were performed on
geriatric and associated physical and neurological reha-
bilitation wards in a regional secondary care hospital. Data
from electronic medical records, laboratory data, and cur-
rent treatment regimens were complemented with a novel
structured patient interview performed by a clinical phar-
macist. The structured interview questioned patients on
administration issues, prescribed medication, self-medica-
tion, and allergies. The reviews included the use of current
treatment guidelines, the Medication Appropriateness
Index, the Screening Tool of Older People’s Prescriptions
(STOPP, v2), and the Screening Tool to Alert to Right
Treatment (START, v2). The potential relevance of the
DRPs was estimated using the German version of the
CLEO tool.
Results In 110 patients, 595 DRPs were identified, aver-
aging 5.4 per patient (range 0–17). The structured inter-
views identified 249 DRPs (41.8%), of which 227 were not
identified by any other source of information. The majority
of DRPs (213/249, i.e. 85.5%) identified by patient inter-
view were estimated to be of minor clinical relevance (i.e.
limited adherence, knowledge, quality of life, or
satisfaction).
Conclusion We demonstrated that structured patient
interviews identified additional DRPs that other sources did
not identify. Embedded within a comprehensive approach,
the structured patient interviews were needed as data
resource for over one-third of all DRPs.
Key Points
This observational study highlights the benefits of
structured patient interviews as part of
comprehensive clinical medication reviews within a
geriatric ward setting.
The medication reviews included the use of implicit
and explicit criteria and allowed for their critical
appraisal.
The interviews were needed to identify over one-
third of all causes for potential drug-related
problems, most prominently due to insufficient
patient knowledge and incomplete patient
documentation.
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s40266-018-0557-z) contains supple-
mentary material, which is available to authorized users.
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1 Background
Inappropriate prescribing is common throughout Europe
and is estimated to affect almost one-quarter of elderly
patients (22.5%) in Switzerland, leading to increased
morbidity and mortality [1, 2]. Patients experiencing
potentially inappropriate prescribing either receive poten-
tially inappropriate medications (PIMs), are over- or
underdosed, or experience potential prescribing omissions
[3]. As the use of PIMs is associated with a higher risk for
adverse drug reactions (ADRs), their use causes hospitali-
sations [4–6]: the management of ADRs is estimated to
account for 5–10% of all hospital admissions [7]. A drug-
related problem (DRP) is defined as ‘‘an event or circum-
stance involving drug therapy that actually or potentially
interferes with desired health outcomes’’ [8]. DRPs are
estimated to account for 10–30% of all hospital admissions
in the elderly population [9]. Moreover, hospitalised
patients are prone to additional DRPs as potentially inap-
propriate prescribing is higher in inpatients and medication
errors are assumed to affect most hospitalised patients
[3, 10]. Potentially inappropriate prescribing as a cause for
potential DRPs needs to be addressed in order to reduce
drug-associated morbidity and mortality in the older pop-
ulation. This challenge may be approached by imple-
menting national guidelines and detecting DRPs early
[2, 4].
Identifying and resolving DRPs is best approached in a
structured and comprehensive manner: diverse interven-
tions need to be combined into a multifaceted, complete,
and global assessment of pharmacotherapy [11]. An
approach tested in Belgium, where pharmacotherapy opti-
misation strategies were identified by a clinical pharmacist
present on the ward, showed a significant reduction of
misprescribing, overprescribing, and underprescribing
[9, 12]. The clinical pharmacist used implicit and explicit
criteria of potentially inappropriate prescribing to identify
potential prescribing optimisation opportunities. Implicit
and explicit tools to assess potentially inappropriate pre-
scribing are means to lower the risk of hospitalisation due
to DRPs [6]. Resolving DRPs identified by these tools is
shown to decrease ADRs and to improve medication
appropriateness [5, 6]. Explicit tools are rigid, criterion-
based rules that may be applied with little or no clinical
judgement, but fail to address individual differences in
patients. Implicit tools are adaptive to the individual patient
and may integrate patient preferences, but are time-con-
suming and depend on the user’s judgement. As done by
clinical pharmacists in Belgium, including both types of
tools in a structured assessment provides an efficient
method to assess the appropriateness of a prescription as it
combines the advantages of both approaches [6]. Although
a ward-based intervention with different tools is compre-
hensive with regard to the systematic analysis of medical
and clinical data, relevant problems may be missed; patient
interviews have been shown to identify DRPs with a high
clinical significance in home-dwelling patients, as well as
in hospitalised patients [13, 14]. Hence, combining explicit
and implicit criteria of inappropriate prescribing with the
information obtained in patient interviews seems beneficial
with regard to the identification of DRPs in hospitalised
patients.
1.1 Objective
We aimed to investigate the inclusion of pharmacist
interviews as part of medication reviews (including the use
of explicit and implicit criteria of inappropriate prescrib-
ing) to identify DRPs in older inpatients.
2 Methods
2.1 Study Design and Compliance with Ethical
Standards
This was an observational study conducted over a
10-month period from February to November 2016. The
regional Ethics Committee ‘Ethikkommission Nordwest-
und Zentralschweiz’ (EKNZ) approved the study under
number 44/13. All participating patients provided written
informed consent.
2.2 Setting and Patients
We recruited patients from five geriatric and associated
physical and neurological rehabilitation wards with access
to clinical pharmacy services in a Swiss regional secondary
care hospital with 617 beds [15]. Patients were eligible for
study inclusion if they were admitted to a participating
ward and if they had sufficient knowledge in written and
spoken German. We excluded patients with medical con-
ditions preventing meaningful conversations (e.g. delirium,
acute psychosis, severe dementia, aphasia, and cognitive
impairment), patients treated as part of palliative or ter-
minal care, and patients who had already benefited from
other clinical pharmacy services. Clinical pharmacy ser-
vices are already present on these wards, comprised of
irregular ward rounds and phone consultations.
2.3 Recruitment and Interviews
We consecutively screened patients admitted to the par-
ticipating wards, for inclusion and exclusion criteria. The
resident physician or nurse responsible was required to give
D. Sta¨mpfli et al.
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permission to visit the patient prior to the first interaction of
patient and researcher in order to respect acute deteriora-
tions that were not yet documented in the electronic patient
documentation (i.e. delirium, acute psychosis, acute cog-
nitive impairment). Patients were approached within 72 h
of admission to the ward. Following patients’ consent at the
initial visit, their medical records were retrieved from the
wards as preparation for the structured patient interview. At
the second visit, taking place within 24 h of the initial visit,
the interview was conducted and answers were recorded
into an electronic protocol. We noted the time taken for the
interview.
The structured interview combined a modified Swiss
Polymedication Check (PMC) questionnaire [16] with the
Beliefs about Medicines Questionnaire [17]. The Swiss
PMC questionnaire focuses on medication adherence,
patient knowledge, and handling of medicines, and has
been shown to identify a significant number of DRPs
[16, 18]. With the modified PMC, we questioned patients
on administration issues (splitting, swallowing, and con-
fusing their tablets), prescribed medication (regimen,
knowledge, adherence, concerns, and ADRs), self-medi-
cation (reason, satisfaction, and frequency), and allergies.
The structured patient interviews followed a strict protocol
(see electronic supplementary Appendix S1). The exact
number of questions depended on the number of the
patient’s medications as most questions were tailored to the
individual medication regimen. Because this was an
observational study, immediate interventions were only
performed if deemed ethically necessary (i.e. giving
advice, encouraging adherence).
2.4 Data Collection
In addition to the interview data, we collected data from
electronic medical records, laboratory data, and handwrit-
ten case notes for the current treatment regimens for all
included patients. Electronic medical records contained
documented diagnoses, current health status, and vital
parameters (i.e. blood pressure, heart rate, stool frequency,
and blood glucose levels). Primary data collection was
performed on a handwritten case report form (CRF), and
the ad hoc data entry of the structured patient interview was
performed by using the online questionnaire form Flexi-
form, version 2.7.1 g (IT services University of Basel), on
iPads, version Air 2 (Apple Inc., Cupertino, CA, USA).
This procedure was piloted with inpatients to sort out any
technical difficulties.
2.5 Medication Reviews
With the collected data, type 3 medication reviews (ac-
cording to Pharmaceutical Care Network Europe [PCNE]
nomenclature [19]) were performed, which involves the
analysis of medication appropriateness with the help of
medication information, clinical data, and patient state-
ments. The reviews were performed by one board-certified
clinical pharmacist (DS) using implicit and explicit criteria
on medication appropriateness. Implicit criteria consisted
of current treatment guidelines (i.e. SURF-med: Guide-
lines Medizin der Schweiz [20]) and use of the Medication
Appropriateness Index (MAI) [21]. The MAI consists of a
set of 10 criteria, which a reviewer uses to rate each
medication taken by a patient using the levels ‘appropri-
ate’, ‘marginally appropriate’ or ‘not appropriate’. For
ratings deemed to be ‘marginally appropriate’ or ‘not
appropriate’, a weighted score is applied [22]. Medications
with a higher MAI overall sum are less appropriate. The
criteria judged ‘marginally appropriate’ or ‘not appropri-
ate’ indicate possible DRPs for the medication in question.
Interrater reliability for the MAI has been shown [23].
Screenings on the criterion drug–drug interaction were
performed using the mediQ online database [24]. As
explicit criteria, we chose the Screening Tool of Older
People’s Prescriptions (STOPP) and Screening Tool to
Alert to Right Treatment (START) criteria, versions 2 [5].
The application of the STOPP/START criteria have been
shown to detect adverse drug events, improve medication
appropriateness, and reduce ADRs [5]. We used the
explicit statements exclusively and disregarded the implicit
section A of the STOPP criteria.
Every medication review was repeated independently by
a second board-certified clinical pharmacist working in a
specialised geriatric hospital (AG) to reduce subjectivity
potentially introduced by implicit criteria for medication
appropriateness [6]. Discrepancies between medication
reviews on the presence and type of a DRP were resolved
by discussion between both clinical pharmacists until
consensus was reached. As this was an observational study,
the identified DRPs were only communicated to the resi-
dent physician responsible when ethical considerations
regarding patient harm were present.
The potential relevance of the DRPs was assessed using
the German version of CLEO (CLEOde) [25]. CLEO
allows clinicians to assess the potential relevance of DRPs
in three separate dimensions: ‘clinical’ (perspective of the
patient), ‘economic’ (perspective of the institution), and
‘organisational’ (perspective of the care team). Clinical
relevance is estimated by assigning different levels of
potential harm to an unresolved DRP by the identifiers
themselves. CLEOde was tested for reliability in another
study, showing good interrater reliability and excellent
test–retest reliability among 10 clinical pharmacy raters
[26].
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2.6 Data Classification
We classified the medication using the Anatomical Ther-
apeutic Chemical (ATC) classification [27]. DRPs and their
causes were classified using the GSASA (Swiss Associa-
tion of Public Health Administration and Hospital Phar-
macists) classification system for the documentation of
DRPs [28]. The GSASA classification system adapted the
PCNE classification system v6.2 to Swiss needs and aimed
to improve application in daily practice. It consists of five
categories: ‘detected problem’, ‘type of problem’, ‘cause of
intervention’, ‘intervention’, and ‘outcome of interven-
tion’. Interrater reliability has been shown [28].
2.7 Statistical Analysis
We analysed the dataset using IBM SPSS Statistics for
Windows, version 24.0 (IBM Corporation, Armonk, NY,
USA). The dichotomous and qualitative answers to the
structured interviews were preprocessed using RStudio,
version 1.0.136 (RStudio Inc., Boston, MA, USA) running
R, version 3.3.2 (R Foundation for Statistical Computing,
Vienna, Austria). We used descriptive statistics for the
main analysis. Correlations were examined using Spear-
man’s rank correlation coefficient (q), and values were
interpreted as follows: q = 0.1, weak correlation; 0.3,
intermediate correlation; and 0.5, strong correlation.
3 Results
3.1 Recruitment
During the enrolment period from February to November
2016, we recruited 110 patients from a total of 437
admissions to the five wards. Figure 1 summarises the
recruitment flow.
3.2 Patient Characteristics
The mean age was 76.9 years (standard deviation [SD]
10.3), the percentage of females was 69.1%, and the mean
number of prescribed drugs was 11.0 (SD 4.2), including
drugs prescribed as needed and used within the last 72 h.
Further characteristics of the study population are pre-
sented in Table 1.
3.3 Prevalence of Drug-Related Problems (DRPs)
We identified a total of 595 DRPs with our medication
reviews, averaging 5.4 DRPs per patient (range 0–17).
Overall, 108 patients had at least one DRP (98.2%). Of the
595 DRPs, 34 (5.7%) were evaluated as being ‘manifest’,
i.e. the patient showed signs or symptoms of an adverse
drug event, therapy failure, or non-treatment. A total of 299
DRPs (50.3%) were due to medication that was prescribed
prior to admission.
3.4 Identification of DRPs by Patient Interviews
From the interview data, we identified 227 DRPs (38.2%)
that were not detected by any other information source.
‘Insufficient patient knowledge’ (e.g. the patient not
knowing the indication of the drug) and ‘incomplete patient
documentation’ (e.g. missing diagnoses or treatments)
caused the majority of these DRPs, i.e. 137 (56.6%) and 42
(18.5%), respectively. In 78 cases (56.9%) of ‘insufficient
patient knowledge’, the affected medication was prescribed
prior to admission, suggesting that the lack of knowledge
about the medication was present prior to hospitalisation.
Swallowing, splitting, and confusing their tablets were
mentioned by 8.2, 5.5, and 1.8% of patients, respectively.
Reasons for the swallowing difficulties were general
aversion towards the medication, or being related to
specific drugs, i.e. acetaminophen, atorvastatin, metformin,
and calcium ? cholecalciferol. Splitting issues were men-
tioned for levetiracetam, metformin, and pravastatin.
The mean time needed for the interviews was 16.6 min
(SD 6.5) [range 5–40 min].
3.5 Identification of DRPs Using Implicit
and Explicit Criteria
Implicit and explicit criteria contributed differently to the
detection of DRPs (see Table 2). A total of 84 DRPs
(14.1%) were identified by using the treatment guidelines
and clinical experience. We detected 59 DRPs with two or
more identification sources.
A total of 100 patients (90.9%) had an MAI[ 0,
meaning that at least one medication was judged as ‘mar-
ginally appropriate’ or ‘not appropriate’. The mean MAI
value of the study population was 9.0 (SD 9.1) [range
0–52], and the MAI score strongly correlated with the
number of identified DRPs (Spearman’s rank correlation
coefficient q 0.65, p\ 0.05).
3.6 Characterisation of DRPs and Potential
Relevance
Classification of the detected DRPs is presented in Table 2.
The various identification sources detected different types
of DRPs. On the drug-class level, analgesics were
accountable for most DRPs (71 DRPs, 13.7%), with acet-
aminophen being the most frequent cause in this class (26
DRPs). On the individual drug level, pantoprazole had the
highest number of DRPs (35 DRPs, 6.3%), followed by
D. Sta¨mpfli et al.
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Fig. 1 Study recruitment process
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acetaminophen (26 DRPs, 4.7%) and calcium ? cholecal-
ciferol (19, 3.4%). Drug classes and the frequency of DRPs
are shown in Fig. 2.
The potential relevance of the DRPs by identification
source, as evaluated using CLEOde, is shown in Table 3.
The clinical dimension of CLEOde estimated the potential
relevance of the DRPs to be ‘null’ (47 DRPs, 7.9%), ‘mi-
nor’ (399, 67.1%), ‘moderate’ (106, 17.8%), ‘major’ (40,
6.7%), and ‘life-saving’ (3, 0.5%).
Table 1 Study population
characteristics
Characteristic Value
Demographics [n = 110]
Age, years [mean ± SD] 76.9 ± 10.3
Female 76 (69.1)
Clinical status
Glomerular filtration ratea [CKD-EPI], mL/min [mean ± SD] 70.5 ± 20.5
Calculated moderate renal insufficiency to renal failure,\ 60 mL/min 29 (27.7)
Diagnosed heart insufficiency 4 (3.6)
Diagnosed liver insufficiency 0 (0.0)
Diagnosed COPD 10 (9.1)
Diagnosed diabetes 24 (21.8)
Medication
Prescribed drugs, including used reserveb [mean ± SD] 11.0 ± 4.2
Most prescribed drug groups [ATC 4 digits]
Antithrombotic agents [B01A] 143 (11.8)
Other analgesics and antipyretics [N02B] 131 (10.8)
Opioids [N02A] 83 (6.8)
Drugs for peptic ulcer and gastro-oesophageal reflux disease [A02B] 70 (5.8)
Drugs for constipation [A06A] 60 (4.9)
Lipid-modifying agents, plain [C10A] 44 (3.6)
Antidepressants [N06A] 39 (3.2)
Antiepileptics [N03A] 37 (3.0)
Antipsychotics [N05A] 33 (2.7)
Blood glucose-lowering drugs, excluding insulins [A10B] 32 (2.6)
Calcium [A12A] 32 (2.6)
Selective calcium channel blockers with mainly vascular effects [C08C] 32 (2.6)
High-ceiling diuretics [C03C] 27 (2.2)
b-Blocking agents [C07A] 27 (2.2)
ACE inhibitors, plain [C09A] 24 (2.0)
Hypnotics and sedatives [N05C] 22 (1.8)
Adrenergics, inhalants [R03A] 22 (1.8)
Vitamin A and D, including combinations of the two [A11C] 20 (1.6)
Other mineral supplements [A12C] 19 (1.6)
Angiotensin II antagonists, combinations [C09D] 18 (1.5)
Insulin and analogues [A10A] 17 (1.4)
Vitamin B12 and folic acid [B03B] 17 (1.4)
Anti-inflammatory and antirheumatic products, non-steroids [M01A] 15 (1.2)
Anxiolytics [N05B] 15 (1.2)
Angiotensin II antagonists, plain [C09C] 13 (1.1)
Data are expressed as n (%) unless otherwise specified
SD standard deviation, ATC Anatomical Therapeutic Chemical classification system, CKD-EPI Chronic
Kidney Disease Epidemiology Collaboration, COPD chronic obstructive pulmonary disease, ACE angio-
tensin-converting-enzyme
aMissing values n = 5
bUsed within the last 72 h
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4 Discussion
We performed 110 type 3 medication reviews for con-
senting patients on geriatric and associated physical and
neurological rehabilitation wards, and identified 595 man-
ifest and potential DRPs, averaging 5.4 per patient. This
average was lower than in similar studies, where means of
approximately 10 DRPs per patient were reported [12, 13],
a discrepancy that may be explained by clinical pharmacy
services already being established prior to our observation
period, leading to an educational bias [9]. The structured
interviews identified 249 DRPs, of which 227 were not
identified by any other information source. Although most
of the DRPs identified by the interviews were estimated to
be of ‘minor’ clinical relevance, the results suggest a
contribution of the interviews to the data completion nec-
essary for DRP identification. The most prominent causes
for potential DRPs were insufficient patient knowledge and
incomplete patient documentation (i.e. missing medication,
missing diagnoses). Questioning patients on the indication
for the medications accounted for most DRPs identified
during the interviews, even for medication prescribed prior
to admission. The proportion of 299 DRPs (50.3%) due to
medication that was prescribed prior to admission suggests
that these issues could have already been addressed in the
primary care setting prior to hospital admission. Insuffi-
cient knowledge on the medication regimen may be a sign
of health illiteracy, which is linked to reduced health out-
comes [29]. As pharmacotherapy is individualised to
account for diverse patient goals, patients need to be
Table 2 Identified DRPs, as classified by the GSASA classification system [28], and their identification sources
Description General Interviews MAI START STOPP
Detected problem
Safety of treatment 182 (30.6) 19 (7.6) 145 (55.6) 2 (14.3) 44 (93.6)
Patient dissatisfaction 154 (25.9) 151 (60.6) 6 (2.3) 0 (0.0) 0 (0.0)
Treatment effectiveness 107 (18.0) 32 (12.9) 54 (20.7) 2 (14.3) 0 (0.0)
Untreated indication 52 (8.7) 9 (3.6) 1 (0.4) 10 (71.4) 0 (0.0)
Treatment costs 7 (1.2) 0 (0.0) 7 (2.7) 0 (0.0) 2 (4.3)
Classification not possible 93 (15.6) 38 (15.3) 48 (18.4) 0 (0.0) 1 (2.1)
Cause of intervention
Insufficient patient knowledge 138 (23.2) 138 (55.4) 5 (1.9) 0 (0.0) 1 (2.1)
Incomplete patient documentation 118 (19.8) 45 (18.1) 62 (23.8) 0 (0.0) 3 (6.4)
No concordance with guidelines or contraindication 60 (10.1) 0 (0.0) 27 (10.3) 4 (28.6) 15 (31.9)
Drug not indicated, or duplication 46 (7.7) 4 (1.6) 40 (15.3) 0 (0.0) 21 (44.7)
Treatment not received 46 (7.7) 7 (2.8) 1 (0.4) 10 (71.4) 0 (0.0)
Interaction 36 (6.1) 0 (0.0) 35 (13.4) 0 (0.0) 2 (4.3)
Overdose 29 (4.9) 3 (1.2) 25 (9.6) 0 (0.0) 0 (0.0)
Underdose 25 (4.2) 4 (1.6) 21 (8.0) 0 (0.0) 0 (0.0)
Inappropriate therapy duration 20 (3.4) 3 (1.2) 18 (6.9) 0 (0.0) 4 (8.5)
Insufficient compliance 19 (3.2) 19 (7.6) 1 (0.4) 0 (0.0) 0 (0.0)
Inappropriate timing or frequency of administration 14 (2.4) 3 (1.2) 14 (5.4) 0 (0.0) 0 (0.0)
Adverse effect 12 (2.0) 6 (2.4) 1 (0.4) 0 (0.0) 1 (2.1)
Dose not adjusted to organ function 9 (1.5) 2 (0.8) 7 (2.7) 0 (0.0) 0 (0.0)
Inappropriate dosage form 7 (1.2) 6 (2.4) 2 (0.8) 0 (0.0) 0 (0.0)
Error in the medication process 3 (0.5) 2 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
Insufficient knowledge of caregivers 2 (0.3) 2 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
Prescribed drug not available 1 (0.2) 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0)
Classification not possible 10 (1.7) 5 (2.0) 1 (0.4) 0 (0.0) 0 (0.0)
Total 595 249 261 14 47
Data are expressed as n (%). Some DRPs were identified by multiple sources. Percentages relate to column data for each detected problem or
cause of intervention
MAI Medication Appropriateness Index, STOPP Screening Tool of Older People’s Prescriptions, START Screening Tool to Alert to Right
Treatment, DRP drug-related problem, GSASA Swiss Association of Public Health Administration and Hospital Pharmacists
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educated on its specific rationale to improve adherence
[30]. Complete patient documentation (e.g. medication
histories) is especially important to prevent harm in older
patients taking a large number of medications [31]. Our
results support previous research on the necessity of bed-
side interventions and patient counselling by clinical
Fig. 2 Number of drug-related problems within drug classes (ATC
codes) [27], aggregated in terms of estimated clinical relevance
according to CLEOde [26]. ATC Anatomical Therapeutic Chemical
classification system, CLEO CLinical, Economic, and Organizational,
CLEOde German version of CLEO
Table 3 Potential relevance of
the DRPs by identification
source, as evaluated using
CLEOde
Potential clinical relevancea General Interviews MAI START STOPP
Null 47 16 30 0 4
Minor 399 213 153 9 32
Moderate 106 17 47 2 7
Major 40 3 31 0 4
Life-saving 3 0 0 3 0
DRPs may have been identified by multiple sources or by application of guidelines only. Null: no effect on
the patient in regard to clinical situation, knowledge, satisfaction, adherence or quality of life. Minor: effect
on patient in regard to clinical situation, knowledge, satisfaction, adherence or quality of life OR damage
that does not necessitate surveillance or treatment. Moderate: damage that necessitates surveillance or
treatment but does not lead to hospitalisation or prolongation thereof. Major: damage that leads to hos-
pitalisation or prolongation thereof OR damage that leads to disablement or impairment. Life-saving:
damage that leads to intensive care treatment or death
MAI Medication Appropriateness Index, STOPP Screening Tool of Older People’s Prescriptions, START
Screening Tool to Alert to Right Treatment, DRP drug-related problem
aLevels (translated from German)
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pharmacists; Viktil et al. detected 39.9% of all 421 DRPs
within the hospital setting through interviews performed by
clinical pharmacists [14]. Similar to our results, their study
found missing medication, medical chart errors, and the
need for patient education, to be more frequently identified
through interviews [14]. However, individual patient
interviews as a source of information are time-consuming;
the interview times in our study ranged from 5 to 40 min,
averaging 16.6 min per interview. Similarly, the clinical
pharmacists in the study by Viktil et al. spent 20.3 min
(range 5–60 min) for their interviews. Nonetheless, in their
meta-analysis of clinical pharmacy services, Perez and
colleagues calculated a pooled median benefit-to-risk ratio
of 4.81–1 across 15 studies, showing $4.81 in reduced costs
or other economic benefits for every $1 spent on clinical
pharmacy services [32], thereby justifying expenditures by
the hospital due to clinical pharmacists performing medi-
cation reviews inclusive of patient interviews.
Use of the MAI identified 43.9% of all DRPs and the
patient’s score strongly correlated with the patient’s num-
ber of DRPs, which highlights the benefits of using a
structured and implicit approach towards the assessment of
prescribing appropriateness. This correlation may also be
used to measure the effect of interventions that target
suboptimal prescribing [33]. Hence, we support the sug-
gestion that the MAI should be part of routine practice in
drug regimen reviews [9]. However, it must be taken into
consideration that patient statements are indispensable for
certain MAI criteria (i.e. ‘Is the medication effective for
the condition?’; ‘Are the directions practical?’). Thus, the
combination of MAI together with patient interviews, as
shown here, seems beneficial. The STOPP and START
criteria identified 7.9 and 2.4% of DRPs, respectively. A
study on DRPs of community-dwelling older patients
concluded that 81% were not represented in either the
STOPP or START criteria [34]. However, the low pro-
portion in our results might be associated with our decision
to use the explicit criteria only and to exclude all implicit
criteria. In other studies, the implicit criterion ‘no indica-
tion present’ was one of the most identified DRPs [34]. We
covered this criterion by using the MAI. Additionally, the
START criterion ‘Vitamin K antagonists or direct throm-
bin inhibitors or factor Xa inhibitors in the presence of
chronic atrial fibrillation’ was responsible for the identifi-
cation of the three DRPs estimated to be of ‘life-saving’
clinical relevance (Table 3). Although all three prescribing
omissions were also identified by the application of current
treatment guidelines, this circumstance allows for a posi-
tive appraisal of the START criteria.
We identified analgesics as the main drug class associ-
ated with the identified DRPs. Similar results were
obtained in studies conducted on internal medicine and
rheumatology wards: opioids, non-steroidal antirheumatic
drugs, antithrombotic agents, and agents acting on the
renin–angiotensin system were the main contributors [35].
On a drug level, we found pantoprazole to be associated
with most DRPs. Proton-pump inhibitors (PPIs) are known
to be associated with overprescribing, and it is estimated
that 25–70% of patients with PPIs have no appropriate
indication [36]. Our population consisted of geriatric
patients, of whom 11.8% received an antithrombotic agent.
Prevention of upper gastrointestinal bleeding was a possi-
ble, but not mandatory, indication for PPIs in Switzerland.
The clinical dimension assessed by CLEOde estimated
the potential relevance of DRPs to be ‘minor’ for 67.1% of
cases (n = 399). Furthermore, of the 249 DRPs identified
only by patient interviews, 85.5% were estimated to be of
‘minor’ clinical relevance (n = 219). This stands in con-
trast to other research where approximately 66% of DRPs
found during the interviews were assessed by the inter-
viewers to be of ‘major’ or ‘extremely important’ clinical
relevance. CLEOde assigns patient-level interventions (i.e.
improved adherence, knowledge, quality of life, or satis-
faction) to its ‘minor’ level. The assignment of patient-
centred DRPs such as these to minor clinical relevance is
related to the use of CLEOde to estimate potential clinical
relevance, as CLEOde focuses on direct and prompt con-
sequences. However, this is debatable, since health illiter-
acy and swallowing difficulties are risk factors for DRPs
and non-adherence, and may cause patient harm over the
long-term [37, 38].
4.1 Strengths and Limitations
To our knowledge, this is the first study that highlights the
information gained by structured patient interviews within
a hospital setting as part of type 3 medication reviews,
which involved implicit and explicit criteria for medication
appropriateness. Described as a necessity for optimising
geriatric pharmacotherapy, we display the potential of an
approach, which was multifaceted with regard to the
assessment of medication appropriateness (implicit and
explicit criteria), complete with regard to the performed
medication review, and global with regard to the involve-
ment of the patients [11]. In addition, the medication
reviews were performed by one clinical pharmacist, which
ensured consistency in assessment and coding [39], and
were independently repeated by a second clinical phar-
macist, which improved validity by reducing subjectivity.
As we were limited to an observational study, the
identified DRPs were not resolved (e.g. by suggesting PPI
deprescription) unless ethically necessary. Hence, we could
not report clinical outcomes or acceptance rates. However,
we know from previous studies that interventions based on
patient interviews are of high relevance in two-thirds of
DRPs assessed [14]. Generalisation of our results to other
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areas of clinical practice is limited as the study was con-
ducted on specific wards and the exclusion criteria were
restrictive; ‘state which does not allow a meaningful con-
versation’ prevented the enrolment of 159 patients
(43.6%). Verbal communication is a necessity for struc-
tured interviews and was also respected by Viktil et al.
Similar reasons led to the exclusion of 84 patients (46.7%)
in the corresponding study [21]. The implementation of
structured patient interviews in routine clinical practice, as
described in this study, does not seem probable as both the
interviews and the use of implicit criteria of potentially
inappropriate prescribing were time-consuming. However,
countries such as Denmark already compel their hospitals
to perform regular patient interviews as part of medication
reconciliation processes, displaying awareness of both the
necessity and feasibility of these strategies [40].
5 Conclusions
We were able to demonstrate that structured patient inter-
views contribute to the identification of DRPs within a
comprehensive approach. The interviews exposed DRPs
that are only accessible in dialogue with patients, such as
limited adherence, patient knowledge, quality of life, or
satisfaction. Structured patient interviews should mainly
focus on the patient’s knowledge of the indication of the
medication, and on the integrity of the patient documen-
tation. An approach including implicit and explicit PIM
tools seems mandatory to enable the identification of DRPs
with various causes.
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v. Risk of Drug-Induced Qtc Interval Prolongation – A step closer to a cli-
nical Risk management
In order to investigate the RISQ-PATH score’s ability to predict QTc intervals, a mode-
rated hierarchical regression analysis was performed on the 156 observed patient cases. 
Regression analyses are used to analyse associations between a dependent variable and 
numerous independent variables. They may be used to describe an association (e.g. 
between proposed scores and measured traits) or to predict the value of the dependent 
value (e.g. measured QTc interval). Hierarchical regression analyses – also described 
as step-wise regression analyses – allow for the identification of statistically significant 
models that describe an association between the dependent and the independent vari-
ables. The independent variables are entered in blocks and only kept if they improve 
the model. Besides generating a model, this process also displays a hierarchy of stati-
stically significant associations with the most important variable being on top. These 
identified associations may be moderated by a third variable, which partitions the inde-
pendent variable (i.e. RISQ-PATH score) into subgroups and influences the strength of 
the relation to the dependent variable (i.e. measured QTc interval). These moderators 
need to be identified in order to understand the model’s restrictions.
For the evaluation of the RISQ-PATH score’s performance in a population of Swiss 
geriatric inpatients, this thesis provided the statistical procedures (hierarchical and mo-
derated hierarchical regression analyses) to the draft presented here. These analyses 
permitted simultaneous investigation of the association between the score and the mea-
sured QTc intervals and the identification of possible moderators affecting this associ-
ation.
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Background 
Numerous drugs are known to evoke a QT-interval prolongation by affecting the cardiac repolarization. The 
prolongation of the corrected QT interval (QTc) is assessed by electrocardiogram (ECG) and can be used as a 
surrogate marker of impending ventricular arrhythmia such as torsade de pointes (TdP). TdP is life threatening 
as it may lead to sudden cardiac death due to ventricular fibrillation [1]–[3]. 
Over the last few years progress has been made in the understanding of the mechanism of the drug-induced 
QTc interval prolongation and the knowledge about its risk factors has become more accurate [4]–[7]. The 
University of Arizona’s Center for Education and Research on Therapeutics (Arizona CERT) has ranked over 
220 drugs that induce QTc prolongation (QTDrugs) into four distinct lists: Drugs with known risk for TdP 
(QTDrug list 1), drugs with possible risk for TdP (QTDrug list 2), drugs with conditional risk for TdP (QTDrug 
list 3), and drugs to avoided by patients with congenital long QT syndrome (LQTS) [8]. 
Although there are known associations between QTDrugs and the combination with risk factors for increasing 
the QTc interval prolongation, precise prediction of the risk for a QT-interval prolongation and TdP remains 
difficult [9], [10]. Hence, prescribers need to carefully balance the possible risks against the therapeutic 
benefits of a QTDrug. Dhanani and colleagues mentioned the importance of clinical pharmacists in a clinical 
healthcare team when prescriptions are reviewed and balanced [11]. This is particularly apparent in a 
multimorbid geriatric population, which combines the presence of several risk factors with being exposed to 
numerous QTc-prolonging drugs [4]. Daily clinical risk management is especially difficult, as no guidelines 
on reducing QTc prolongation risk exist. 
To date, two research groups (Tisdale et al. and Vandael et al.) each have developed a risk score to predict the 
potential for QTc interval prolongation. Based on their observational studies they weighed identified risk 
factors. With a summated risk score Tisdale et al. divided patients into low, moderate, and high risk patients 
for QTc prolongation [12]. Vandael et al. developed a preliminary risk score, the RISQ-PATH score, which 
includes concomitant risk factors based on a systematic review of observational studies. The score should 
guide clinical decision making by estimating the risk of QTc interval prolongation for individual patients and 
should therefore facilitate the prescribing process of QTDrugs. The RISQ-PATH score was validated with a 
patient population starting Haloperidol or a QTc prolonging antibiotic or antimycotic [6], [13]. 
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This retrospective study aimed to determine the prevalence of administered QTDrugs and present risk factors 
in a large hospital-based geriatric cohort. The magnitude of the combined risk factors for QTc interval 
prolongation should be qualified. This provided an opportunity to investigate and externally validate the 
RISQ-PATH score within a clinical setting. 
Methods 
Patient selection, study design 
This observational, cross-sectional study was performed on rehabilitation, acute geriatric wards, and internal 
medicine wards of a Swiss regional secondary care hospital. For six weeks (December 2016 to January 2017), 
every other day (Monday, Wednesday and Friday) newly admitted inpatients were recruited from the wards 
when the inclusion criteria ≥ 18 years and ≥ one drug with risk for QTc prolongation as listed on 
crediblemed.org were present [8]. Demographic and medication data of the inpatients were gathered from the 
electronic patient file of the hospital. 
Study procedure, RISQ-PATH score 
On the index day (Monday, Wednesday or Friday), the RISQ-PATH score was calculated for each patient 
with clinical diagnoses, inpatient medication list, and laboratory data according to the following criteria [13]: 
- Medication of the inpatient: all actual medications were recorded on the index day. The ATC-Code of 
the World Health Organization [14] was allocated to all drugs of the inpatient. All drugs with a 
potential risk for QTc interval prolongation were categorised according to crediblemeds.org into 
QTDrug list 1: known, list 2: possible and list 3: conditional risk for QTc interval prolongation.  
- Demographical values: Age, sex, weight, height, body mass index (BMI), and smoking habit 
- Diagnoses of hypertension, cardiomyopathy, arrhythmia, thyroid disturbance, liver failure, and 
diabetes  
- Laboratory results recorded on the sample day or newest result (max. 1 week old) of serum potassium, 
calcium, C-reactive protein (CRP) and estimated glomerular filtration rate based on Cockcroft-Gault 
equation (GFR) 
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- QTc time (corrected according to Bazett’s formula[15]) collected from performed ECG during 
hospitalization under a treatment with a QTDrug. 
As defined by Vandael et al. [13], points were given for each risk factor based on their evidence level. The 
RISQ-PATH score was summated as follows:  
- Very high evidence: 6 points for prolonged QTc [≥450(m)/470(f) ms] and potassium ≤ 3.5 mmol/l;  
- High evidence: 3 points for age ≥ 65 years, female gender, smoker, (ischemic) cardiomyopathy, 
arrhythmia, thyroid disturbances, calcium < 2.15 mmol/l;  
- Moderate evidence: 1 point for BMI ≥ 30 kg/m2, liver failure and CRP > 5 mg/l;  
- Low evidence: 0.5 point for positive diabetes anamneses and GFR < 30 ml/min;  
- QTDrug list 1: 3 points, QTDrug list 2: 0.5 points, and QTDrug list 3: 0.25 points.  
The risk factor “neurological disorder” was not included in this study as it was considered to be too subjective 
due to its unclear definition. The points of the RISQ-PATH score were summed up for each patient. 
Statistical analysis 
The dataset of patient cases was analysed for association of the RISQ-PATH score with the measured QTc 
intervals. Cases were excluded when data was missing, i.e. ECG measurements were not available. Outlier 
identification was performed by using z-scores checking for normal distribution (variables: RISQ-PATH 
score, measured QTc intervals). 
Simple scale correlations between the calculated RISQ-PATH score and the measured QTc interval were 
assessed by Spearman’s rank correlation coefficient rho (ρ),1 which we interpreted as: ρ=.1 as weak, .3 as 
moderate, and .5 as strong [16]. Moreover, the results were divided in 4 percentiles according to the ascending 
RISQ-PATH score to investigate the distribution per quantile. 
A hierarchical regression analysis was performed to identify risk factors of the RISQ-PATH score 
significantly contributing to the prediction of the measured QTc intervals. To assess whether these identified 
risk factors acted as moderators of the associations, we performed moderated hierarchical regression analyses 
following the procedure described by Aiken, West, and Reno [17]. All other risk factors of the RISQ-PATH 
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score were entered in a first block. The risk factors identified by the hierarchical regression analysis were then 
entered in the next block. Finally, the interaction terms between the identified risk factors and the RISQ-PATH 
score were entered in the last block. When an interaction was found to be significant, which highlighted a 
significant moderation effect, the measured QTc interval by the RISQ-PATH score were graphed separately 
with the moderator used as categorical variable. Separate multiple regression analyses were used to evaluate 
whether the slopes in the graphs were significantly different from zero [17]. 
We defined statistical significance as p-values <.05. The statistical analyses were performed using IBM SPSS 
Statistics for Windows, Version 25.0 (Armonk, NY: IBM Corp.), and Microsoft Excel, Version 1712 (2016). 
Results 
Study population 
Figure 1 shows the flow chart of the inclusion process. During the enrolment period, 248 inpatient entries 
were scanned. 202 (81.5%) patients were included in the study from the internal medicine (N=73 (36.1%)), 
rehabilitation (N=86 (42.6%)), and acute geriatric (N=43 (21.3%)) units. The study population consisted of 
77 male (38.1%) and 125 female (61.9%) inpatients. The detailed demographical data is presented in Table 1. 
Within the enrolment period, 794 QTDrugs were registered. Thereof, 460 QTDrugs were prescribed as a fix 
medication as shown in Figure 2 with their corresponding ATC Code [14]. Resulting in 81.5% of all screened 
patients receiving at least one QTDrug after the hospital admission (Table 1). One-third of all patients (33.7%, 
N=68) was exposed to at least one QTDrug list 1. 
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Figure 1 Flow chart of data collection. 
 
Figure 2 Flow chart of QTDrug in the baseline therapy and the most frequently used three of each category in accordance to their ATC-Code. 
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Table 1 Demographical data of the inpatients. 
Characteristic Total patient population 
(N=202) in [number] (%) 
Age [median, range] 83 [44-99] 
Gender  
 Female 125 (61.9) 
 Male 77 (38.1) 
Unit  
 Internal Medicine 
 Rehabilitation 
 Acute Geriatric 
73 (36.1) 
86 (42.6) 
43 (21.3) 
Number of patients with a QTDrug 202 
 ≥1 QTDrug list 1 68 (33.7) 
 ≥1 QTDrug list 2 52 (25.7) 
 ≥1 QTDrug list 3 182 (90.1) 
QTDrug lists: crediblemeds.org; QTDrug list 1 = known, list 2 = possible, list 3 = conditional risk for QTc interval prolongation 
 
The antidepressants citalopram (N=5) and its enantiomer escitalopram (N=26) accounted for 39.7 % of 
CredibleMeds list 1 QTDrugs. 14 antibiotics (chinolone N=7, clarithromycin N=7) and 2 antimycotic 
(fluconazol) with known risk for QTc prolongation were prescribed during the hospitalisation. The most 
frequently used medication was pantoprazole (QTDrug list 3) which was found on 130 medication lists. The 
most popular diuretic of the QTDrug list 3 used in this population was torasemide (N=94).  
RISQ-PATH score 
The RISQ-PATH score was determined for 156 patients for whom a recent ECG was available. The calculated 
preliminary RISQ-PATH score for each inpatient ranged from 4 to 30 points, with a median of 14.6 points. 
Of the available ECGs, 20.6% (N=20 of 97) women and 61% (N=36 of 59) men had a prolonged QTc. The 
RISQ-PATH score of each patient divided into four quartiles is shown in Table 2. A total of 76.8% of QTc 
prolongation occurred in the 3rd and 4th quartiles. 
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Table 2 Results of the study population (N= 156) with an ECG related to a QTDrug treatment divided into 4 quartiles according to the points of 
the RISQ PATH score. 
RISQ PATH risk factor Total patient 
population 
(N=156) in 
number (%) 
1st quartile: 
RISQ PATH 
score 0-11.25 
points (N=39) 
2nd quartile:  
RISQ PATH 
score 11.5-
14.5 points 
(N=39) 
3rd quartile: 
RISQ PATH 
score 14.75-
19.25 points 
(N=39) 
4th quartile: 
RISQ PATH 
score 19.25-
30 points 
(N=39) 
      
RISQ PATH score [median (range)] 14.625 (4-30) 8.75 (4-11.25) 13.25 (11.25-
14.5) 
16.75(14.75-
19.25) 
22.5 (19.5-30) 
Age ≥ 65 years  137 (87.8%) 29 35 36 37 
Female sex 97 (62.2%) 27 23 19 28 
Smoker 28 (17.9%) 5 7 7 9 
BMI ≥30 kg/m2 16 (10.3%) 4 4 3 5 
(ischemic) cardiomyopathy 16 (10.3%) 2 4 5 5 
Hypertension 102 (65.4%) 20 20 28 34 
Arrhythmia 59 (37.8%) 1 12 19 27 
ECG  
  - prolonged QTc ≥450 ms (m) 
  - prolonged QTc ≥470 ms (f) 
 
36 (23.1%) 
20 (12.8%) 
 
1 
0 
 
11 
1 
 
16 
6 
 
8 
13 
Thyroid disturbances 19 (12.2%) 0 3 4 12 
Liver failure 27 (17.3%) 7 7 5 8 
Diabetes 37 (23.7%) 3 9 11 14 
Potassium ≤3.5 mmol/L 11 (7.1%) 0 0 3 8 
Calcium <2.15 mmol/L 62 (39.7%) 6 14 18 24 
CRP >5 mg/L 97 (62.2%) 26 21 23 27 
Estimated GFR (Cockroft-Gault) ≤30 mL/min 32 (20.5%) 2 12 6 12 
CredibleMeds QTDrug list 1  50 (32.1%) 5 8 12 25 
CredibleMeds QTDrug list 2 41 (26.3%) 11 12 6 12 
CredibleMeds QTDrug list 3 142 (91.1%) 35 34 37 35 
 
Statistical analysis 
Preliminary steps with case exclusions due to missing ECG measurements reduced the analysed dataset to a 
total of 156 observations, consisting of 97 female and 59 male patients. No outliers were identified. 
The RISQ-PATH score showed a moderate correlation with the measured QTc interval (Spearman’s rank 
correlation ρ = .39, p < .01). Hierarchical regression analysis was first calculated for the whole dataset. 
Identified significant contributors to the prediction of measured QTc intervals were the risk factors ‘Prolonged 
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QTc’ (β = 0.76, p < .001) and ‘QTDrug list 3’ (β = -0.11, p = .03). Moderated hierarchical regression analyses 
were performed with the interaction terms between these two predictors (i.e. ‘Prolonged QTc’ and ‘QTDrug 
list 3’) and the RISQ-PATH score, controlling for all risk factors not significantly contributing to the 
prediction (i.e. all other risk factors of the RISQ-PATH score). These analyses showed one significant 
interaction term (see Table 3): ‘Prolonged QTc’ (β = 0.49, p = .03) moderated the association between RISQ-
PATH score and measured QTc interval. The interaction term between ‘QTDrug list 3’ and RISQ-PATH score 
was not found to improve the model significantly if ‘Prolonged QTc’ was present as control variable within 
the model. As shown in Figure 3, the RISQ-PATH score was significantly associated with measured QTc 
intervals (β = 0.31, p = .02) for inpatients with a prolonged QTc interval, such that higher RISQ-PATH scores 
were related to longer QTc intervals, whereas in patients without a pre-existing prolonged QTc interval there 
was no significant association between the RISQ-PATH score and measured QTc intervals (β = -0.06, p = 
.52). 
Table 3 Moderated Hierarchical regression analysis. 
 Value 
Step 1 R2 of total model 0.17 
Step 2a Prolonged QTc on a baseline ECG 0.78** 
 RISK-PATH score x ‘Prolonged QTc on a baseline ECG’ 0.49* 
 ઢR2 of interaction 0.01* 
 R2 of total model 0.65* 
Step 2b List 3 QT-drug CredibleMeds -0.12* 
 RISK-PATH score x ‘List 3 QT-drug CredibleMeds’ -0.08 
 Delta R2 of interaction 0.0* 
 ઢR2 of total model 0.64* 
Coefficients are standardised regression coefficients if not otherwise indicated. Step 1: Model with all risk factors except 
‘Prolonged QTc on a baseline ECG’ and ‘List 3 QT-drug CredibleMeds,’ i.e. Age ≥65 years, female sex, smoking, 
BMI ≥30 kg/m2, (ischemic) cardiomyopathy, hypertension, arrhythmia, thyroid disturbances, liver failure, neurological disorders, 
diabetes, potassium ≤3.5 mmol/L, calcium <2.15 mmol/L, CRP >5 mg/L, estimated glomular filtration rate ≤30 mL/min, for 
each list 1 QT-drug CredibleMeds, for each list 2 QT-drug CredibleMeds. Step 2a: Model with ‘Prolonged QTc on a baseline 
ECG’ and the interaction term RISQ-PATH score x ‘Prolonged QTc on a baseline ECG’ as predictors for measured QT interval, 
controlled for risk factors entered in step 1. Step 2b: List 3 QT-drug CredibleMeds and the interaction term RISQ-PATH score x 
‘List 3 QT-drug CredibleMeds’ interaction terms as predictors for measured QT interval, controlled for risk factors entered in 
step 1. 
* p < .05 
** p < .001 
Projects
97
Assessments of Risk and Relevance
Page 10 of 14 
 
Figure 3 Associations of RISQ-PATH scores and measured QTc interval (A: patients without previously prolonged QTc interval, N = 101; B: 
patients with previously prolonged QTc interval, N = 55). Standardised regression coefficients (β) and p-values are presented next to the slope. 
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Discussion 
From the internal medicine, rehabilitation, and acute geriatric wards, 81% of admitted patients were exposed 
to one or more QTDrug. This high utilization rate of QTDrugs highlights the requirement of a clinical risk 
management to balance risks against therapeutic benefits. We adopted the RISQ-PATH score in our 
observational, cross-sectional study aiming to investigate its benefits for a broader population of inpatients. 
Based on the hierarchical regression analysis we report an association between the RISQ-PATH score and the 
measured QTc interval. Concerning our specific dataset of 156 patients, we identified the risk factor 
‘Prolonged QTc’ as a moderator for this association. The association between the RISQ-PATH score with the 
measured QTc interval was significant for the patients with a present prolonged QTc interval. This result 
implies that the RISQ-PATH score is highly dependent on one specific risk factor. Concluding, if a prolonged 
QTc interval is present, an association between the RISQ-PATH score and the measured QTc interval exists, 
whereas with no previously prolonged QTc interval no association between RISQ-PATH score and the QTc 
interval may be expected.  
From the RISQ-PATH score median of 14.6 points a wider spreading of the QTc interval over the definite 
prolonged QTc time (range 360-540 ms) could be assessed. Furthermore, a small number of patients (N= 11) 
with a RISQ-PATH score ≤ 15 points had a prolonged QTc interval (mean=471.5 ms ±8.5) which leads to the 
assumption that a QTc interval prolongation event rarely occurs in this patient population.  
There was no association between QTc intervals and number of QTDrugs. This implies that the prediction of 
the risk for QTc interval prolongation by solely focusing on the medication is not sufficient. This finding is 
supported by Jardin and colleagues [18], who screened inpatients for risk factors of QTc interval prolongation 
and reported an association of QTDrug list 1 alone or concomitant with other QTDrugs with QTc interval 
prolongation, whereas QTDrug from the list 2 and 3 did not show any association with QTc interval 
prolongation. The study hence questioned the clinical relevance of drug-drug interactions between two 
QTDrugs of the list 2 or 3. In our population, 68.6% of the patients receiving a QTDrug list 1 did not have a 
prolonged QTc interval. These results support the conclusion that the prediction of a drug-induced QTc 
interval prolongation or a TdP remains difficult [10]. 
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Many studies have been claiming female sex as a risk factor, which is consequentially, because women 
generally have a longer QTc interval than men [19]–[21]. This prevalence did not occur in our study. We 
detected a higher number of men (N=35) having a QTc interval prolongation compared to 20 women with 
prolonged QTc interval. Rabkin reported no difference of the QTc interval in women and men at older ages 
[22]. The older age of our population, which comprised 86.6% (N=175) patients over 65 years old with a mean 
age of 83 years, would support Rabkin’s outcome that the gender is a neglected factor in older patients when 
estimating the risk for QTc interval prolongation. 
Only 16 (ischemic) cardiomyopathy cases were clearly documented in all patients’ diagnosis list. The number 
of cardiomyopathy slightly increased with the ascending RISQ-PATH score. Cardiac failure on the 
myocardium is linked to a higher risk for QTc prolongation [23]. As the risk factors hypertension and 
arrhythmia were increased with higher RISQ-PATH scores as well, we may support the findings by other 
studies, which have reported patients with advanced heart diseases as being at higher risk for QTc interval 
prolongation [6]. 
Thyroid disturbance was determined by a positive diagnosis and by finding the substitution with levothyroxine 
on the medication list. An increasing number of patients with thyroid disturbances was observed with higher 
RISQ-PATH scores, which supports the effects of thyroid disturbance on ECG measurements [24]. 
Hypokalaemia and hypocalcaemia affecting the cardiac ion channels and resulting in changes of the QTc 
interval is widely shown [5], [6], [9], [25], [26]. A n electrolyte disorder should be treated before exposing the 
patient to further risk factors such as prescribing a QTDrug. 
Strengths and limitations 
A strength of this study mark the unrestrictive inclusion criteria of inpatient aged older than 18 years with a 
minimum of one QTDrug, which resulted in a diverse study population at a size of 202 patients. A 
representative broad population was further enabled by performing this study on three different wards. 
Limitations of this study firstly include that missing patient data such as incomplete diagnoses lists or rare 
documented information of smoking habits led to lower points on the RISQ-PAHT score, since missing values 
were entered as no risk factor. Hence, the RISQ-PATH score was lower than if all risk factors were available. 
Secondly, the QTc time was taken from the newest available ECG during a QTDrug treatment and varied 
Projects
100
Drug-Related Problems
Page 13 of 14 
from an ECG on the index day to ECGs being 14 days old. Yet another limitation was the QTDrug 
categorization, which was adopted from CredibleMeds.org. The categorization of pantoprazole as QTDrug 
list 3 led to the inclusion of a high number of patients (N=130). The mechanism of pantoprazole to induce a 
QTc interval prolongation is explained by its changes to the intestinal pH, which may lead to reduced 
absorptions of magnesium and potassium [27]. But so far, only case reports have linked hypomagnesemia 
caused by proton pump inhibitors with arrhythmia. On the other hand, amiodarone (QTDrug list 1) rarely 
provokes TdP and has cardio protective effects, yet is categorized as QTDrug list 1 [28]. These examples show 
the difficulties associated with predicting the severity of a drug’s risk by solely using its classification. 
Conclusion 
With 81.5 % of inpatients being exposed to at least one QTDrug, this study highlights the requirement of a 
drug-induced QTc interval prolongation risk management. The RISQ-PATH score was associated with QTc 
interval prolongation, with the risk factor ‘prolonged QTc interval’ as the moderator of this association. We 
hence suggest the development of a different scoring and interpretation of the RISQ-PATH score for patients 
without a previously present prolonged QTc interval. Having two separate scale interpretations would increase 
the RISQ-PATH score’s capability as a guiding tool for ECG measurements. The RISQ-PATH score 
summates and weighs risk factors associated with a prolonged QTc interval with the necessary respect to 
pharmacodynamic drug interactions. Our analyses on this meticulously developed tool however support a 
simple code of practice: ECG measurements before starting a QTDrug in a patient with a documented 
prolonged QTc interval. 
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The goals of this thesis were (1) the validation of the Drug-Associated Risk Tool 
(DART) – a self-administered patient questionnaire as a risk-stratification tool on DRPs 
– and (2) the external validation of the RISQ-PATH score as a risk-stratification tool 
on drug-induced QT-prolongation. Concerning the validation of the DART, the study 
design necessitated the translation and adaption of a measure of DRP relevance. With 
CLEOde we present a measure of relevance for pharmacists’ interventions in the Ger-
man language, assessed regarding comprehensiveness and linguistic style by clinical 
pharmacy experts from all German-speaking countries and tested for its interrater and 
test– retest reliability with 10 Swiss clinical pharmacists. The validation of the DART 
also necessitated conducting patient interviews in the context of MRs Type 3. The ne-
wly developed structured patient interview combined an already established Swiss co-
gnitive service by community pharmacists, the Polymedication Check (PMC), with the 
Beliefs about Medicines Questionnaire (BMQ), and hence questioned about medication 
adherence, patient knowledge, handling of medicines, and drug-related concerns about 
the therapy. The structured patient interview was used for 110 patient engagements and 
demonstrated its expected additional value by identifying over 41.8% of all DRPs. With 
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the aid of CLEOde and the structured patient interview, the concurrent criterion validity 
of the DART was assessed by correlation with data retrieved from MRs Type 3. The 
statistical analysis demonstrated the ability of the questionnaire to discriminate patients 
with lower and higher numbers of DRPs: Patients ticking 8 risk factors in the DART 
showed a median of 3 DRPs, whereas patients ticking 15 risk factors showed 8 DRPs. 
Discriminant function analysis identified the questions on polypharmacy, adherence, 
concerns about becoming too dependent on the medicines, heart insufficiency, and di-
abetes as important discriminators between patients with lower and higher numbers of 
DRPs. The summated risk score of these five items had an association with the number 
of DRPs, and therefore allowed validation of the DART at the same time as enabling 
item reduction. Concerning the external validation of the RISQ-PATH score, we were 
able to report an association between the score and the measured QTc intervals in a 
population of hospitalised patients. Our analyses highlighted a significant moderation 
effect by one of the included risk factors, “Prolonged QTc on a baseline ECG.” This 
moderation effect has implications for practice, as it necessitates the categorisation of 
patients before interpreting the RISQ-PATH score and drawing conclusions.
I. cleode
As preparatory steps for the validation study of the DART, we translated the French tool 
for the assessment of relevance of pharmacists’ interventions. We closely followed the 
“ISPOR Principles of Good Practice for the Translation and Culture Adaption Process 
for Patient-Reported Outcomes Measurement.”82 The 10 steps included forward and 
backward translations by 2 independent professional translators, a linguistic evalua-
tion by clinical pharmacists from all 3 German-speaking countries, close contact with 
the original developers, and a strict documentation of changes, which allowed for a 
translation being both close to the original and adapted to local modalities. Within a 
time period of 13 days, we collected 324 interventions performed in routine services 
by clinical pharmacists in three Swiss hospitals. This sample was used to display ac-
ceptability and feasibility of the tool as well as the perceived relevance of the clinical 
pharmacists’ work. The pharmacists who used the tool in their practice reported a time 
needed of “less than one minute” per intervention, which supports future use of CLE-
Ode. As CLEO was designed to be a self-assessment tool for pharmacists, we evaluated 
the reliability of CLEOde focusing on interrater and test–retest reliability in a samp-
le of 10 clinical pharmacists and 10 cases. The clinical dimension, which focuses on 
patient-centred impacts (e.g. adherence, quality of life, prolongation of hospital stay, 
additional treatments), achieved good interrater and excellent test–retest reliability, de-
monstrating generalisability of the ratings. The obtained interrater reliabilities were in 
line with the results of the original CLEO: Vo and colleagues reported moderate (cli-
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nical), substantial (economic) and fair (organisational) interrater reliability between a 
sample of pharmacists working at a centralised chemotherapy preparation unit and peer 
reviewing pharmacists.86 Hence we were able to present CLEOde as a reliable approach 
to the estimation of clinical relevance of pharmacists’ interventions and, more import-
antly, to include the tool in the validation study of the DART. The studies on CLEOde 
also highlighted that the tool’s multidimensionality posed issues for clinical pharma-
cists: The organisational dimension, which focuses on impacts on the work of other 
care team members, only achieved poor interrater reliability. We argued that in contrast 
to the clinical dimension, clinical pharmacists might not yet be familiarised with jud-
ging their interventions from the perspective of other caregivers: When proposing an 
intervention, they may not take into account the impact on time expenditure, work load, 
work place safety, and collaborations of other professions. Interventions do occur, such 
as warning nurses about the cancerogenous potential of the tablets they are about to 
crush. With CLEOde, the estimation of this intervention’s impact on the nurses instead 
of the patient was possible, but new. We hence stated that the additional point of view 
presented by CLEOde might foster awareness of currently neglected impacts of inter-
ventions. We proposed a more intensive introductory session on CLEOde and regular 
team assessments to use our tool in clinical practice.
II. validation of the DARt
The DART was able to discriminate between patients with lower and higher numbers 
of DPRs, identified by MRs Type 3. The MRs Type 3 included the use of the Medica-
tion Appropriateness Index,32 the START/STOPP criteria version 2,31 current treatment 
guidelines,87 and patient interviews. The dataset of 110 patients displayed two clusters: 
a cluster of patients with a high number of DRPs and a high DART score, and a cluster 
of patients with a low number of DRPs and a low DART score. By performing a di-
scriminant function analysis, we were able to highlight important items and to improve 
the correlation of the score with the number of DRPs from weak to moderate at the 
same time. These results displayed the added benefits of using a cluster analysis and a 
subsequent discriminant function analysis over scale correlations. The five highlighted 
items were polypharmacy, diabetes, concerns about becoming too dependent on the 
medicines, heart insufficiency, and adherence.
– Polypharmacy may be defined as the prescribing of multiple medications to one 
individual, to treat one complex condition or multiple conditions present simul-
taneously.88 The term is inconsistently used with either a neutral or a negative 
connotation and with various numbers of medications.89 In the DART, we defined 
polypharmacy as the presence of five or more medications without regard to their 
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appropriateness. Self-reported polypharmacy was one of the five discriminatory 
items for the patient collective with higher numbers of present potential and mani-
fest DRPs within the validation study. This result was in line with research on hos-
pitalisations: Polypharmacy was a determinant for the 332 potentially preventable 
medication-related hospital admissions of the total of almost 13,000 screened un-
planned admissions by Leendertse and colleagues in The Netherlands. Within the 
multivariate analysis, equal to or greater than 5 chronically used drugs presented 
with an odds ratio of 2.7 for a preventable ADE including medication errors. The 
risk of an ADE is estimated to rise from 13% for two concomitantly prescribed me-
dications to 58% for five and 82% for seven or more medications.90 Polypharmacy 
remains an independent contributor to the likelihood of truly identified DRPs in 
hospitalised patients even when MRs are only performed on automated alerts trig-
gered by other risk factors.91 Polypharmacy is hence often used as risk factor and 
simple trigger for pharmacists’ interventions:92 Adding a new drug to a persisting 
drug regimen gets more difficult with each additional treatment.62
– As for diabetes mellitus, non-adherence in patients is associated with negative out-
comes. The retrospective cohort study of 11,532 patients with diabetes mellitus in 
a managed care organisation by Ho and colleagues93 identified 2,456 non-adherent 
patients with diabetes mellitus. These non-adherent patients showed significantly 
higher rates of hospitalisation and death, even though they were younger and had 
fewer comorbidities than the control group. Insulin and oral antidiabetics are drug 
classes frequently associated with pharmacists’ interventions during a hospitalisa-
tion,92 as they are associated with DRPs – as reported by a review over 21 studies.94
– The item of the DART on concerns about becoming too dependent on the medici-
nes stems from the BMQ. In 1999, Horne and colleagues introduced the BMQ.75 
With their questionnaire they aimed to develop a method to score cognitive proces-
ses involved in medication non-adherence. The final score of the questionnaire is 
obtained with adherencepromoting feelings of necessity and adherence-repressing 
thoughts of harm and dependency, rated in 10 questions. In our early research 
into the risks for developing DRPs, we identified aversion to medication as a risk 
factor. In our opinion, aversion to medication was best represented with the adhe-
rence-repressing items of the validated BMQ. Adherence and concerns about be-
coming too dependent on the medication are now both validated items of our five 
items, the reduced DART score.
– Heart insufficiency/heart failure was one of the five discriminatory items for the 
patient collective of higher numbers of DRPs. A Mann-Whitney U test also revea-
led a statistically significant correlation between “Yes”-answers on heart failure 
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and DRPs estimated to be of high clinical relevance. We therefore proposed to 
use heart failure as trigger for an immediate MR Type 3. Patients with heart fai-
lure are required to follow their drug regimen as any other patient collective, but 
their non-adherence quickly leads to hospitalisation.95 Missing doses of prescribed 
diuretics or digoxin will aggravate the symptoms of the disease until inpatient 
treatment is necessary. Appropriate prescribing is difficult when heart failure is 
present, as the medicinal treatment of comorbidities may worsen its symptoms.96 
Interventions consisting of MRs and post-discharge follow-up may reduce the hos-
pital admission rate of older people with heart failure.97
– In the study of Leendertse and colleagues, non-adherence was one of the risk fac-
tors leading to preventable medication-related hospital admissions.6 Contrary to 
our validation study, nonadherence was not self-reported but calculated with phar-
macy refill data, objectifying and hence solidifying our results. In general, omissi-
on of drugs is a frequently identified DRP.54 98
Besides performing the cluster analysis with the whole dataset, we re-applied the same 
methods to a reduced dataset that focused on the DRPs only detectable in patient in-
terviews in order to select items that highlight patients benefiting the most from direct 
engagement in an MR Type 2a: Within this reduced dataset we identified the use of 
drugs (non-steroidal antirheumatics, antidiabetics, and digoxin) and restricted kidney 
function, concerns about dependency, concerns about having to use medicines, use of 
therapeutic skin patches, preparation of medicines by homecare, and polypharmacy as 
predictors of patients who benefited the most of interviews. These risk factors for DRPs 
should be seen in light of the population and the approach we used, which encompas-
sed a patient interview with older, hospitalised patients: In this step of the statistical 
analysis, all the identified items may lead to counselling of patients, with their under-
lying problem being patients’ insufficient medicines knowledge. Insufficient medicines 
knowledge by the patient as cause of potential DRPs accounted for 23.2% of all identi-
fied issues. Older patients are known to be prone to insufficient medicines knowledge.99
Assessing the correlation between DART items and DRPs estimated to be of high clini-
cal relevance revealed four additional risk factors to be considered for future adaption 
of the questionnaire: Mann-Whitney U-Tests showed a statistically significant correla-
tion between DRPs with the CLEO estimates “major” and “lifesaving” and the DART 
items on issues such as tabletsplitting, heart failure, and use of oral anticoagulants. Use 
of steroids was associated with DRPs with “moderate” clinical relevance. Steroids and 
anticoagulants are drugs frequently associated with rehospitalisation or adverse drug 
events;20 100-103 tablet-splitting may lead to problems with handling and subsequently 
adherence.104 The items on tablet-splitting and use of oral anticoagulants or steroids 
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were not of discriminatory value for the two initial clusters of patients. However, they 
correlated with DRPs estimated to be of high clinical relevance, and hence should be 
used for risk stratification and as triggers for immediate services. These findings de-
monstrated the benefits of using different statistical approaches for the identification of 
correlations.
The combination of the results of different statistical analyses allowed the compiling 
of a comprehensive table linking items of the DART with suggestions on clinical phar-
macy services with different time requirements, allowing resource allocation (Table 2, 
excerpt from chapter 3 „Assessing the ability of the Drug-Associated Risk Tool (DART) 
questionnaire to stratify patients according to their risk of Drug-Related Problems“). 
The items may be used to trigger either an immediate or a later MR Type 3 using me-
dical records, laboratory measurements, and structured patient interviews as source of 
information, or an MR Type 2 only using medical records and structured patient inter-
views as source of information.
Table 2 Combination of DART items and possible triggered clinical pharmacy services.
DARt item (translated from german) clinical pharmacy service
I have a heart weakness/heart performance weakness. Consider immediate MR Type 3
I have trouble taking my medicine because of splitting
tablets. Consider immediate MR Type 3
I use Marcoumar® (phenprocoumon), Xarelto® (rivaroxaban),
Sintrom® (acenocoumarol), Eliquis® (apixaban),
Lixiana® (edoxaban), or Pradaxa® (dabigatran) at home.
Consider immediate MR Type 3
I use cortisone at home. Consider immediate MR Type 3
I have diabetes. Consider MR Type 3
I take more than 5 drugs every day, which are prescribed by my physician. Consider MR Type 3
Do you sometimes forget to take your medicine? Consider MR Type 3
I sometimes worry about becoming too dependent on my
medicines. Consider MR Type 3
I use medicines against rheumatism/inflammation at home. Consider MR Type 2a
I use insulin/medicines against diabetes at home. Consider MR Type 2a
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I use digoxin at home. Consider MR Type 2a
I sometimes worry about the long-term effects of my
medicines. Consider MR Type 2a
Having to take this medicine worries me. Consider MR Type 2a
I apply my medication in the form of skin patches. Consider MR Type 2a
I have a restricted kidney function/kidney dysfunction/kidney
disease. Consider MR Type 2a
The preparation of my medicine is done by a homecare
institution. Consider MR Type 2a
MR Type 3: Medication Review Type 3; Drug therapy evaluations using medical records, laboratory measure-
ments, and the patient’s opinions and experiences (i.e. patient interviews). MR Type 2a: Medication Review Type 
2a; Drug therapy evaluations using medical records and the patient’s opinions and experiences (i.e. patient inter-
views), without laboratory measurements.38
 
It is possible to compare the performance of the DART to other risk-stratification tools 
by addressing measures as Area under the Receiver Operating Characteristic curve 
(AuROC; also known as C-statistic), specificity, and sensitivity.61 AuROC quantifies 
the probability that a patient classified for the cluster of patients with higher numbers 
of DRPs had a higher score of the reduced five items at the same time. The five items 
achieved an AuROC of 0.865 (SE=0.035, p<.001, 95% CI [.797, .932]), which transla-
tes into good performance.61 At greater than one yes-answer (> 1) for these five items, 
the ROC curve showed a sensitivity of 74% and a specificity of 82%. These numbers 
are reassuring, as a lower sensitivity could result in a misclassification of a high-risk 
patient with resulting patient harm and poor specificity would incorrectly flag low-
risk patients for intervention.61 These numbers also allow for a direct comparison of 
risk-stratification tools, which was done by Falconer and colleagues in the systematic 
review on models for predicting adverse drug event risks in inpatients.61 This review 
identified 10 studies that described the development of a new risk prediction model but 
only the BADRI risk score was deemed to be sufficient regarding model development, 
validation and performance. As already presented earlier, the BADRI risk score con-
sists of the variables hyperlipidaemia, number of drugs (> 8), length of hospital stay (≥ 
12 days), use of antidiabetics, and high white cell count on admission.64 These variables 
necessitate the deployment of either a care team member or an algorithm in comparison 
to our patient-administered questionnaire. The BADRI model achieved an AuROC of 
0.74 (95% CI 0.68-0.79), a sensitivity of 80% and a specificity 55% at a cutoff at one 
present risk factor.61 These numbers were achieved during an external validation, which 
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elevates the performance above our study results from an internal validation. It is inte-
resting to note, however, that our patient-administered questionnaire performs similarly 
to a sophisticated model in its primary validation.
Tools like the BADRI risk score take advantage of being deployable as computer-based 
algorithms that allow for an automated surveillance of the whole hospital.31 105 This 
advantage over paper-based solutions like the DART, however, shifts caregivers away 
from the patients. The WHO expects pharmacists to focus on patient-centred care (i.e. 
respect the patient’s opinions and concerns).1 6 Patients’ opinions and concerns cannot 
be assessed with automated algorithms processing electronic documentation. We ho-
wever highlighted the necessity of the assessment of patients’ knowledge, opinions, 
and sorrows for the identification of DRPs. With the DART, we present a paper-based 
questionnaire that asks the patients about their medicine-use. The questionnaire is in-
tended to be completed by the patient to trigger clinical pharmacy services promoting 
patient self-care.
III. Identified Drug-Related Problems and Contribution of Patient Inter-
views
In our validation study of the DART we identified 595 DRPs in 110 patients, with only 
2 patients having no DRP. This result conforms with other research, where at least one 
manifest or potential DRP was reported in 96% of investigated patients.98 The develop-
ment of a structured patient interview was a necessity for the validation of the DART as 
existing tools to detect DRPs in the elderly do not consider the patient’s perspective.98 
Our results demonstrated the supplementary value of direct patient engagement in a 
Swiss geriatric ward and hence support the addition of the patient’s perspective to me-
thods of DRP identification: Accessing our patients in direct patient contact accounted 
for the identification of 41.8% DRPs. And 38.2% of DRPs were only identifiable via 
interviews but not with any other method of identification (i.e. Medication Appropri-
ateness Index, the START/STOPP criteria version 2). The ability of patient interviews 
to detect important DRPs has already been shown by others: Viktil and colleagues con-
cluded their study on DRPs in hospitalised Norwegian patients with the statement that 
almost two fifths of the DRPs were identified during patient–pharmacist contact.53 The 
issues detected in the interviews of Vitkil and colleagues were mainly underprescribing, 
medical chart errors, patient adherence, and the need for patient education. We are able 
to complement these findings with the main issues we identified during our interviews: 
We also coded as much as 50.7% of the causes for potential DRPs as lack of medici-
nes knowledge, issues in patient documentation, and missing indication of prescribed 
drugs. Insufficient knowledge of the patients as cause of the DRP was identified most 
110
Drug-Related Problems
General Discussion and Conclusion
prominently in 23.2% of all cases. Maniaci and colleagues reported that 15% of their 
study participants were unaware of the newly prescribed medication at their discharge 
and only 64% of all participants knew the purpose of their medication.99 Poor health 
literacy is associated with a higher mortality rate.106
By using CLEOde, we assigned the clinical relevance of minor to the identified DRPs 
on patient knowledge, adherence, and quality of life because there was no acute danger 
of hospitalisation or need of an additional treatment or increased surveillance. CLEOde 
focuses on direct and prompt consequences and hence lowers the estimated clinical 
relevance of primarily patient-centred DRPs. Patient-centred DRPs like health illiter-
acy and swallowing difficulties are, however, potential causes of non-adherence, and 
may cause patient harm in the long run.106 107 Kwint and colleagues were not bound 
to predefined levels of an assessment tool and demonstrated that DRPs identified by 
pharmacists visiting homecare patients were assigned a higher relevance and led to 
recommendations on drug changes more frequently compared to those identified from 
objective data (i.e. drug regimen and medical records).84
START/STOPP criteria version 2 contributed only 7.9% and 2.4% of identified DRPs, 
respectively. These proportions are reinforced by findings by Verdoorn and colleagues, 
who reported a contribution of 19% by the START/STOPP criteria to the overall num-
ber of identified DRPs.108 However, our reported small contributions were influenced 
by (1) ward personnel being trained in clinical pharmacy activities before study deplo-
yment and (2) our decision to exclude the implicit content of the criteria: The STOPP 
criterion “No indication present” was one of the most identified DRPs in the study by 
Verdoorn and colleagues108 and translates into our “missing indication for prescribed 
medication,” covered by our use of the MAI. The MAI was an important contributor 
for the identification of DRPs: The implicit approach identified 43.9% of DRPs and the 
patient’s score strongly correlated with the patient’s number of DRPs. Some criteria 
of the MAI (i.e. “Is the medication effective for the condition?”, “Are the directions 
practical?”) necessitate information only retrievable from the patients themselves, hen-
ce the effectiveness of the MAI to identify DRPs should be regarded in the context of 
our patient interviews. The combination of both, MAI and patient interviews, seems 
beneficial for the identification of DRPs, but brings together the most timeconsuming 
approaches. In circumstances like these, the DART could be used to select the patients 
benefiting the most.
Because we coded the ATC codes for each DRP, we were able to investigate the frequen-
cy with which certain drug classes were associated with DRPs. To our knowledge, this 
is the first such analysis for Swiss geriatric wards. Agents that are reported as frequent 
triggers for pharmacists’ interventions are antibacterial agents, antithrombotic agents, 
analgesics, and drugs for acid-related disorders.109 Similarly, we identified analgesics, 
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antithrombotic agents, and drugs for acid-related disorders and additionally psycholep-
tics as drug classes most frequently associated with the identified DRPs. Misprescribed 
analgesics may lead to unsatisfactory pain relief for patients, again only identifiable 
via direct patient engagement. Under- or overprescribing of antithrombotic agents may 
lead to serious ADEs, i.e. myocardial infarction or bleeding. Drugs for acid-related 
disorders are a drug class frequently associated with overprescribing: 25% to 70% of 
all proton-pump inhibitor (PPIs) prescriptions have no clear indication.110 As an examp-
le, PPIs are appropriately prescribed to prevent upper gastro-intestinal bleeding when 
non-steroidal anti-inflammatory drugs are used in the elderly to target ossification pro-
cesses after prosthesis insertions.87 However, PPIs are often not terminated in regards to 
the therapy duration.110 The drug class of psycholeptics, which is additional to other stu-
dy results, may be explained by our study population: The geriatric and rehabilitation 
wards were treating chronic pain, such as chronic pain in the lumbar regions associated 
with intervertebral disk displacement and eradiating nerve pain. Besides treatment with 
analgesics, this kind of chronic pain is also treated with psycholopetics as co-analge-
sics.87 Patients’ knowledge of this kind of medication seems especially important as 
patient leaflets may state unsettling ADRs associated only with higher doses than those 
used in the treatment of chronic pain. The results on the drug classes most frequently 
associated with our identified DRPs may be used to adapt the resident physicians’ cur-
riculum during training on geriatric wards: The training should encompass guideline 
compliance concerning the prescription of analgesics, antithrombotic agents, and PPIs, 
as well as patient counselling.
Iv. RIsQ-PAth score and Prolonged Qtc Intervals
By performing a hierarchical regression analysis, a moderated hierarchical regression 
analysis, and a multiple regression analysis, a procedure described by Aiken, West, and 
Reno,111 we aimed to investigate the association between the RISQ-PATH score and 
measured QTc intervals with a potential moderation effect in mind, such a moderator 
being a qualitative or quantitative third variable, which partitions an independent va-
riable (i.e. RISQ-PATH score) into subgroups and hence influences the strength of the 
relation to a dependent variable (i.e. measured QTc interval). We were able to report an 
association between the RISQ-PATH score and the measured QTc interval. Concerning 
our specific dataset of 156 hospitalised patients, we identified the risk factor “Prolonged 
QTc on a baseline ECG” as a moderator for this association: The association between 
the RISQ-PATH score with the measured QTc interval was found to be significant only 
in patients who already had a previously present prolonged QTc interval, which implied 
that the RISQ-PATH score is highly dependent on one specific risk factor. We explained 
that if a prolonged QTc interval is present, an association between the RISQ-PATH sco-
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re and the measured QTc interval exists, whereas with no previously prolonged QTc in-
terval no association between RISQ-PATH score and the QTc interval may be expected. 
With the performed statistical analysis, we were hence able to suggest the development 
of a different scoring and interpretation of the RISQ-PATH score for patients without 
a previously present prolonged QTc  interval. Having two separate scale interpretations 
would increase the RISQ-PATH score’s capability as a guideline for initiation of ECG 
measurements. Furthermore and more importantly, we were able to suggest a simple 
code of practice when starting a drug with the potential to prolong the QTc interval: 
With due respect to all risk factors and pharmacodynamic drug interactions, just order 
a ECG measurement for a patient with an already prolonged QTc interval.
v. limitations
Limitations of this thesis mainly include the generalisability of the results:
– The validation study of the DART, also including the newly developed structured 
patient interviews, only included patients admitted to geriatric and rehabilitation 
wards. The mean age was 76.9 years (SD 10.3), and the mean number of prescribed 
drugs was 11.0 (SD 4.2). This represents an elderly, highly polymedicated popu-
lation. This population further deviated from generalisability by excluding pati-
ents with eye-sight, handling, cognitive, or language levels prohibiting independent 
completion of the questionnaire. These criteria led to the exclusion of patients with 
already arguable health literacy, and importantly, to the exclusion of patients with 
cognitive impairment (i.e. dementia) – a patient collective that is known to be as-
sociated with medication-related hospitalisation.6 However, we see the DART as a 
tool to promote patient-empowerment and self-management – constructs that may 
be already externally restricted in patients dwelling in nursing homes because of 
their cognitive impairment.
– The external validation of the RISQ-PATH score only included inpatients from ge-
riatric and rehabilitation wards. As such, 137 of the analysed 156 patient datasets 
(87.2%) were already fulfilling one of the respected risk factors, “age > 65 years.” 
This puts constraints on our results regarding applicability to any other patient po-
pulation and to the validation of this specific score item. 
– Five of the ten clinical pharmacists involved in the validation process of CLEOde 
had a clinical working experience of less than one year, which may affect their 
perception of clinical relevance. However, this composition of clinical pharmacists 
represents the current situation within the Swiss hospitals involved.
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Besides restricted generalisability, limitations of this thesis also encompass the absen-
ce of outcomes such as re-hospitalisation or mortality. We developed the DART as 
a screening tool, and as such, the DART is dependent on interventions that change 
any measurable prospective outcomes (e.g. re-hospitalisation rates). We considered it 
a necessity to evaluate the performance of our tool before linking it with certain inter-
ventions. Falconer and colleagues even called for proven external validity prior to im-
pact studies and implementation in practice.61 The study design respected this decision 
by focusing on currently present potential and manifest DRPs instead of prospective 
outcome measures; however, it may now be argued that higher scores in the DART are 
associated with higher numbers of DRPs and DRPs are associated with poor health out-
comes in general.95 The correlation of higher DART scores and poor health outcomes 
may hence be assumed.
vI. Implications for Practice
As a validated tool, the DART may be used as a risk-stratification tool in order to provide 
medication reviews to inpatients who need it the most. Distributed at the beginning of a 
hospitalisation, the DART may be completed by the patients themselves without increa-
sing the workload of any caregiver. The statistical analyses allowed for a linkage of items 
of the questionnaire with certain methods of the study: Based on the answers from the 
patients clinical pharmacists may decide to perform either an immediate or postponed 
MR Type 3 or a structured patient interview to identify DRPs (i.e. MR Type 2a). The tool 
will hence aid clinical pharmacists in allocating their restricted resources and in approa-
ching patients with the appropriate depth of review. When not wishing on a paper-based 
solution, the few identified risk factors, which do not require direct patient contact, may 
be incorporated into automated algorithms for patient selection.
We demonstrated the benefits of direct inpatient engagement as opposed to the use of au-
tomated algorithms, as we highlighted the number of DRPs only detectable in structured 
patient interviews on geriatric wards. We were able to pilot a structured patient interview 
based on the PMC, with only slight modifications by adding items of the BMQ. This mo-
dified PMC may be used for future inpatient engagements by hospital clinical pharmacy 
services to target the patients’ medication literacy and documentation and hence help in 
reducing the number of preventable medication-related hospitalisations.
Structured assessments of medication therapies like those described in this thesis may 
identify a vast number of DRPs with various implications on treatment safety – from neg-
ligible to lifesaving relevance. With CLEOde we adopted an evaluation tool that should 
help German-speaking clinical pharmacists in self-reflecting on their own interventions. 
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Used in daily practice and teaching, clinical pharmacists should quickly learn to priori-
tise their identified DRPs. This prioritisation of DRPs marks a necessity for focused and 
efficient interdisciplinary communication. When used in research, CLEOde will help in 
subsetting datasets on the interventions’ relevance and in visualising findings.
By identifying a moderation effect for the association between the RISQ-PATH score and 
the measured QTc intervals, we were able to support a simple code of practice for one 
specific DRP: performing an ECG measurement before starting a drug with the potential 
to prolong the interval for a patient with an already prolonged interval. For this specific 
subset of patients, the now externally validated tool may be used to predict the QTc inter-
val. For other patients, we gathered the evidence to suggest the development of a different 
scale interpretation.
vII. outlook
As the DART is now validated for a population of hospitalised older patients without co-
gnitive impairment, the questionnaire should be examined for regular pharmacy clients, 
including adults with an age of below 65 years. This validation would set the foundation 
for the DART to be used in community pharmacies that aim to promote their patients’ 
self-management. A screening tool like the DART could be used to select patients who 
actually need an adherence intervention like the PMC. The study on the effectiveness 
of the PMC concluded with no significant positive effects on adherence and argued that 
these results were influenced by selection bias as only highly motivated pharmacies and 
patients agreed to participate.112 The application of the DART as a screening for patients 
who would benefit from the PMC seems especially beneficial as the newly developed 
structured patient interview was based on the PMC. The structured patient interviews 
detected a proportion of 41.8% of all DRPs that were used to validate the DART. Hence 
it may be assumed, that the DART identified patients at risk of DRPs who would benefit 
from a PMC.
Barenholtz-Levy validated her paper-based risk stratification questionnaire on DRPs si-
milarly to our study.65 Her questionnaire also identified patients presenting with higher 
numbers of DRPs, but the study population consisted of 40 patients aged over 60 years, 
recruited at three pharmacies, taking a mean number of 7.3 drugs. It would be of interest 
to examine our five discriminative items of the DART together with Barenholtz-Levy’s 
questionnaire, both administered at the same time in a community pharmacy. Studying 
the convergent validity of the DART and of Barenholtz-Levy’s measure would further 
display both questionnaires’ ability to be used as a risk-stratification tool on DRPs.
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Concerning CLEOde, a big dataset of interventions coded for relevance would facilitate 
the examination of factors that influence the perceived impact. Are there certain interven-
tions that are consistently estimated to be of higher relevance? Are interventions made re-
gularly that are estimated to be of minor clinical relevance but require greater resources? 
This dataset may be generated by adding CLEOde to an intervention classification (e.g. 
GSASA classification113) for a longer period of time.
Regarding the RISQ-PATH score, the datasets used for the internal and the external va-
lidation could be combined. This would generate a large dataset to re-weigh the score’s 
items for patients without an already prolonged QTc interval. By generating this addi-
tional scale interpretation, the association between the score and the measured interval 
could improve even in the absence of the identified moderator “previously present pro-
longed QTc interval.” Enabling this association would reveal the score’s true potential as 
a risk-stratification tool for patients without pre-existing conditions.
vIII. conclusion
This thesis presents measures of risk and relevance for DRPs: The DART as a measure 
of risk is now validated regarding its ability to discriminate between low- and high-risk 
inpatients for DRPs. As a self-administered questionnaire, the DART can be used to stra-
tify hospitalised patients according to their need for clinical pharmacy services. When 
implemented in practice, the DART will help in hospital pharmacy resource allocation 
without increasing the workload of any  health care professional.
CLEOde is a translated and culturally adapted tool to estimate the relevance of DRPs in 
three different dimensions. The German version was evaluated in hospital practice and 
we assessed interrater and test–retest reliability of CLEOde, which proved the tool’s abili-
ty to be used by the intervening pharmacists themselves. When implemented in practice, 
CLEOde will help in focusing on the most relevant clinical interventions in practice, rese-
arch, and teaching.
The RISQ-PATH score as measure of risk for a specific DRP is now externally validated. 
The validation process identified important limitations of this risk-stratification tool and 
proposed a code of practice for initiating ECG measurements. 
This thesis also reports on the performance of a structured patient interview to identify 
issues on drug-related adherence and patient documentation of hospitalised patients. The 
combination of the PMC and the BMQ may be used as a template for direct inpatient en-
gagement to improve patients’ medication literacy and documentation.
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This thesis hence presents a validated self-administered patient questionnaire to stratify 
for drug-related risk, a validated assessment to estimate the relevance of drug-related 
problems, a structured patient-interview to identify issues on drug-related adherence 
and patient documentation, and a valid score to detect patients at risk of drug-induced 
QT-prolongation. Assessing the risk and relevance of DRPs remains a challenge worth 
pursuing in order to increase patient and drug safety.
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Appendices
I. Project: translation and validation of a tool to Assess the Impact of 
clinical Pharmacists’ Interventions  
CLEOde
Evaluation of the impact of a pharmacist’s intervention (PI) with the CLEOde tool
Klinische Auswirkung
Grundsatz: Die klinische Auswirkung wird nach einem wahrscheinlichem Szenario und nicht nach schlimmstem/bestem
Szenario bewertet.
Die klinische Auswirkung wird aus Sicht des Patienten bewertet.
Erläuterung:
Schaden: Körperlicher Schaden - Beeinträchtigung der physischen und/oder psychischen Fähigkeiten des Patienten.
Lebensqualität: Physische Aspekte (Autonomie, körperliche Fähigkeiten, Fähigkeit tägliche Aufgaben zu erledigen, etc.), psychologische 
Aspekte (Ängste, Depression, Emotionalität, etc.), soziale Aspekte (bezogen auf das familiäre oder professionelle Umfeld, Freundeskreis, Pflege 
persönlicher Beziehungen, Teilnahme an Sozial- und Freizeitaktivitäten, etc.) und somatische Aspekte (Symptome der Krankheit).
Überwachung: Nachkontrollen, labormedizinische Kontrollen.
Behandlung: Änderung der Therapie oder zusätzliche medizinische/chirurgische Behandlung.
Score Auswirkung Definition
-1C schädlich/ negativ
Die pharmazeutische Intervention (PI) kann zu negativen Ergebnissen hinsichtlich des klinischen Zustandes, 
des Wissenstandes, der Zufriedenheit, der Therapietreue (Adhärenz) und/oder der Lebensqualität des 
Patienten führen.
0C ohne Die PI hat keine Auswirkung auf den Patienten hinsichtlich des klinischen Zustandes, des Wissenstandes, der Zufriedenheit, der Therapietreue (Adhärenz) und/oder der Lebensqualität des Patienten.
1C gering
Die PI kann den Wissensstand, die Zufriedenheit, die Therapietreue (Adhärenz) und/oder die Lebensqualität 
des Patienten verbessern.
ODER
Die PI kann einen Schaden beim Patienten verhindern, der keine Überwachung/Behandlung erfordert.
2C mittel Die PI kann einen Schaden beim Patienten verhindern, der eine Überwachung oder Behandlung erfordert, aber keine Hospitalisierung herbeiführt oder einen bestehenden Spitalaufenthalt verlängert.
3C erheblich
Die PI kann einen Schaden verhindern, welcher einen Spitalaufenthalt des Patienten verursacht oder 
verlängert.
ODER
Die PI kann einen Schaden beim Patienten verhindern, der eine dauerhafte Invalidität oder Beeinträchtigung 
verursacht.
4C lebensnotwendig Die PI kann einen Schaden beim Patienten verhindern, der eine intensiv-medizinische Behandlung nach sich zieht oder zum Tod des Patienten führt.
NB nicht beurteilbar Die verfügbaren Informationen erlauben es nicht, die klinische Auswirkung zu beurteilen.
Wirtschaftliche Auswirkung
Grundsatz: Die Kosten der medikamentösen Behandlung beziehen sich auf die finanziellen Kosten des Krankenhauses.
Erläuterung:
Die Kosten der medikamentösen Behandlung beinhalten zwei prinzipielle Aspekte:
■ Arzneimittelkosten
■ Die Kosten der Überwachung der medikamentösen Behandlung (z.B. Folgeuntersuchungen, Labor, etc)
Score Auswirkung Definition
-1E höhere Kosten Die PI erhöht die Kosten der medikamentösen Behandlung des Patienten.
0E keine Veränderung Die PI verändert die Kosten der medikamentösen Behandlung nicht.
1E geringere Kosten Die PI reduziert Kosten bei der medikamentösen Behandlung des Patienten.
NB nicht beurteilbar Die verfügbaren Informationen erlauben es nicht, die wirtschaftliche Auswirkung zu beurteilen.
Organisatorische Auswirkung
Grundsatz: Die organisatorische Auswirkung beschreibt den Einfluss auf die Qualität des Behandlungsprozesses aus Sicht
des medizinischen Personals.
Erläuterung:
Folgende Aspekte sind insbesondere zu berücksichtigen:
■ Zeitersparnis ■ Vereinfachung der professionellen Tätigkeit ■ Erhöhte Sicherheit für das Personal
■ Verbesserte Kenntnisse ■ Vereinfachte Zusammenarbeit ■ Kontinuität der Behandlung
Score Auswirkung Definition
-1O verringert Die PI reduziert die Qualität des Behandlungsprozesses.
0O ohne Die PI hat keinen Einfluss auf die Qualität des Behandlungsprozesses.
1O erhöht Die PI erhöht die Qualität des Behandlungsprozesses.
NB nicht beurteilbar Die verfügbaren Informationen erlauben es nicht, die organisatorische Auswirkung zu beurteilen.
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CLEO: Factsheet 
Translation of a French Tool to Assess the Impact of Clinical Pharmacists' 
Interventions
For what stands the abbreviation CLEO? 
The abbreviation CLEO represents the three dimensions of the tool: Clinical, Economic, and Organisational 
What is CLEO? 
CLEO is a multidimensional scale to assess potential impacts of pharmacists’ interventions (PI’s). The tool 
displays 3 dimensions, which may be influenced by an intervention. CLEO is based on a systematic review 
of existing tools and evaluation models of health care interventions.1
Who developed CLEO? 
The development process was part of the PhD-thesis of Mrs. Thi-Ha VO at the University Grenoble Alpes 
in France. Seven clinical pharmacists, belonging to the French Society of Clinical Pharmacy, were involved 
in the development. 
Why was CLEO developed? 
Clinical pharmacists are increasingly engaged in detecting and resolving drug-related problems within 
multidisciplinary ward rounds. The majority of existing tools to assess the significance of applied 
interventions are mainly focused on clinical aspects and fail to detect comprehensive impacts. The goal was 
to develop a simple, multidimensional, comprehensive, and reliable tool. 
Who will use CLEO? 
In Switzerland: After successful translation and re-validation, the tool will be used by Swiss clinical 
pharmacists and candidates of the „Fähigkeitsausweis Klinische Pharmazie FPH” to assess the significance 
of their interventions, which are documented with the GSASA-classification system.2 A direct implementation 
of CLEO within the GSASA-classification is planned. 
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How to use CLEO? (Example) 
The pharmacist’s intervention may avoid an allergic reaction, which would prolong the ongoing 
hospitalisation: The clinical impact according to CLEO is +3Cl. But the new drug is more expensive: The 
economic impact is -1E. The patient was changed from i.v. to oral administration: This regimen is simpler 
and less time-consuming for health care staff: The intervention has a positive organisational impact of +1O.
References 
1. Vo TH, Charpiat B, Catoire C, Juste M, Roubille R, Rose FX, Chanoine S, Bosson JL, Conort O, 
Allenet B, Bedouch P. Tools for Assessing Potential Significance of Pharmacist Interventions: A Systematic 
Review. Drug safety 2015. 
2. Maes KA, Tremp RM, Hersberger KE, Lampert ML. Demonstrating the clinical pharmacist's activity: 
validation of an intervention oriented classification system. International journal of clinical pharmacy 2015; 
37: 1162-71. 
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Adapted Excerpt FlexiForm Questionnaire: «Kognitives Debriefing der deutschen CLEO-Version»
Hintergrund
CLEO ist ein multidimensionales Evaluierungssystem zur Bewertung der Auwirkung von klinisch-
pharmazeutischen Interventionen. Die Entwicklung des französischen Evaluierungssystemes war Teil der 
Doktorarbeit von Frau Thi-Ha VO an der Universität Grenoble.
Ziel
Ziel ist eine deutsche Übersetzung des Evaluierungssystemes anzufertigen. Für den Abschluss der 
Übersetzungsarbeiten wird ein kognitives Debriefing durch die Zielpopulation benötigt. Die Zielpopulation 
besteht bei CLEO aus klinisch tätigen Pharmazeuten. Im Zuge des kognitiven Debriefings sollte das 
CLEO Evaluierungssystem an Repräsentanten der Zielpopulation in der neuen Anwendersprache nach 
Verständlichkeit und sprachlichem Stil getestet werden. Daher bitten wir Sie, jedes Level der deutschen 
Übersetzung des CLEO-Evaluierungssystemes einzeln nach den Kriterien 1. Inhaltliche Verständlichkeit 
und 2. Sprachlicher Stil zu bewerten. Das Fernziel ist die Integration des CLEO-Evaluierungssystemes in 
das Schweizer Klassifizierungssystem für klinischpharmazeutische Interventionen.
Auftrag
Bitte füllen Sie den Fragebogen vollständig aus. Nach Beurteilung eines Levels können Sie jeweils 
Kommentare/ Meinungen zu dem jeweiligen Level anbringen. Am Ende jeder Dimension können Sie 
jeweils Kommentare/ Meinungen zur jeweiligen Dimension anbringen. Diese sind erwünscht. Die letzte 
Seite bietet Platz für eine persönliche Einschätzung des CLEO Evaluierungssystemes. Beachten Sie bitte, 
dass wir als Übersetzer keinen Einfluss auf das zugrundeliegende Konzept haben. Wir wären Ihnen sehr 
dankbar für eine ausführliche Rückmeldung, da es uns hilft, die Übersetzung vor der geplanten 
Revalidierung weiter zu verbessern. Zeitaufwand: ca. 30 min.
Fragen
Jeder Inhaltsblock von CLEO wird einzeln auf einer Likert-Skala zu inhaltlicher Verständlichkeit bewertet: 
schlecht/ schwach/ ungenügend/ genügend/ gut/ sehr gut.
Jeder Inhaltsblock von CLEO wird einzeln auf einer Likert-Skala zu sprachlichem Stil bewertet: schlecht/ 
schwach/ ungenügend/ genügend/ gut/ sehr gut.
Klinische Auswirkung
 Grundsatz: Die klinische Auswirkung wird nach wahrscheinlichem Szenario bewertet und nicht 
nach schlimmstem/bestem Szenario. Die klinische Auswirkung wird aus Sicht des Patienten 
untersucht.
 Erläuterung: Behandlung: Änderung der Therapie oder zusätzliche medizinische/chirurgische 
Behandlung.
 Schaden: Körperlicher Schaden - Beeinträchtigung der physischen und/oder psychischen 
Fähigkeiten des Patienten.
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 Lebensqualität: Physische Aspekte (Autonomie, körperliche Fähigkeiten, Fähigkeit tägliche 
Aufgaben zu erledigen, ect. ), psychologische Aspekte (Ängste, Depression, Emotionalität., etc.), 
soziale Aspekte (bezogen auf das familiäre, freundschaftliche oder professionelle Umfeld, 
persönliche Beziehungen pflegen, Teilnahme an Sozial- und Freizeitaktivitäten, etc.) und
somatische Aspekte (Symptome der Krankheit).
 Überwachung: Nachkontrollen, labormedizinische Kontrollen.
 -1C = schädlich/ negativ: Die pharmazeutische Intervention (PI) kann zu ungünstigen Ergebnissen 
hinsichtlich des klinischen Zustandes, des Informationsstandes, der Zufriedenheit, der 
Medikamententreue und/oder der Lebensqualität des Patienten führen.
 0C = ohne: Die PI hat keine Auswirkung auf den Patienten hinsichtlich des klinischen Zustandes, 
des Informationsstandes, der Zufriedenheit, der Medikamententreue und/oder der Lebensqualität 
des Patienten.
 1C = gering: Die PI kann den Informationsstand, die Zufriedenheit, die Medikamententreue 
und/oder die Lebensqualität des Patienten verbessern. ODER Die PI kann einen Schaden 
verhindern, der keine Überwachung/Behandlung erfordert.
 2C = mittel: Die PI kann einen Schaden beim Patienten verhindern, der eine Überwachung oder 
Behandlung erfordert, aber keine Hospitalisierung herbeiführt oder einen bestehenden 
Spitalaufenthalt verlängert.
 3C = erheblich: Die PI kann einen Schaden verhindern, welcher einen Spitalaufenthalt des 
Patienten verursacht oder verlängert ODER Die PI kann einen Schaden verhindern, der eine 
dauerhafte Invalidität oder Behinderung verursacht.
 4C = lebensnotwendig: Die PI kann einen Schaden verhindern, der möglicherweise eine intensive 
Behandlung nach sich zieht oder zum Tod des Patienten führt.
 NE = Nicht ermittelt: Die verfügbaren Informationen erlauben es nicht, die klinischen 
Auswirkungen zu ermitteln.
Wirtschafltiche Auswirkung
 Grundsatz: Die Kosten der medikamentösen Behandlung beinhalten zwei prinzipielle Aspekte: Die 
Kosten der medikamentösen Behandlung beziehen sich auf die finanziellen Kosten des Spitals. 
Medikamentenkosten und die Kosten der Überwachung der medikamentösen Behandlung (z.B. 
Folgeuntersuchungen, Labor, etc).
 -1E = höhere Kosten: Die PI erhöht die Kosten der medikamentösen Behandlung des Patienten.
 0E = keine Veränderung: Die PI verändert die Kosten der medikamentösen Behandlung nicht.
 1E = geringere Kosten: Die PI spart Kosten bei der medikamentösen Behandlung des Patienten.
 NE = Nicht ermittelt: Die verfügbaren Informationen erlauben es nicht, die wirtschaftlichen 
Auswirkungen zu ermitteln.
Organisatorische Auswirkung
 Grundsatz: Die organisatorische Auswirkung umfasst den gesamten Einfluss auf die Qualität des 
Behandlungsprozesses aus Sicht des medizinischen Personals. Folgende Aspekte sind zu 
berücksichtigen: Zeitersparnis, Verbesserte Kenntnisse, Vereinfachung der professionellen 
Aufgaben.
 Erläuterung: Vereinfachte Zusammenarbeit, Erhöhte Sicherheit für das Personal, Kontinuität der 
Behandlung.
 -1O = verringert: Die PI verringert die Qualität des Behandlungsprozesses.
 0O = ohne: Die PI hat keinen Einfluss auf die Qualität des Behandlungsprozesses.
 1O = erhöht: Die PI erhöht die Qualität des Behandlungsprozesses.
 NE = Nicht ermittelt: Die verfügbaren Informationen erlauben es nicht, die organisatorischen 
Auswirkungen zu ermitteln.
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Kommentare zu CLEO
 Wie ist Ihr erster Eindruck von CLEO?
 Das CLEO-System könnte ein geeignetes Instrument für die Evaluierung von pharmazeutischen 
Interventionen in Zukunft sein.
 Haben Sie Anregungen und/oder Verbesserungsvorschläge für das Evaluierungssystem CLEO?
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Adapted Excerpt FlexiForm Questionnaire: «Fragebogen zur Benutzung des Tools CLEOde»
Einleitung
Herzlichen Dank, dass Sie CLEOde für uns getestet haben! Ihre evaluierten klinisch-pharmazeutischen 
Interventionen liefern uns wichtige Daten für die Validierung von CLEOde. Wir bitten Sie nun diesen 
Fragebogen auszufüllen, um uns ihre Meinung zum Evaluierungssystem CLEOde mitzuteilen.
Ziel des Fragebogens ist es Erkenntnisse über die Appropriateness, Acceptability, Feasabillity und 
Precision des Evaluierungssystemes zu bekommen.
Der Fragebogen enthält 12 Fragen, das Ausfüllen dauert ca. 5min.
Die Umfrage ist anonym.
Bitte wählen Sie jeweils die Aussage, welche für Sie am Besten zutrifft.
Besten Dank!
Fragen
Jede Frage: Likert-Skala: gar nicht einverstanden, nicht einverstanden, einverstanden, völlig 
einverstanden, keine Äusserung
 Das Evaluierungssystem CLEOde ist vollständig und beinhaltet alle Dimensionen zur Beurteilung 
einer klinisch-pharmazeutischen Intervention
 Ich hatte keine Probleme für die klinisch-pharmazeutischen Intervention eine Evaluierung nach 
CLEOde zu tätigen
 Es sind genügend Evaluierungsstufen vorhanden in der Dimension Klinische Auswirkung
 Es sind genügend Evaluierungsstufen vorhanden in der Dimension Wirtschaftliche Auswirkung
 Es sind genügend Evaluierungsstufen vorhanden in der Dimension Organisatorische Auswirkung
 Die Evaluierungsstufen innerhalb der Dimension Klinische Auswirkung sind klar definiert und 
voneinander abgegrenzt
 Die Evaluierungsstufen innerhalb der Dimension Wirtschaftliche Auswirkung sind klar definiert und 
voneinander abgegrenzt
 Die Evaluierungsstufen innerhalb der Dimension Organisatorische Auswirkung sind klar definiert 
und voneinander abgegrenzt
 CLEOde ist einfach zu gebrauchen
 Das Schulungsvideo mit Fallbeispielen reichen aus um CLEOde anwenden zu können
 Der Zeitaufwand für die Evaluation einer klinisch-pharmazeutischen Intervention mit CLEOde ist 
angemessen
 Wie lange wurde jeweils für eine Evaluation benötigt? (<10 Sek/ <30 Sek/ <1min/ <2min/ über 
2min)
 Ich könnte mir vorstellen das Evaluierungssystem CLEOde auch in Zukunft in meiner praktischen 
Tätigkeit zu nutzen
 Im Allgemeinen bin ich zufrieden mit dem Evaluierungssystem CLEOde
 Das CLEOde-System wäre ein geeignetes Instrument für die Evaluierung von klinisch-
pharmazeutischen Interventionen
 Haben Sie Anregungen und/oder Verbesserungsvorschläge für das Evaluierungssystem CLEOde?
evaluation Questionnaire
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Validation Cases CLEOde
PI-Doc Fallbeispiele
F) Frau B., 70 Jahre, 168 cm, 72 kg, wurde wegen einer intraventrikulären Blutung stationär in der Klinik 
für Neurochirurgie behandelt. Die Blutung wurde operativ versorgt. Die wiederholte mikrobiologische 
Analyse des Liquors ergab eine Infektion mit einem multiresistenten Koagulase-negativen Staphylococcus 
aureus. Eine 10-tägige i.v.-Therapie mit Zyvoxid (Linezolid) Beutel à 300 mL 1-0-1 (Fr. 184.50 /Tag) 
wurde begonnen. Nach der Verlegung auf die periphere Station zeigt sich die Patientin in einem guten 
Allgemeinzustand. In der Krankenakte sehen Sie, dass die Patientin Vollkost zu sich nimmt. Einer raschen 
Entlassung steht auch aus medizinischer Sicht nichts entgegen. Sie schlagen vor, die i.v.-Antibiose auf 
Tabletten (Fr. 94.15 /Tag) umzustellen, da dies zu einer 5 Tage früheren Entlassung der Patientin führen 
kann.
G) Frau A., 81 Jahre, 167 cm, 59 kg, wird wegen ihres entgleisten Diabetes mellitus Typ 2 behandelt. 
Aufgrund einer bestehenden depressiven Erkrankung erhält sie laut Kurve Seropram (Citalopram) 20 mg 
Tabletten 0-0-1 (Fr. 1.10 /Tag). Seit ihrer Einlieferung klagt die Patientin über Schlafstörungen. Sie fragen 
die Patientin, warum das Präparat abends verordnet wurde. Es fand sich kein plausibler Grund für die 
abendliche Einnahme. Daher schlagen Sie eine morgendliche Einnahme vor.
H) Frau W., 58 Jahre, 175 cm, 82 kg, wird wegen einer flächigen Entzündung der unteren Extremität in 
Verbindung einer Fussinfektion bei Diabetes mellitus Typ 2 eingeliefert. Die Patientin hat eine koronare 
Herzkrankheit (KHK), eine Herzinsuffizienz und erlitt vor einiger Zeit sowohl einen Herzinfarkt als auch 
einen zerebrovaskulären Insult. Zudem ist sie durch eine Niereninsuffizienz dialysepflichtig. Sie erhält 
Calcium-Acetat 500 mg Tabletten 1-1-1 (Fr. 0.80 /Tag). Infektiologische Parameter: CRP: +36 mg/L 
(Referenz: < 5 mg/L), Leukozyten: 13 /nL (Referenz: 3,6 – 10,5 /nL). Die Fussinfektion wird mit Ciproxin 
(Ciprofloxacin) 500 mg Tabletten ½ - 0 – ½ (Fr. 2.70 /Tag) in Kombination mit Dalacin C 300 mg 
(Clindamycin) Kapseln 1-1-1 (Fr. 5.50 /Tag) behandelt. Die Infektionsparameter sind darunter leicht 
fallend und die Patientin hat weder Durchfall noch Erbrechen. Sie erkennen eine Wechselwirkung durch 
die Kombination Ciprofloxacin und Calcium-Acetat und schlagen vor, die beiden Medikamente im Abstand 
von mindestens 2 Stunden getrennt einzunehmen.
I) Herr F., 80 Jahre, 172 cm, 54 kg wurde wegen einer traumatischen subduralen Blutung auf der 
neurochirurgischen Intensivstation behandelt. Zusätzlich hat er eine chronische obstruktive 
Atemwegserkrankung (COPD), die mit Unifyl Continus (Theophyllin) 200 mg Retardtabletten 1-0-1 (Fr. 
0.50 /Tag), Pulmicort Turbuhaler (Budesonid) 0.2 mg 1 Hub 1-0-1 (Fr. 0.55 /Tag) und Oxis Turbohaler 
(Formoterol) 6 µg 1 Hub 2-0-2 (Fr 1.50 /Tag) prästationär behandelt wurde. Auf der Station verschlechtert 
sich die pulmonale Situation des Patienten. Nach Rücksprache mit dem Patienten vermuten Sie, dass das 
Problem in der mangelhaften Handhabung des Turbuhalers und/oder der Inhalationstechnik begründet 
sein kann. Sie schlagen dem Patienten das Kombinationspräparat Vannair (Budesonid 0.1 mg, Formoterol 
6 µg) als Dosieraerosol vor, 2-0-2 (Fr. 3.40 /Tag). Bei dem Patienten sind keine Allergien bekannt.
validation cases
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J) Frau K., 77 Jahre, 165 cm, 66 kg, wird wegen einer Unterschenkelfraktur auf der Unfallchirurgie 
behandelt. Die Patientin hat zudem postoperativ eine Kreatinin-Clearance von 22 mL/Min (nach Cockroft-
Gault) und soll laut Verordnungsblatt wie bereits stationär Aldactone (Spironolacton) 50 mg Tabletten 2-0-
0 (Fr. 1.10 /Tag) wegen ihres Zustandes nach Myokardinfarkt erhalten. Sie bemerken, dass Sprinolacton 
in diesem Fall nicht verordnet werden darf und empfehlen dem Arzt, die Therapie mit Spironolacton nicht 
weiter fortzusetzen.
CLEO FR Fallbeispiele
Beschreibung: Für einen Patient wird aufgrund einer Streptokokkentonsilitis mit Rovamycin (Spiramycin; 
Makrolid, in der CH ausser Handel) Tabletten 500 mg morgens und abends während 10 Tagen 
verschrieben. Arzneimittel-bezogenes Problem: Die Dosierung von Spiramycin wird in Mio. U.I. 
angegeben und beträgt morgens und abends 3 Mio. U.I. Klinisch-pharmazeutische Intervention: Die 
Dosierungsangabe wird korrigiert auf die korrekte Bezeichnung von 3 Mio. U.I. morgens und abends.
Beschreibung: Patient wird aufgrund einer Dermatophyteninfektion mit Nizoral (Ketoconazol) Crème 2% 2 
Mal täglich behandelt (Fr. 3.10 /Tag). Arzneimittel-bezogenes Problem: Für Dermatophyteninfektionen ist 
eine 1 Mal tägliche Applikation zugelassen, Art und Ausmass der Infektion schreiben keine höhere Dosis 
vor. Klinisch-pharmazeutische Intervention: Die Applikationsfrequenz wird auf 1 Mal täglich reduziert (Fr. 
1.55 /Tag).
Beschreibung: Verschreibung von Colchicin (in der CH ausser Handel) und Klacid (Clarithromycin) 
Tabletten 2 x 500 mg /Tag. Arzneimittel-bezogenes Problem: Kombination ist absolut kontraindiziert. Die 
CYP3A und P-gp-Hemmung von Clarithromycin führt zu einer klinisch sehr relevanten 
Plasmakonzentrationserhöhung von Colchicin mit toxischen Symptomen kommen kann. Speziell 
Patienten mit Niereninsuffizienz sind stark betroffen, es kam zu Todesfällen. Klinisch-pharmazeutische 
Intervention: Stopp von Colchicin.
Beschreibung: Kind mit 38 kg wird wegen einer Infektion der Atemwege mit Augmentin (Amoxicillin, 
Clavulansäure) Sirup gewichtsadaptiert 1 Mal pro Tag während 7 Tagen behandelt. Arzneimittel-
bezogenes Problem: Die Verabreichungsfrequenz ist nicht angemessen und birgt das Risiko einer 
Unterdosierung mit subsequentem Therapiemisserfolg. Klinisch-pharmazeutische Intervention: 
Frequenzsteigerung auf 3 gewichtsadaptierte Dosiseinheiten pro Tag.
Beschreibung: Patient mit linkventrikulärer Herzinsuffizienz therapiert mit Digoxin Tabletten 0,25 mg 1x 
/Tag. Arzneimittel-bezogenes Problem: Der aktuelle Kaliumwert beträgt 3,1 mmol/L (Referenz: 3,3 bis 4,5 
mmol/L). Eine Hypokaliämie erhöht die Toxizität von Digoxin (Gefahr von Herzrhythmusstörungen). 
Klinisch-pharmazeutische Intervention: Start Kalium Hausmann (Kaliumcitrat, Kaliumhydrogencarbonat) 
Effervetten 3 x 1 /Tag und Monitoring des Kaliumspiegels.
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II. Project: Assessing the ability of the Drug-Associated Risk tool 
(DARt) questionnaire to stratify patients according to their risk of 
Drug-Related Problems  
Drug-Associated Risk Tool (DART)
	 	 DART	
	 	 Patient	code:	__	__.	__	‐	__	__	‐	__	__	__	
Date:	__	__.	__	__	.	__	__	__	__	 Page	1	of	2	 V2.4	
	
Questionnaire	for	patients	
General	information	
What	is	your	preferred	language	of	communication?	_____________________	
What	is	your	current	age?	_____________________	
	
My	state	of	health	
Yes	 No	 	
	 	 I	have	a	restricted	kidney	function/kidney	dysfunction/kidney	disease	
	 	 I	have	a	liver	disease/liver	dysfunction	
	 	 I	have	a	heart	weakness/heart	performance	weakness	
	 	 I	have	a	chronic	respiratory	disease	
	 	 I	have	diabetes	
	 	 I	have	trouble	remembering	things	or	tend	to	be	forgetful	
	
If	you	do	not	take	any	medication,	the	questionnaire	is	finished	for	you.	
	
My	medicine	
Yes	 No	 	
	 	 I	regularly	take	medicine,	which	I	bought	myself	without	a	prescription	from	my	physician	(including	vitamin	supplements).	
	 	 I	take	more	than	5	drugs	every	day,	which	are	prescribed	by	my	physician.	
	
I	use	the	following	drugs	at	home	(before	my	hospital	stay):	
Yes	 No	 	
	 	 Sleeping	pills	
	 	 Cortison	
	 	 Medicine	against	epilepsy	
	 	 Phenprocoumon,	Rivaroxaban,	Acenocoumarol,	Apixaban,	Edoxaban,	or	Dabigatran	
	 	 Trimipramin,	Amitriptylin,	Imipramin,	Doxepin,	Dibenzepin,	Clomipramin,	or	Melitracen	
	 	 Medicine	against	rheumatism	/	inflammation	
	 	 Medicine	for	drainage	(diuretics)	
	 	 Digoxin	
	 	 Tolterodin	
	 	 Insulin	/	Medicine	against	diabetes	
	
Please	turn	the	page	and	fill	out	the	second	page	of	the	questionnaire.	
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	 Page	2	of	2	
	
Yes	 No	 	
	 	 Do	you	sometimes	forget	to	take	your	medicine?	
	
Yes	 Partially	 No	 	
	 	 	 Having	to	take	this	medicine	worries	me.	
	 	 	 I	sometimes	worry	about	the	long	term	effects	of	my	medicines.	
	 	 	 My	medicines	are	a	mystery	to	me.	
	 	 	 My	medicines	disrupt	my	life.	
	 	 	 I	sometimes	worry	about	becoming	too	dependent	on	my	medicines.	
	
I	feel	well	informed	about	my	medicine.	
Strongly	disagree	 Disagree	 Agree	 Strongly	agree	
	 	  	
	
Application	of	medicine	
The	preparation	of	my	medicine:	
Yes	 No	 	
	 	 is	done	by	myself	
	 	 is	done	by	a	relative	/	a	friend	
	 	 is	done	by	a	pharmacy	
	 	 is	done	by	a	home	care	institution	
	
I	am	having	trouble	with	the	application	of	my	medicine:	
Yes	 No	 	
	 	 when	splitting	
	 	 when	identifying	
	 	 when	swallowing	
	
I	use	one	of	the	following	application	forms:	
Yes	 No	 	
	 	 Inhalation	device	
	 	 Syringe	for	self	injection	
	 	 Skin	patch	
	
Would	you	like	to	tell	us	more	about	your	health	and	medicine?	
	________________________________________________________________________________________________________________________________	
	________________________________________________________________________________________________________________________________	
Thank	you	very	much	for	taking	the	time	to	fill	out	this	questionnaire.	
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Zielsetzungen und Zweck
Hintergrund, Begründung und Ziel der Studie
Jeder Übertritt eines Patienten aus der ambulanten Situation in ein Akutspital und danach zurück nach 
Hause oder in ein Pflegeheim stellt eine entscheidende Schnittstelle bei der Arzneimittelversorgung 
dar. Während des Aufenthalts im Krankenhaus werden Therapien fortgeführt, abgesetzt oder neu 
begonnen. Dosis- und Formulierungsänderungen, Substitution oder Änderungen des 
Einnahmeregimes sind typisch für den Spitalaufenthalt. So zeigte eine Befragung von betreuenden 
Apothekern in Deutschland, dass bei Einlieferung ins Krankenhaus durchschnittlich vier Medikamente 
abgesetzt wurden. Bei der Entlassung hatten die Patienten im Schnitt sieben Arzneimittel auf ihrer 
Medikamentenliste, fünf davon wurden im Spital neuverordnet [1]. Eine Studie aus der Schweiz zeigt, 
dass beim Krankenhausaufenthalt ca. 60% der Medikation verändert wird und 50% der Arzneimittel 
für den Patienten neu sind [2]. Dies kann zu Arzneimittel-bezogenen Problemen führen und braucht 
deswegen besondere Aufmerksamkeit und Massnahmen, um die Therapiesicherheit zu garantieren. 
Bei Spitalaustrittsrezepten stellen wir fest, dass bei 26,0% der Verordnungen klinisch relevante 
Arzneimittel-bezogene Probleme vorhanden sind [3]. 
Als effizienter Lösungsansatz steht unter anderem die intensivierte pharmazeutische Betreuung zur 
Diskussion [4]. Diese kann in den Schweizer Spitälern jedoch aufgrund beschränkter personeller 
Ressourcen bis heute nur punktuell und nicht systematisch eingeführt werden. Andererseits benötigen 
nicht alle Patienten im gleichen Ausmass eine pharmazeutische Betreuung. Es gilt somit die 
beschränkte Ressource an klinisch-pharmazeutischer Kompetenz gezielt für jene Risikopatienten 
einzusetzen, welche den grössten Nutzen erfahren könnten. 
Aufgrund der Bedeutung von Arzneimittel-bezogenen Problemen (DRP) und Arzneimittel-assoziierten 
Rehospitalisationen, könnte ein gezieltes Screening zur Früherkennung von Risikopatienten einen 
essentiellen Beitrag zur Verbesserung der Patientenbetreuung leisten. Patienten mit einem erhöhten 
Risiko für DRP könnten bei Spitaleintritt besser erkannt und während dem Spitalaufenthalt und bei 
Spitalaustritt individuell und optimal pharmazeutisch betreut werden. 
Vor diesem Hintergrund entstand die Idee, ein ausgesprochen praxistaugliches Hilfsmittel zu 
entwickeln. Als Arbeitstitel wählten wir die Bezeichnung „Drug Associated Risk Tool“ (DART). 
Seit Projektbeginn wurden relevante Risikofaktoren für die Entstehung von DRPs in einem 
Triangulationsprozess aus Literaturrecherche und wissenschaftlich geführter Expertenrunde (Nominal 
Group Technique) identifiziert [5]. Aus diesen Faktoren wurde ein Patientenfragebogen erstellt, 
welcher vom Patienten während des Spitalaufenthaltes als Self-Assessment ausgefüllt wird und 
dadurch mögliche Risikopatienten aufdecken kann. Ziel dieser Studie ist es, den Fragebogen zu 
validieren (Verständlichkeit und Machbarkeit; Sensitivität und Spezifität der einzelnen Fragen; 
Korrelation mit identifizierten Arzneimittel-bezogenen Problemen). Aus dem validierten Fragebogen 
soll anschliessend in Abhängigkeit der ermittelten Sensitivität und Spezifität durch unterschiedliche 
Gewichtung der diversen Fragen ein Risiko-Score erstellt werden. 
Fragestellung/ Studienpopulation
Diese Studie soll als Teilstudie des gesamten DART-Projekts laufen. Das DART ist als zweiseitiger 
Fragebogen konzipiert, welcher als Self-Assessment vom Patienten selber ausgefüllt werden soll. Diese 
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Studie soll aufzeigen, ob die im DART abgefragten Risikofaktoren mit der Anzahl an identifizierten 
Arzneimittel-bezogenen Problemen korrelieren. Die im Fragebogen erfassten Punkte repräsentieren 
Faktoren, welche mit einem Risiko verbunden sind, ein unerwünschtes Arzneimittelereignis zu 
erleiden. Die Antworten des Self-Assessment Fragebogens sollen mit Art und Anzahl Arzneimittel-
bezogener Probleme verglichen werden, welche mit Hilfe von etablierten Werkzeugen identifiziert 
werden. Die Fragestellung der vorliegenden Studie lautet: „Werden bei Patienten mit einer höheren 
Anzahl an zutreffenden Faktoren im DART eine höhere Anzahl an Arzneimittel-bezogenen Problemen 
identifiziert?“. 
Die Studienpopulation soll so wenig wie möglich eingeschränkt werden, um ein umfassendes Bild zur 
Machbarkeit des Self-Assessments zu erhalten. Weitere Definitionen zur Studienpopulation sind dem 
Einschlusskriterien zu entnehmen. 
Hypothese
Mittels eines strukturierten Fragebogens, welcher vom Patienten selber ausgefüllt wird, kann erkannt 
werden, ob ein Patient die im Vorprojekt als wesentlich definierten Risikofaktoren für das Auftreten 
von Arzneimittel-bezogenen Problemen aufweist. 
Studiendesign
Hauptzielparameter und sekundäre Zielparameter
Hauptzielparameter 
1. Korrelation der Patientenantworten aus dem Self-Assessment (DART) mit objektiven 
Patientendaten aus Krankenakte und Labordaten.  
Studiendesign, Studienablauf, Studiendauer pro Proband, Abbruchkriterien
Studiendesign 
Die Studie soll im Kanton Baselland durchgeführt werden. Als Studienzentrum dient das Kantonsspital 
Baselland am Standort Bruderholz. 
Studienablauf 
Ein Studienapotheker (siehe Liste der Mitarbeitenden) rekrutiert ab einem festgelegten Zeitpunkt alle 
Patienten, welche die Einschlusskriterien erfüllen, persönlich. Die Patienten werden während ihres 
Spitalaufenthaltes vom Studienapotheker besucht und über die Studie informiert. Der Patient erhält 
die Probandeninformation (Appendix I) und hat genug Zeit die Probandeninformation durchzulesen 
und Fragen dazu zu stellen. Bei Interesse an der Studie und nach Unterschreiben der 
Einverständniserklärung (Appendix II) erhält der Patient den Self-Assessment Fragebogen (Appendix 
III) zum Ausfüllen.  
Potentielle oder manifeste Arzneimittel-bezogene Probleme werden durch den Studienapotheker in 
einer systematischen Medikationsanalyse mit den etablierten Werkzeugen „Medication 
Appropriateness Index“ [6], einem Bewertungsschema für die Angemessenheit eines Arzneimittels, 
und „START/STOPP Version 2“ [7], einer Liste mit für geriatrische Patienten möglicherweise 
unangebrachten Wirkstoffen, erfasst. Zusätzlich sollen in einem Patientengespräch weitere Aspekte 
der medikamentösen Therapie systematisch erkannt werden. Dieses soll strukturiert auf Basis des für 
die öffentlichen Apotheken konzipierten Polymedikations-Checks [8] durchgeführt werden. Das 
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Gespräch zwischen Patient und Apotheker soll Beratungsbedarf und Beratungsbedürfnis, sowie 
potenzielle Risiken durch die Medikation, inklusive Selbstmedikation, und 
Anwendungsschwierigkeiten aufzeigen. Das Interview wird anonymisiert mit FlexiForm erfasst [9] 
(siehe Appendix IV). 
Die identifizierten Arzneimittel-bezogenen Probleme werden für alle eingeschlossenen Patienten im 
GSASA Erfassungstool [10] und in DOCUMENT [11] dokumentiert und klassifiziert. 
Die Studiendauer pro Patient beschränkt sich auf die Zeit, welche zum Ausfüllen des Self-Assessment-
Fragebogens und das Durchführen des strukturierten Patientengesprächs benötigt wird und beläuft 
sich schätzungsweise auf maximal 45 Minuten. 
Abbruchkriterien 
Die Teilnahme an der Studie ist freiwillig. Der Proband kann das Interview mit dem Studienapotheker 
jederzeit, ohne Angabe von Gründen, beenden. 
Massnahmen zur Bias-Minimierung
Verblindung 
Die Studienapotheker haben keine Einsicht in die ausgefüllten Fragebogen und behandeln alle 
eingeschlossenen Patienten gleich. 
Randomisierung 
Probanden werden nach Spitalabteilung ausgewählt. Es findet keine Randomisierung statt. 
Als Bias-Minimierung werden konsekutiv alle Patienten eingeschlossen, welche ihr Einverständnis zur 
Studienteilnahme gegeben haben und mit den Einschluss- und Ausschlusskriterien vereinbar sind. Die 
Patienten werden innerhalb eines bestimmten Zeitraumes oder bis zum Erreichen einer bestimmten 
Anzahl fortlaufend rekrutiert resp. eingeschlossen. 
Auswahl von Versuchspersonen
Rekrutierung 
Die Rekrutierung der Probanden findet durch den jeweiligen Studienapotheker am Studienstandort 
Kantonsspital Baselland Standort Bruderholz statt. Ein ärztlicher Mitarbeiter beurteilt die 
medizinischen Einschluss-/Ausschlusskriterien der zu rekrutierenden Probanden/Patienten und 
entscheidet zusammen mit dem Studienapotheker über die Eignung zur Studienteilnahme. Der 
einzelne Patient wird während seines stationären Aufenthaltes vom Studienapotheker mündlich und 
schriftlich über die Studie informiert und erhält bei Interesse den „Self-Assessment Fragebogen“ zum 
Ausfüllen. 
Einschlusskriterien 
1. Alter > 18 Jahre, 
2. ausreichende deutsche Sprachkenntnisse in Wort und Schrift, um sich mit dem 
Studienapotheker zu verständigen und den Fragebogen auszufüllen 
3. stationärer Patient 
Ausschlusskriterien 
1. Gesundheitszustand, welcher eine sinnhafte Unterhaltung nicht zulässt (d.h. Delir, akute 
Psychose, fortgeschrittene Demenz, Aphasie, getrübter Bewusstseinszustand) 
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2. Palliativer oder terminaler Patient 
Bewertung der Wirksamkeit
Nicht anwendbar. 
Bewertung der Sicherheit
Nicht anwendbar. 
Statistik
Mittels geeigneter statistischer Methoden (z.B. Pearsonsche Korrelationskoeffizient) soll die 
Korrelation von Patientenaussagen mit identifizierten Arzneimittel-bezogenen Problemen berechnet 
werden. 
Studienspezifische Pflichten der Versuchsperson
Für die Versuchsperson fallen keine studienspezifischen Pflichten an. 
Pflichten des Prüfers
Die Studie wird gemäss Protokoll, GCP, und den geltenden gesetzlichen Bestimmungen durchgeführt. 
Der Prüfer wird vom Studienkoordinator geschult und verpflichtet sich, sich beim Interviewen des 
Patienten an die strukturellen und inhaltlichen Vorgaben des Prüfplans zu halten. 
Die Studienapotheker verpflichten sich, alle relevanten medizinischen oder pharmazeutischen 
Probleme, welche sie während des Patienteninterviews neu erkennen, an den behandelnden Arzt 
weiterzuleiten. 
Versicherungsdeckung von Schäden
Für Schäden, die im Rahmen dieser Studie durch die Befragung entstehen sollten, sind die Probanden 
durch die Versicherungspolice des Studienzentrums versichert (HDI-Gerling Industrie Versicherung AG, 
Zürich, Police-Nr.: 01055241-14003, Studie 13.034). 
Ethische Überlegungen
Nutzen/Risiko
Der Patient wird zu keinem Zeitpunkt der Studie einem Risiko ausgesetzt. Zusätzlich besteht ein 
möglicher Nutzen für den Patienten insofern, dass durch das Ausfüllen des Fragebogens, das 
strukturierte Patientengespräch und die systematische Medikationsanalyse medizinisch, 
pharmazeutische Probleme neu erkannt und an den behandelnden Arzt weitergeleitet werden 
können. 
Einschluss besonders schützenswerter Personen
Demente Patienten können eingeschlossen werden, sofern eine sinnhafte Kommunikation mit ihnen 
möglich ist. 
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Freiwilligkeit der Studienteilnahme
Sowohl die Teilnahme als Proband, als auch die Mitarbeit als Studienapotheker ist freiwillig und kann 
jederzeit zurückgezogen werden ohne Angaben von Gründen. Zieht ein Studienapotheker die 
Teilnahme zurück, so können die Studienleitung und der Studienkoordinator einen neuen 
Studienapotheker in der Studie einsetzen. 
Qualitätskontrolle und Qualitätssicherung
Umgang mit Daten
Die Auswertung sämtlicher Daten erfolgt in anonymisierter Form. Um die Rückverfolgbarkeit auf den 
Probanden sicherzustellen wird jedem Probanden eine eindeutige Laufnummer zugeteilt und auf dem 
Fragebogen und den zusätzlich ausgefüllten Datenblättern notiert. Die Laufnummer setzt sich aus den 
Variablen Spital/Abteilung/Studienapotheker/Proband zusammen und wird für sämtliche 
Dokumentationen als Identifikation des Probanden gegenüber der Studienleitung verwendet. Der 
Schlüssel wird daher räumlich getrennt von allen weiteren Studienunterlagen aufbewahrt. Eine 
Decodierung wäre damit im Bedarfsfall zu jeder Zeit möglich. 
In sämtlichen aus der Studie resultierenden Publikationen werden die Daten ausschliesslich 
Rückschlüsse auf die Studienpopulation zulassen und keinesfalls auf Einzelpersonen. Autorisierte 
Behörden, sowie die Ethikkommission können jederzeit Einsicht in die Dokumente nehmen. 
Datenmanagement
Die erhobenen Daten werden anonymisiert aus den Fragebogen und den Patientenakten in Excel und 
in das Statistikprogramm SPSS für Windows übertragen. 
Eine Plausibilitätsprüfung wird vor der Datenanalyse stattfinden. Zudem werden die Daten von zwei 
voneinander unabhängigen Personen erfasst. Somit können die Dateneingaben miteinander 
verglichen und bei fehlender Übereinstimmung überprüft werden. 
Archivierung und Vernichtung
Der Investigator ist um geeignete Räumlichkeiten und Einrichtung zur Lagerung der Dokumente 
besorgt (Raum unter Verschluss mit konstanter Temperatur, Ablage über Bodenniveau, von äusseren 
Einflüssen wie z.B. Licht / Wasser geschützt). Elektronisch gespeicherte Dokumente werden auf einem 
zentralen Server passwortgeschützt abgelegt. Zugang zu den Dokumenten haben einzig autorisierte 
Personen (= Studienleitung, Studienkoordinator). Studiendokumente werden bis 10 Jahre nach 
Studienende vom Studienleiter unter Verschluss gehalten und anschliessend unter seiner Aufsicht 
vernichtet.  
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Probandinnen-/ Probandeninformation 
zur Studie „Drug associated risks: Development of an assessment tool“ 
Sehr geehrte Probandin, sehr geehrter Proband 
1. Auswahl der ProbandInnen 
Sie wurden für die Studie angefragt, weil Sie Patientin/Patient des Kantonsspitals Baselland Standort Bruderholz 
sind. 
2. Ziel der Studie 
Das Ziel der Studie ist es, mit Hilfe eines Fragebogens mehr über Ihre Gesundheit und Ihre Medikamente zu 
erfahren. Wir möchten untersuchen, ob dieser Fragebogen geeignet ist, wesentliche Probleme im Zusammenhang 
mit Ihren Medikamenten zu entdecken. Längerfristig wollen wir damit die medizinischen Leistungen im Spital 
verbessern. 
3. Allgemeine Informationen zur klinischen Studie 
Diese Studie wird nach geltenden Schweizer Gesetzen und nach international anerkannten Grundsätzen 
durchgeführt. 
4. Freiwilligkeit der Teilnahme 
Ihre Teilnahme an dieser Studie ist freiwillig. Wenn Sie auf die Teilnahme an dieser Studie verzichten, haben Sie 
keine Nachteile für Ihre weitere medizinische Betreuung zu erwarten. Das gleiche gilt, wenn Sie Ihre dazu gegebene 
Einwilligung zu einem späteren Zeitpunkt widerrufen. Diese Möglichkeit haben Sie jederzeit. Einen allfälligen 
Widerruf Ihrer Einwilligung bzw. den Rücktritt von der Studie müssen Sie nicht begründen. Im Falle eines 
Widerrufes werden die bis zu diesem Zeitpunkt erhobenen Daten weiter verwendet. 
5. Studienablauf 
Nach Ihrer Einwilligung bekommen Sie von uns einen Fragebogen ausgehändigt. Dieser Fragebogen ist zum 
selbständigen Ausfüllen gedacht. Wir interessieren uns dabei insbesondere für Ihre Gesundheit und Ihre 
Medikamente. Zu einem späteren Zeitpunkt werden wir ein Gespräch zu Ihren Medikamenten mit Ihnen führen, 
welches ca. 20 Minuten dauert. 
Im Rahmen dieser Studie finden keine körperlichen Untersuchungen und keine Blutentnahmen statt. 
6. Nutzen für die Probandin/den Probanden 
Die Teilnahme an dieser Studie steht nicht im Zusammenhang mit Ihrer derzeitigen Behandlung. Falls wir jedoch 
relevante medizinische Probleme erkennen, werden wir den zuständigen Arzt informieren, damit diese Probleme 
behoben werden können. Dank Ihrer Studienteilnahme können die Ergebnisse später auch anderen Personen 
zugutekommen. 
7. Vertraulichkeit der Daten 
In dieser Studie werden persönliche Daten von Ihnen erfasst. Diese Daten werden anonymisiert. Die 
anonymisierten Daten sind nur Fachleuten zur wissenschaftlichen Auswertung zugänglich. Ebenso kann die 
zuständige Ethikkommission Einsicht in die Originaldaten nehmen. Während der ganzen Studie wird die 
Vertraulichkeit strikt gewahrt. Ihr Name wird in keiner Weise in Rapporten oder Publikationen, die aus der Studie 
hervorgehen, veröffentlicht. 
8. Kosten 
Die in dieser Probandeninformation erwähnten Befragungen sind kostenlos. Es entstehen für Sie keine Kosten. 
9. Kontaktpersonen 
Bei Unklarheiten, welche während der Studie oder nach deren Abschluss auftreten, können Sie sich jederzeit an 
die untenstehenden Kontaktpersonen wenden.
Dr. phil. II Markus L. Lampert 
Spitalapotheker FPH 
Tel. +41 61 436 23 63 
E-Mail: markus.lampert@unibas.ch 
Dominik Stämpfli 
Eidg. dipl. Apotheker, Doktorand 
Tel. +41 61 436 23 54 
E-Mail: dominik.staempfli@unibas.ch 
Patient study information
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Schriftliche Einverständniserklärung des Probanden 
zur Teilnahme an einer Studie mit Erhebung gesundheitsbezogener Daten 
 Bitte lesen Sie dieses Formular sorgfältig durch. 
 Bitte fragen Sie, wenn Sie etwas nicht verstehen oder wissen möchten. 
Titel der Studie „Drug associated risks: Development of an assessment tool“ 
Prüfer/in:
Name und Vorname 
Proband/in:
Name und Vorname 
Proband/in:
Geburtsdatum
__ __ . __ __ . __ __ __ __ 
Ich wurde vom unterzeichnenden Prüfer mündlich und schriftlich über die Ziele, den Ablauf der Studie, 
sowie über mögliche Vor- und Nachteile informiert. 
Ich habe die zur oben genannten Studie abgegebene schriftliche Probandeninformation gelesen und 
verstanden. Meine Fragen im Zusammenhang mit der Teilnahme an dieser Studie sind mir 
zufriedenstellend beantwortet worden. Ich kann die schriftliche Probandeninformation behalten und 
erhalte eine Kopie meiner schriftlichen Einverständniserklärung. 
Ich hatte genügend Zeit, um meine Entscheidung zu treffen. 
Ich weiss, dass meine persönlichen Daten nur in anonymisierter Form an aussenstehende Institutionen 
zu Forschungszwecken weitergegeben werden. Ich bin einverstanden, dass die zuständigen Fachleute 
der Ethikkommission Nordwest- und Zentralschweiz (EKNZ) zu Prüf- und Kontrollzwecken in meine 
Originaldaten Einsicht nehmen dürfen, jedoch unter strikter Einhaltung der Vertraulichkeit. 
Ich nehme an dieser Studie freiwillig teil. Ich kann jederzeit und ohne Angabe von Gründen meine 
Zustimmung zur Teilnahme widerrufen, ohne dass mir deswegen Nachteile bei der weiteren 
medizinischen Betreuung entstehen. 
Im Interesse meiner Gesundheit kann mich der Prüfer jederzeit von der Studie ausschliessen. Zudem 
orientiere ich den Prüfer über die Behandlung bei einem anderen Arzt sowie über die Einnahme von 
Medikamenten (vom Arzt verordnete oder selbständig gekaufte). 
Ort, Datum  Unterschrift der Probandin/des Probanden 
Bestätigung des Prüfers: Hiermit bestätige ich, dass ich diesem Probanden/dieser Probandin Wesen, 
Bedeutung und Tragweite der Studie erläutert habe. Ich versichere, alle im Zusammenhang mit dieser 
Studie stehenden Verpflichtungen zu erfüllen. Sollte ich zu irgendeinem Zeitpunkt während der 
Durchführung der Studie von Aspekten erfahren, welche die Bereitschaft des Probanden/der Probandin 
zur Teilnahme an der Studie beeinflussen könnten, werde ich ihn/sie umgehend darüber informieren. 
Ort, Datum  Unterschrift des Prüfers 
Probandencode: __ __. __ - __ __ - __ __ __ 
written patient consent
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Adapted Excerpt FlexiForm Questionnaire «DART Validierung: Patientengespräch 
Erfassungsbogen»
Hintergrund, Ziel
 Ich möchte Ihnen nun einige Fragen zum Alltag mit Ihren Medikamenten stellen.
 Dabei möchte ich überprüfen, ob Ihre Medikamente für Sie angepasst sind, wozu ich auch Ihre 
Meinung brauche.
 Das Gespräch dauert normalerweise ca. 20 Minuten.
 Sie können das Interview natürlich jederzeit unterbrechen oder abbrechen, und Sie können auch 
einzelne Antworten verweigern.
 Ziel des Gespräches ist es, Schwierigkeiten aufzudecken. Diese werde ich entweder direkt mit 
Ihnen oder in Absprache mit dem Arzt lösen.
 In diesem Gespräch gibt es keine richtige oder falsche Antwort.
Einverständnis
 Ist das für Sie in Ordnung?
Probandencode
Datum des Interviews
Check Anwendungen
 Beginnen möchte ich mit der Anwendung und dem Umgang mit Ihren Medikamente.
 Wer übernimmt die Bereitstellung zuhause? (ich selbst/ Apotheke/ Arzt/ Spitex/
Bekannte/Verwandte/ Etwas anderes)
 Falls andere Person/Institution: Kommen Sie regelmässig für die Medikamente vorbei? Nehmen 
Sie das ganze Dosierbox-Abteil (z.B. die morgendliche Einnahme) gleichzeitig ein?
 Wie werden die Medikamente bereitgelegt / Wie bereiten Sie die Medikamente vor? (ohne/
Dosette/ Etwas anderes)
 Sie sind zufrieden mit dieser Art der Bereitstellung?
 Haben Sie Schwierigkeiten wenn Sie die Medikamente teilen müssen?
 Bei welchen (Teilen)?
 Wie gut erkennen Sie die Medikamente?
 Bei welchen (Erkennen)?
 Haben Sie Probleme beim Schlucken von Medikamenten?
 Bei welchen (Schlucken)?
 Was benutzen Sie für spezielle Anwendungsformen? (Inhalationsdevice/ Spritze/Pen/ Pflaster/
Tropfen (oral)/ Tropfen (okulär)/ keine/ Etwas anderes)
 Brauchen Sie noch weitere Informationen von mir zur Anwendung Ihrer Medikamente?
Ist aus Sicht des Apothekers Beratung notwendig?
III. Project: Patient Interviews as Part of a comprehensive Approach 
Contribute to the Identification of Drug-Related Problems on Geriat-
ric wards  
Patient Interview
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Check ärztlich verordnete Medikamente
Falls Dosette oder nicht selbst gerüstet, nicht zwingend einzeln durchgehen.
 Ich möchte jetzt gerne alle Ihre Medikamente einzeln mit Ihnen durchgehen.
 Wie viele Medikamente wenden Sie derzeit am Morgen an? Abgleich mit der Liste.
 Falls Dosette vorhanden: Nehmen Sie alle Medikamente gleichzeitig ein? Vor oder nach dem 
Essen?
Matrix Medikamente (für jedes einzelne Medikament)
 Haben Sie das Medikament bereits vor dem Spitalaufenthalt eingenommen?
 Wie nehmen Sie XY ein? Wann? Wie oft? Vor oder nach dem Essen?
 Was denken Sie, weshalb müssen Sie dieses Medikament anwenden?
 Vergessen Sie manchmal, Ihr Medikament einzunehmen?
 Macht Ihnen die Einnahme von XY Sorgen?
 Vertragen Sie das Medikament gut?
 Denken Sie, dass Sie momentan weitere Beratung zu XY brauchen könnten?
Check Selbstmedikation
 Weiterfahren möchte ich mit Medikamenten, welche Sie selbst kaufen.
 Nehmen Sie Medikamente ein, die Sie ohne ein Rezept des Arztes in der Apotheke oder Drogerie 
kaufen oder von Freunden und Bekannten erhalten (z.B. Aspirin, Abführmittel, Mittel gegen 
Magenbrennen)? Dazu gehören auch Vitaminpräparate und pflanzliche Produkte.
Matrix OTC Medikamente (für jedes einzelne Medikament)
 Weshalb nehmen Sie dieses Medikament ein? Welche Beschwerde behandeln Sie damit?
 Hilft das selbst gekaufte Medikament? Brauchen Sie ein weiteres für die Beschwerden?
 Wie oft wenden Sie dieses Medikament an?
Verdacht auf behandelte UAW OTC?
Verdacht auf Interaktion OTC?
Varia
 Sind bei Ihnen Allergien auf Medikamente bekannt?
 Sind die Allergien in den Patientenakten dokumentiert?
Abschluss
 Sind Sie einverstanden, wenn ich einzelne Punkte mit den Ärzten besprechen werde?
 Ich möchte Ihnen nochmals ganz herzlich für Ihre Teilnahme an diesem Gespräch danken.
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